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Abbreviations 
AICD activation induced cell death 
ANA anti-nuclear autoantibodies 
APC antigen presenting cell 
BM bone marrow 
cDC conventional DC 
CLP common lymphoid progenitor  
CMP  common myeloid progenitor 
cTEC cortical thymic epithelial cells 
DC  dendritic cell 
DLL1 Notch ligand delta-like 1 
DLL4 Notch ligand delta-like 4 
DN1-4 CD4 CD8 double negative subpopulations 1-4 in the thymus 
DP CD4 CD8 double positive subpopulation in the thymus 
EKLF erythroid Kruppel-like factor 
EPLM early progenitor with lymphoid and myeloid potential 
ETP early thymic progenitor 
HA hemagglutinin from influenza virus 
HCL Hairy cell leukemia 
HSC  hematopoietic stem cell 
ISP immature single positive CD8 subpopulation in the thymus 
ITAM immunoreceptor tyrosine-based activation motifs 
LSK lineage- Sca1+ c-kit+ hematopoietic precursor 
MPP multi-potent progenitor  
mTEC medullary thymic epithelial cells 
pDC plasmacytoid DC 
pTreg in the periphery induced Treg 
SCF stem cell factor 
SP CD4 or CD8 single positive population in the thymus 
Treg  regulatory T cell 
tTreg thymus-derived Treg 
Tx thymectomized
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General Summary 
The immune system can discriminate between self and non-self, thus assuring 
clearance of infections by both innate and adaptive effector cells without auto-
aggression, thus, establishing tolerance. Projects discussed within this thesis focus on 
hematopoiesis with special emphasis on T cell development and acqusition of self-
tolerance. 
 
The set-up of a protective lymphocyte repertoire commences, in adults, in the bone 
marrow. A multitude of signals derived from cell-cell interactions and/or cytokine 
signaling determine the first developmental steps of HSC’s differentiating towards the 
lymphoid lineage. Many cytokines in the BM, e.g. IL-7 allowing proliferation of early 
B and DC precursor subsets, seem to work in a permissive way. Instructive cytokine 
signaling that drives cells into differentiation towards the next progenitor stage or a 
specified cell type by actively switching genes on or off is rarely known. Our data 
from project I, introduces FLT3L as a cytokine with such an effect. FLT3L was 
shown to have a direct negative impact on erythropoiesis and, in addition, to drive 
development of multi-potent progenitors into the myeloid/lymphoid lineages. 
Therefore, alteration in FLT3L levels affects the balance between erythrocyte, 
myeloid and lymphoid cell development. Both, myeloid and lymphoid progenitors 
express the FLT3L receptor (FLT3) and deletion of either the receptor or its ligand 
leads to defective developmental potential of hematopoietic progenitors. In the 
present study it was found that, in vivo administration of FLT3L promotes expansion 
of progenitors, which have a combined myeloid and lymphoid potential. Additionally, 
transgenic mice expressing high levels of human FLT3L were generated to investigate 
the role of FLT3L overexpression in hematopoietic development. In FLT3L 
transgenic mice we observed a dramatic expansion of dendritic and myeloid cells, 
which lead to splenomegaly and blood leukocytosis. Both myeloid and lymphoid 
progenitors in the bone marrow were significantly increased in numbers with full 
retention of their normal developmental potential. Furthermore, transgenic mice 
developed anemia together with a reduction in blood platelet numbers. This finding 
could be confirmed by FLT3L injection into wild-type mice, which resulted in a rapid 
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reduction in erythrocyte numbers. All findings together suggest, that FLT3L acts on 
multi-potent progenitors in an instructive way, inducing their development into 
myeloid/lymphoid lineages while suppressing their megakaryocyte/erythrocyte 
potential. 
However, other cytokines might become limiting as shown for B cells; here 
progenitors were reduced in BM likely due to a shortage of IL-7. Instructive cytokines 
might be useful in therapy to increase transiently a certain cell type for a particular 
purpose. Thus, for example, FLT3L administration results in an increase of pDCs 
producing IFN-α, which might be one strategy to combat certain viral infections as 
well as some malignancies, e.g. HCL. However, increasing IFN-α levels systemically 
may trigger autoimmune disease, e.g. psoriasis, and therefore therapy approaches are 
challenging.  
Since within this study, we showed a positive effect of FLT3L overexpression on 
myeloid/lymphoid lineage progenitors, one could assume that thymic T cell 
development might be directly affected. However, we did not observe alterations in T 
cell development or an overall increase of the T cell compartment due to transgenic 
overexpression of FLT3L. It might be that the thymic niche for ETP’s is limited in 
size and therefore, only a specified number of lymphoid progenitors might be able to 
settle in the thymus. Thus, an increase in lymphoid progenitors in the BM would not 
affect T cell development due to niche limitations.  
 
The aim of project II was to set up an in vitro T cell culture system which is not based 
on OP9-DL1 or OP9-DL4 stromal cell lines for studying early T cell development 
prior to T cell selection. Notch-ligand expression by OP9 stromal cells may vary; 
thus, reproducibility of culture conditions has been proven difficult. To address 
timing, durability and reversibility of Notch signaling effects on hematopoietic 
precursors, the “plastic thymus” in vitro culture system was developed. To provide 
precursors with an adequate signal, a DLL4-Fc fusion protein is immobilized at the 
surface of cell culture flasks. The Fc-part of the fusion molecule is fixed to the surface 
by means of a monoclonal IgG anti-Fc antibody, thus directing the orientation of 
DLL4 towards the cells. We have studied the ability of surface-bound DLL4-Fc to 
induce prolonged and extensive expansion of ex vivo isolated Sca1+ c-kit+ fetal liver 
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or adult BM haematopoietic progentiors (LSK’s). Functionality of in vitro generated 
pro T cells could be demonstrated by transplantation experiments. “Plastic thymus” 
derived pro T cells could be shown to reconstitute the thymus of irradiated CD3-/-,  
preTalpha-/- or WT mice and generate a functional peripheral T cell compartment of 
both CD8+ and CD4+ antigen reactive T cells. 
The ability to differentiate and culture T cell progenitors starting with ScaI+ c-kit+ BM 
cells could become a promising research tool and might even be adapted for clinical 
applications. Patients suffering from diseases leading to low T cell frequencies, as e.g. 
HIV infected patients, often suffer from infections, which in people with a functional 
T cell system usually are easily cleared. However, for final T cell development a 
functional thymus is needed, thus, this approach applied for the clinic implies that 
potential patients possess a normal differentiated thymus. Furthermore, the presence 
of Treg cells is a prerequisite since freshly differentiated T cells otherwise will show 
uncontrolled proliferation upon activation, which eventually might lead to 
autoimmunity. Thus, we are currently investigating systems in which mice are 
coinjected with either sorted CD25high WT Treg’s or FoxP3 transduced proT cells to 
increase Treg levels at early time points. 
  
Autoimmune diseases develop when self-reactive T cells that escaped negative 
selection initiate a harmful immune response against self-antigens. However, factors, 
which influence the initiation and progression of an autoimmune response, remain 
incompletely understood. In order to study the influence of the antigen expression 
level on central and peripheral tolerance, transgenic mice showing different 
expression levels of the neo-self antigen hemagglutinin from influenza virus (HA) 
were generated. The neo-self antigen HA was expressed under control of the CD11c 
promoter together with a CD4 T cell derived TCR specifically recognizing that HA 
antigen in the context of the MHC molecule I-ED. Differences in HA expression levels 
dramatically affected the set up for T cell tolerance. In both tested double transgenic 
mice, characterized by either low or high expression level of HA antigen, HA reactive 
T cells could escape negative selection by expression of a second endogenous TCR α-
chain. Thus, T cells expressing two TCR’s at the same time could be identified in the 
periphery of these mice.  
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In the thymus, these cells could be selected into the T cell repertoire due to an altered 
affinity to the HA antigen or due to a different specificity. Surprisingly, the resulting 
phenotype among mice expressing low or high levels of HA antigen differed 
dramatically. While moderate self-antigen expression levels favored the development 
of self-antigen-specific regulatory T cells and established a tolerogenic environment, 
high dose of antigen expression resulted in a very stringent negative selection process 
and in poor development of self-antigen-specific regulatory T cells. In animals with 
very low or practically not detectable levels of Treg cells, especially at a very early 
age, animals suffer from a dramatic disease phenotype characterized by an early onset 
of anemia and splenomegaly, and the late development of arthritis accompanied by 
high titers of IgG anti-nuclear autoantibodies. In such a setting, T cells will get 
strongly activated due to the high antigen expression level in the periphery. A lower 
antigen expression level could be shown to drive T cell activation and proliferation in 
vitro, however not to the extent observed with a high antigen load. It was shown that a 
high affinity is needed to fully activate T cells and to drive proliferation. In that 
respective study affinity but not avidity was taken into account, and it could well be 
that in case of a given affinity between TCR and antigenic peptide, avidity decides 
about the actual outcome. The observation that Treg cells recognize the respective 
(self-) antigen with a high affinity and that the number of antigen specific T cells 
correlates inversely with the number of antigen specific Treg cells proposes that Treg 
development depends on strong TCR-mediated signaling. Very likely a strong signal 
can be mediated in different ways: a high affinity will lead to a long and intense 
interaction between T cell and APC, however it is conceivable that many short-lived 
interactions which resemble a high avidity might lead to a similar outcome. Probably 
it is a combination of both affinity and avidity, which decides about cell fate during T 
cell development.  
Transfer of antigen-specific regulatory T cells into double transgenic newborns 
expressing the neo-self antigen on a high level ameliorated the early onset signs of 
disease but could not prevent the development of long-term chronic pathologies. It 
might well be that injected Treg cells at one point get exhausted and thus, lose their 
therapeutic effect. Another explanation could be that injected Treg cells might 
become outnumbered, since the thymus in that system constantly releases autoreactive 
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T cells into the periphery where they become activated. These findings might point 
out limitations of Treg based therapy. 
 
The incidence of autoimmune disease in man increases with age. In project IV, the 
findings of high titers of anti-nuclear autoantibodies (ANA) in more than 80% of 10 
months old C57BL/6 (B6) mice, immune complex deposition in glomeruli of kidneys 
as well as lymphocyte infiltrations in salivary glands, resemble this human phenotype. 
It is remarkable that the phenotype of these mice was not only determined by 
activated and infiltrating T cells, but as well by a T cell dependent IgG ANA 
generation, since MHC class II deficient B6 mice failed to produce IgG ANA. Due to 
the fact that IgG ANA production in non-aged mice could be induced by adoptive 
transfer of radio-resistant T cells derived from aged IgG ANA positive mice, it looks 
like B cell selection processes in the BM are not very stringent. Those B cells, which 
will generate IgG ANA’s at a later stage in life, seem to be present already at young 
age, however to be activated, autoreactive T cells are needed which only occur in 
aged individuals.  
Thymectomy of 5-week-old B6 mice accelerated the onset of the autoimmune 
phenotype seen in old B6 mice. Thus, the findings in this study indicate, that 
disturbed T cell homeostasis may drive the onset of some autoimmune symptoms, like 
ANA production. Therefore both, a tolerant T cell repertoire as well as T cell 
homeostasis, seem to be superior prerequisites for the set-up of tolerance. This 
assumption could be strengthened by the observation that reconstitution of T cell 
deficient mice with T cell progenitors derived from an in vitro culture system (the so-
called plastic thymus described in project II) lead to the development of IgG ANA’s 
over time. Thus, one single wave of developing T cells can trigger the onset of that 
autoimmune feature.  
Spontaneous IgG ANA production was not only dependent on age but as well on the 
genetic background of the mice. Whereas B6 mice were prone to IgG ANA 
production, mice of the DBA/2 strain were not. However, BDF1 mice, an intercross 
between the B6 and the DBA/2 strains, showed an intermediate incidence of IgG 
ANA generation.  
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In old B6 mice the T cell phenotype was shifted towards a memory phenotype. 
Increased levels of IFN-γ and IL-2 in aged B6 mice indicated, that T cells are 
activated, even though old B6 mice show increased Treg levels compared to young 
counterparts. This gain can very likely be explained by the increased IL-2 availability 
in such an autoimmunity-prone setting. However, no obvious therapeutic effect could 
be observed.  
To summarize, the set-up of T cell tolerance is important to circumvent immediate T 
cell derived autoimmune features. Additionally, there is evidence that a tightly 
controlled homeostatic T cell repertoire is needed to ensure B cell tolerance. 
 
	
   8	
  
Introduction 
1. Lymphocyte development 
Models of hematopoiesis 
In adults, hematopoetic stem cells (HSC) home to the stem cell niches in the bone 
marrow where they remain life-long in an undifferentiated stage until a differentiation 
signal allows HSCs to leave their niche and to differentiate. All hematopoietic 
lineages develop via intermediate multi-potent progenitor cells. The classical model 
for hematopoiesis is the Weissman model [1, 2], which proposes a hierarchical 
development of hematopoietic lineages. According to this model developing cells 
gradually loose their multi-potency. At the branching point for the postulated 
common myeloid (CMP) or common lymphoid progenitors (CLP), the multi-potent 
progenitors (MPPs) eventually have to commit themselves irreversibly to the 
lymphoid or the myeloid lineage. However, this model was refined when the high 
plasticity of Pax5-deficient pro B cell clones could be shown by reconstitution of both 
myeloid and lymphoid lineages in vitro and in vivo respectively [3-5]. In 2005, the in 
vivo equivalent of the Pax5-deficient pro-B cell was discovered – an early progenitor 
with lymphoid and myeloid potential (EPLM) that equals the pre-pro B cell in mouse 
BM [6, 7]. EPLM (as Pax5-/- pro B cells) express B220 and c-kit and are negative for 
CD19 and NK1.1. Furthermore, EPLM express IL-7Rα (CD127), Flt3 (CD135) and 
CD93. The plasticity of EPLMs led to the proposal of the pairwise relationship model 
of hematopoiesis. This model describes hematopoiesis as “a series of invariant 
pairwise developmental relationships between the various hematopoietic lineages” 
[8]. Thus, there are several different intermediate progenitors that may differentiate 
towards one final cell fate. While progressing in development, these progenitors seem 
to keep a certain degree of their plasticity, that allows reversing cell fate choices at 
different developmental levels. In 2005, Rolink and colleagues described CD117+ 
DN1 cells, the earliest subpopulation of thymic precursors, giving rise also to myeloid 
cell lineage development and thus, confirmed the pairwise relationship model of 
hematopoiesis [6]. This finding could be assured in 2008 by Bell and Bhandoola [9].  
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FLT3L in hematopoiesis 
Hematopoieses is a highly complex and tightly regulated process. Several 
transcription factors (e.g. Pax5, EKLF, GATA-1, AP-1), signaling proteins, adhesion 
molecules and cytokine receptors are known factors, that are involved in regulating 
hematopoiesis. Several cytokines, e.g. IL-7, were identified as crucial factors for 
generation of different hematopoietic lineages due to their ability to impart 
environmental signals into hematopoietic development. Recently, in our laboratory, 
the positive role of Flt3L in dendritic cell (DC) development and its importance for 
survival and expansion of lymphoid and myeloid progenitors could be shown 
(manuscript in preparation). When HSC’s are provided with sufficient FLT3L signal, 
they will predominantly give rise to lympho-myeloid progenitors. In contrast, HSC’s 
that only receive a weak FLT3L signal due to either low FLT3 expression or low 
FLT3L levels in the microenvironment will develop into megakaryocyte-erythrocyte 
progenitors (manuscript in preparation). Myeloid, erythroid and B cell lineages 
differentiate within the BM as one of the two primary lymphoid organs. Early thymic 
progenitors (ETPs) leave the BM at an early progenitor stage and enter via blood 
vessels [10] the thymus – which is the second primary lymphoid organ - for 
differentiation into mature T cells.  
 
2. T cell development 
Early T cell development 
The earliest T cell precursor found in the thymus is the ETP. ETPs are defined as Lin- 
c-Kit+ Flt3+ CD24-/lo CD44+ CD25-. Their frequency is about 0.01% of all thymocytes. 
To keep a functional T cell repertoire, the thymus has to be colonized constantly with 
BM derived ETP’s [10]. Ceredig et al proposed that about five bone marrow-derived 
precursors per day colonize the thymus and hence, sustain T cell development [11]. 
Therefore, the thymus needs to provide, for instance, chemokines to attract progenitor 
cells, survival factors and specification signals to induce and maintain differentiation 
towards distinct cell fates. Recently, it was postulated that there are four main factors 
necessary for the set up of an environment in which T cell development can take place 
efficiently. The factors are the chemokines CCL25 and CXCL12, the cytokine stem 
cell factor (SCF) and the Notch ligand Delta-like 4 (DLL4) which all are all absent in 
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the primitive thymus anlage in fetal mice deficient of FoxN1 transcription factor [12]. 
CCL25 and CXCL12 are important for the regulation of homing of hematopoietic 
precursors to the fetal thymus [12, 13]. In addition, CXCL12 was shown to increase 
efficiency of the transition from DN3 to DP in adult mice (DN3 - subset of CD4 and 
CD8 double negative population in the thymus; DP - subset of CD4 and CD8 double 
positive population in the thymus; detailed description will follow) [14]. Notch 
signaling via Notch 1 and one of its ligands, DLL4, is crucial for the induction of T 
cell development. Conditional inactivation of the receptor [15] or DL4 [16, 17] results 
in complete abrogation of T cell development. Furthermore, it could be shown that in 
the absence of DLL4 - dependent on the presence of SCF and/or Cxcl12 – only 
myeloid and/or B cells develop in the thymus [12]. Thus, DLL4 signaling is key for T 
cell development and has highest priority within the four listed signaling pathways 
[12]. Another important factor for T cell development in adult mice is the cytokine 
IL-7. The contribution of IL-7 was not addressed in the study mentioned above, since 
IL-7 was still found to be present in the primitive thymus anlage in fetal mice 
deficient of FoxN1 transcription factor. Additionally, it was shown that fetal T cell 
development is IL-7 independent [18]. However, for T and B cell development in 
adult mice, IL-7 is a critical cytokine since IL-7 deficient mice exhibit severe 
lymphoid abnormalities [19]. Analysis of CD127 expression, the α-chain of the IL-
7R, revealed only a very weak signal on thymocytes up to the DN2 stage (subset of 
CD4 and CD8 double negative population in the thymus) using the monoclonal 
antibody (mAb) A7R34. However, it could be shown that in vitro, ETP and DN1 
(subset of CD4 and CD8 double negative population) survival and growth is strictly 
dependent on IL-7 [20]. Furthermore, IL-7R signaling was shown to be critical, not 
only in early thymocyte expansion prior to T cell receptor gene rearrangement, but as 
well for proliferation of early B cell progenitors undergoing immunoglobulin heavy 
chain gene rearrangements [21]. Besides these findings, a blocking activity of IL-7 
during the transition of DN3 (subset of CD4 and CD8 double negative population) to 
the DP (CD4 and CD8 double positive population in the thymus) stage could be 
shown using in vitro assays. Only upon withdrawal of IL-7 cells differentiate further 
into DPs [14, 20]. However, it is worth mentioning, that progenitors isolated from 
adult mice were more susceptible to inhibition of differentiation than fetal liver 
derived progenitors [20] suggesting a difference in lymphoid development comparing 
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fetal and adult progenitors. Furthermore, IL-7 was reported to play a role in the 
development of the CD8 T cell lineage [22, 23]. Summing up, the role of IL-7 in T 
cell development is not quite understood and recent in vitro findings seem 
contradicting concerning a positive or negative impact of IL-7 on T cell development. 
Nevertheless IL-7 seems to play a crucial role in thymic developmental processes.  
Developmental stages in T cell development 
Based on the surface expression of the TCR co-receptors CD4 and CD8, developing 
thymocytes can be subdivided into four major populations. In the developmentally 
earliest stage, thymocytes are CD4- and CD8- and therefore called double negative 
(DN). The maturity of DNs can be examined by analysis of CD25, CD44 and CD117 
expression. According to their differential expression levels one can distinguish four 
different populations; DN1 to DN4. DN1 cells are characterized by high surface 
expression levels of CD44 and CD117, while they are negative for CD25. This stage 
is followed by the DN2 stage, where cells express all three surface markers. High 
levels of CD25 and low levels of both CD44 and CD117 are characteristic for the 
DN3 population [24-26]. At this stage of development, cells complete the 
rearrangement of their β-chain locus. Once, T cell progenitors express a successfully 
rearranged β-chain, there is a negative feedback-loop to stop further rearrangement 
events of this locus and thus, only one locus is rearranged and expressed as protein. 
This procedure is known as allelic exclusion at the TCR β-locus [27, 28]. Developing 
T cells are selected in case of a productive rearrangement in a process called β-
selection. For being selected DN3 cells with a functional β-chain rearrangement 
express the β-chain together with the pre Tα-chain on the surface [29, 30]. Due to 
preTCR-mediated proliferation, DN3 cells expand and eventually differentiate into 
DN4 cells. DN4 cells loose expression of CD25, CD44 and CD117 and directly 
differentiate further into so-called immature single positive (ISP) CD8 cells [24-26] in 
mouse. (In humans there is a similar immature single positive stage, however instead 
of CD8, CD4 is expressed.) ISPs differentiate further into CD4 and CD8 expressing 
cells that are called double positive thymocytes (DP). At the double positive stage, the 
TCR α-locus will rearrange. For the α-locus, there is no allelic exclusion observed. 
Thus, α-chain rearrangement only will terminate as soon as an α-chain is produced 
that can pair with the expressed β-chain and provide the cell with a functional signal. 
This signal eventually composes the end point of all rearrangement events at the αβ-
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TCR locus. As soon as DPs express a functional αβ-TCR on their surface, cells 
undergo positive and negative selection. Thus, only DPs that receive a survival signal 
due to a functional TCR and DPs that are not deleted due to a too strong signal caused 
by high affinity for self antigens, will be able to differentiate further [31, 32]. In this 
stage, most thymocytes die by neglect due to non-functional rearrangements. 
Depending on the class of MHC molecule, which can be recognized by the TCR, 
thymocytes become committed either to the CD4 (TCR-MHC II interaction) single 
positive (SP) or to CD8 (TCR-MHC I interaction) SP T cell lineage. Selected and 
hence self-tolerant CD4 and CD8 SPs are able to leave the thymus through the 
efferent blood vessels and scan for presented antigens in secondary lymphoid organs.  
T cell selection  
During T cell development T cells get selected in order to provide the host with a 
powerful T cell repertoire to recognize foreign antigens but which is at the same time 
tolerant to self. The selection procedure is known as positive and negative selection. 
For being positively selected T cells need to be able to interact with self-MHC to 
receive a survival signal [33]. Without this signal T cells die by neglect. Negative 
selection is based on the recognition of self-peptides presented by MHC molecules in 
the thymus; i.e. T cells that receive a strong signal in the thymus will undergo 
apoptosis [34]. Even though the outcome of these selection processes seems to be 
clear, the actual signaling is not well understood. The affinity with which the TCR 
recognizes the peptide presented by an APC on the MHC molecule was shown to play 
a major role during selection of CD8 positive cells. The finding that there seems to be 
a fixed affinity threshold for negative selection suggests that negative selection – at 
least for CD8 T cells - depends on differences in affinity [35]. High affinity 
interactions will lead to a strong signal due to a prolonged interaction of TCR with the 
respective peptide presenting MHC molecule. This prolonged interaction might result 
in a level of phosphorylation of the immunoreceptor tyrosine-based activation motifs 
(ITAMs) of the CD3 complex that is necessary to initiate negative selection [36]. 
However, there is evidence, that affinity is not the only important factor. Avidity, 
which means the sum of all TCR-APC interactions, can modulate selection 
procedures. Our findings derived from double transgenic mice expressing the HA 
antigen under the CD11c promoter and in addition a transgenic HA-reactive TCR on 
CD4 positive T cells, support this reasoning (manuscript in preparation). Using the 
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HA double transgenic mouse model, we could show that a low expression level of 
peptide on the surface of APCs leads to a completely different outcome compared to a 
high expression level. Negative selection of CD4 positive HA-reactive T cells itself, 
seems not to be altered severely by differential expression levels of the neo-self-
antigen. However, regulatory T cell levels decreased dramatically in case of high 
antigen expression in the thymus. Thus, avidity, which is studied here in context of 
CD4 T cells, appears to have a major influence on the set-up of tolerance. 
Aschenbrenner et al (2010) had similar findings. In their study, due to a decrease of 
MHCII-dependent antigen presentation on TECs, they could observe percentagewise 
an increase in the respective antigen-specific Treg population [37, 38]. Up to date, it 
is discussed whether different APC subsets have specialized function, or whether it is 
the signal strength on its own that decides the outcome of the selection process.  
In vitro T cell development 
The three dimensional network of thymic stromal cells has a major implication on T 
cell development. It provides developing thymocytes with a multitude of exogenous, 
indispensible signals and a customized microenvironment. Even though, in vitro and 
in vivo approaches are described to study detailed processes of T cell development, 
the initiation of this process and the time point upon which T cells are absolutely 
committed to the T cell lineage, as well as the signals for differentiating further 
towards the next thymic developmental stage, are not clarified yet. In 2002, Schmitt 
and Zuniga-Pflucker [39] published the first two dimensional in vitro culturing system 
for developing T cells based on Delta-like 1 (DLL1) expressing OP-9 stroma cell line. 
The possibility to differentiate T cells in vitro opened up new opportunities to study T 
cell development in more detail. However, there are several disadvantages using this 
stroma cell based system, e.g. variation in stromal cell Notch ligand surface 
expression due to several cell passages or varying culturing conditions and unknown 
signaling components provided by stroma cells. Ohishi et al [40] described a feeder-
free system: DLL1 was expressed with a human Fc-tag as a fusion protein and 
coupled to plastic surfaces. Using this system, T cell development could be induced in 
a DLL1 concentration dependent manner [41]. Later on, it was shown that the 
physiologic thymic Notch ligand responsible for T-cell development is DLL4 instead 
of DLL1 [16, 17]. To overcome previous in vitro culture problems, a T cell culture 
system was established in our laboratory – the so-called “plastic thymus” (manuscript 
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in preparation)[14]. In this stromal cell-free system an approach similar to Ohishi is 
used, i.e. the fusion protein DLL4-human IgG1-FC is coupled to a tissue culture plate 
pre-coated with monoclonal anti-human IgG1-Fc antibody (Huf 5.4). With this culture 
system, a powerful tool was generated to study minimal requirements for T cell 
development where conditions can be manipulated easily and in a well controlled 
manner.  
Antigen presenting cells in the thymus 
T cell development in the “plastic thymus” is terminated at the DP stage. For T cell 
development beyond this stage antigen presenting cells (APCs) are needed for T cell 
selection processes. The urge for thymic T cell selection is obvious, auto-reactive T 
cells are deleted and T cells that are not capable to interact with self-MHC molecules 
die by neglect. Antigen presenting cells in the thymus include cortical (cTEC) and 
medullary thymic epithelial cells (mTEC) as well as dendritic cells (DC) and B cells, 
however B cells are only present as a tiny population (about 1% of the starting thymus 
suspension) in the thymus compared to the other APC lineages [42, 43]. cTECs are 
localized in the outer cortical regions of the thymus. cTECs were shown to be able to 
positively select T cells [44, 45]. Besides that, there is some evidence that cTECs also 
might be able to contribute to negative selection [46, 47] as well as to Treg induction 
[48]. The mechanism how cTECs contribute to T cell selection is unknown. One of 
the first models discussed in the field is the “altered peptide model”. cTECs were 
suggested to present “specially tailored” peptides for positive selection . Recently, 
there is evidence that the peptide machinery in cTECs, indeed, differs from 
proteolytic pathways in other cell types, e.g. cTECs preferentially express cathepsin L 
instead of cathepsin S for the degradation of the invariant chain in the MHCII loading 
process [49]. Furthermore, macroautophagy seems to play an important role for the 
cTEC function [50]. cTECs express high levels of surface MHCII, but are particularly 
inefficient to present exogenous proteins using the classical endocytic pathway [51, 
52]. It could be demonstrated, that via macroautophagy, intracellular antigens can be 
delivered to the MHC II pathway and, thus, shape the CD4+ T cell compartment [53]. 
Last but not least, cTECs were shown to express a different subunit in the proteasome 
- β5t instead of β5i – and therefore, protein processing is different compared to 
mTECs and DCs [54]. This finding supports the idea, that the peptide repertoire 
presented by cTECs differs from the one presented by mTECs and DCs. Other models 
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claim, that selection is based on affinity or avidity, hence taking both into account, the 
quality and the quantity during the interaction of MHC presented antigen and TCR 
(refer as well to above). It is very likely, that neither model is correct, and that the 
truth lies in a combination of the two. Subsequent to CD4 or CD8 lineage 
commitment, thymocytes translocate to the medulla where they reside up to 5 days 
prior to exiting the thymus [55]. In the medulla developing T cells undergo a quality 
check. By interacting with mTECs and DCs, self-tolerance of T cells is assured. In 
case of a premature egress of thymocytes or disorganization of the medullary 
architecture, systemic autoimmunity is observed [56, 57]. This shows, that T cell 
deletion during thymic negative selection is a crucial requirement for the set-up of 
central tolerance. mTECs, together with cTECs, are the only non-hematopoietic cells 
with a constitutively high MHC II expression [43]. mTECs were shown to present 
tissue-restricted antigens in the thymus, in part under the control of the autoimmune 
regulator transcription factor AIRE [58]. Their contribution in deletion of auto-
reactive T cells is without controversy [52]. Additionally, mTECs were shown to be 
involved in thymic Treg generation [37].  
The dendritic cell (DC) is another important antigen presenting cell type in the thymic 
medulla. Thymic DCs can be subdivided into three major subsets: conventional 
CD11chigh DCs (cDCs) that are CD11b-CD8α+CD172a- or CD11b+CD8α-/lowCD172a+ 
and CD11cmidCD45RA+ plasmacytoid DCs (pDCs) (reviewed in [59]). Only the 
CD11b-CD8α+CD172a- cDCs, that represent approximately two thirds of the cDC 
compartment, arise in the thymus (autochthonous). CD11b+CD8α-/lowCD172a+ cDCs, 
as well as pDCs, immigrate from periphery into the thymus and therefore are called 
migratory DCs [60-62]. According to a study where several steady-state splenic DC 
subsets were injected intravenously and their homing to the thymus was monitored, 
all three major DC subsets of peripheral cDCs (CD11b-CD8α+ ‘lymphoid’ DCs, 
CD11b+CD8α- ‘myeloid’ DCs and CD11b-CD8α- DCs) showed a similar ability of 
homing to the thymus and additionally, their contribution to negative selection could 
be revealed [63]. However, other experimental approaches could show, that under 
physiological conditions almost all migratory thymic cDCs have myeloid features and 
most circulating cDCs in the blood express CD172a [62], which is expressed by 
peripheral myeloid cDCs [64]. Thus, it is very likely that under physiological 
conditions almost all peripherally derived migratory cDCs in the thymus have a 
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‘myeloid’ phenotype – most likely due to their relative abundance in the circulation. 
After entering the thymus, migratory CD172a+ DCs preferentially localize to the 
medulla and intermingle with autochthonous DCs. They upregulate MHC II and co-
stimulatory molecules, i.e. they undergo further maturation [62]. Interestingly, LPS 
pretreated and adoptively transferred DCs could not home to the thymus anymore, 
suggesting that there is a protection mechanism to prevent central tolerance induction 
towards pathogen-derived antigens taken up in the periphery [63]. In several studies, 
the contribution of migratory DCs to negative selection could be shown [63, 65]. In 
the second study, not only partial deletion of the respective antigen-specific T cells 
could be shown, but, as well, a slight increase in Tregs displaying the very same 
specificity [65]. However, it is under debate, whether a specialized type of APC is 
needed for Treg induction or if Treg development is under T cell-intrinsic 
developmental control. In vitro assays showed, that all thymic APC subsets efficiently 
could promote Treg conversion using immature thymocytes, but not peripheral naïve 
CD4+ T cells [66]. Based on this, different anatomical DC origins could account for a 
‘complete’ pool of peptides presented in the thymus. Migratory DCs were suggested 
to sample serum antigens and well-accessible antigens, whereas autochthonous DCs 
might rather concentrate on antigens that are difficult to be reached by migratory 
DCs. Furthermore autochthonous DCs were shown to be much more efficient, 
compared to migratory DCs, in cross-presenting antigens derived from apoptotic cells 
to CD8+ T cells [61]. In this context, it should be mentioned, that up to date, there is 
only evidence for a uni-directional antigen transfer from mTECs to DCs [67] but not 
from DCs to TECs. Thus, tissue restricted antigens promiscuously expressed by 
mTECs can be presented by DC subsets in the thymus. To sum up, the heterogeneous 
APC subsets in the thymus derived from different anatomical origins, very likely 
altogether, account for the presentation of a broad range of self-antigens and hence, 
they assure the set up of central tolerance.  
 
3. Autoimmunity 
Central tolerance and autoimmunity 
Development of autoimmune disease can be caused by a huge variety of sources. 
Failure in the set-up of central tolerance can be one reason that most likely will lead 
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to autoimmune disease development. These failures can occur at a very early 
developmental stage. Mutations in the FoxP3 gene locus is an example for such a 
scenario. The autoimmune disease phenotype is known as the IPEX syndrome in men 
(typically caused by missense mutations) or the scurfy phenotype (spontaneous 
frameshift mutation or complete knockout of the FoxP3 gene) in mice [68-72]. The 
transcription factor Foxp3 is important for the generation and function of Tregs. A 
defect in FoxP3 will hinder the development and the functionality of Treg cells and 
thus, will lead to autoimmunity [73]. Mutations in the AIRE gene locus can also lead 
to autoimmunity. AIRE is expressed by mTECs in the thymic medulla and is 
responsible for ubiquitous gene expression, including tissue-specific self-antigens, in 
the thymus. Due to non-functional AIRE expression, negative selection for T cells is 
not complete and self-reactive T cells can be released into the periphery causing 
severe autoimmune diseases (reviewed in [74]). However, failures in the set-up of 
central tolerance, even though the auto-antigen is expressed in the thymus can occur. 
In both autoimmune diseases, Myastenia gravis and Diabetes type I, the respective 
auto-antigen is reported to be expressed in the thymus, however on a different level, 
compared to healthy controls [75]. Thus, tolerance can be broken not only due to non-
expression of the auto-antigen but as well due to deregulated expression levels of the 
respective self-antigen in the thymus. In contrary, other autoimmune diseases are very 
likely to develop independently of the thymic selection processes; e.g. rheumatoid 
arthritis.  
Age and autoimmunity 
It is a well-accepted observation that several autoimmune diseases occur in the second 
half of life or peak in the elderly [76, 77]. Rheumatoid as well as giant cell arthritis 
and Sjögren’s syndrome are only few examples [78-80]. Moreover, anti-nuclear 
autoantibodies (ANA) are frequently found in aged individuals [81, 82]. This 
phenomenon can be seen as well in aged mice depending on their genetic background 
(manuscript in preparation). However, up to date, the cellular mechanisms that cause 
the onset of the development of these autoimmune features are only poorly 
understood. The competence of the immune system declines with age. Findings like a 
higher mortality and morbidity upon annual influenza epidemics [83], as well as only 
limited protection upon influenza vaccinations in the elderly population support this 
conclusion [84, 85]. With age the production of T and B cells decreases, thus this 
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decrease is thought to lead to the decline of the immune system’s competence. It 
could be shown that B cell production is reduced with age in mice. Whereas 1 out of 
50 pro B cells isolated from 2 week-old mice can be grown on stromal cells in the 
presence of IL-7 in vitro, in aged mice this frequency is dramatically decreased. In 
aged mice, only 1 out of 500-1000 pro B cells can be cultured and therefore would be 
able to differentiate into terminally differentiated and functional B cells in vivo [86]. 
In man, the drop in B cell generation with age is even more striking as pro- and pre-B 
cells are practically undetectable in the bone marrow of individuals that are older than 
85 years [87, 88]. There is not only a difference in the early B cell populations 
comparing young and adult individuals, but, as well, a difference in their phenotype. 
In adult humans, the peripheral B cell compartment consists to a large extent of 
memory B cells marked by expression of CD27 (reviewed in [89]). So far, in mice, 
memory B cells were not reported. In humans, this finding might be due to the fact 
that the turnover of mature B cells, including memory B cells, is slow or even absent 
due to the lack of competition for space with newly formed B cells from the BM. The 
drop in developmental capability is not only restricted to B cells but also includes T 
cells. T cell generation decreases dramatically with age in mice as well as in humans. 
Thus, the thymus involutes with time [90]. The mechanism for this involution is not 
fully understood. The subsequent decrease of newly generated naïve T cells leads to a 
very low exchange rate of mature peripheral T cells with newly generated ones. Not 
only the peripheral B cells in adult human beings, but as well peripheral T cells 
predominantly have a memory phenotype in mouse and man (reviewed in [91]). This 
might mirror the frequent encounters of the T cell repertoire with foreign antigens in 
adult individuals. Another explanation might very well be, that the homeostatic 
proliferation of T cells in adults is increased due to the reduced thymic output. Thus, 
B and T cell generation are affected by aging.  
The finding of a reduced B and T cell development with age seems contradictory to 
the observation of a higher incidence of autoimmune disease developing in adults. 
This paradox might lead to the conclusion that both B and T cell selection is impaired 
in aged individuals, and hence maybe less strict, however there is no real evidence for 
that reasoning up to date. Another explanation could be that the disturbed turnover, 
and thus an impaired homeostasis, causes autoimmunity. The findings in our study, 
referring to T cells, strongly support the second rationale.  
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The role of genetics in autoimmunity 
Besides age and non-functional central tolerance, genetics also play a major role in 
the development of autoimmune disease. Morbus Bechterew, a disease syndrome also 
known as ankylosing spondylitis, is strongly associated with the expression of HLA-
B27 [92]. The pathogenesis of spondylitis is believed to depend (i) on the HLA-B27 
peptide-presenting specificity (absolute restriction for peptide ligands with arginine at 
position 2 [93]), (ii) on the slow-folding and the high probability for misfolding of the 
HLA-B27 molecule and/or (iii) on the capacity of HLA-B27 to form covalently 
linked heavy chain homodimers that can be recognized by leukocyte receptors. Thus, 
referring to spondylitis, autoimmune disease is believed to be triggered by (i) self-
reactive T cells against a self-ligand of HLA-B27 elicited by a cross-reactive foreign 
antigen, (ii) independently from antigen presentation, as a result of endoplasmatic 
reticulum stress, and/or (iii) immunomodulation of both the innate and adaptive 
immune responses to arthritogenic pathogens due to recognition of heavy chain 
homodimers by leukocyte receptors. Type 1A diabetes is another example of an 
autoimmune disease for which the genetic background is decisive. HLA alleles DQ 
and DR were identified as important determinants of disease and even allow to 
identify at birth individuals at high risk [94].  
 
4. Peripheral tolerance  
Anergy 
Central tolerance is completed by mechanisms that assure tolerance in the periphery. 
Although central tolerance is efficient, not all self-antigens are expressed in the 
thymus. Thus, some lymphocytes only encounter their cognate self-antigen outside of 
the thymus in the periphery. Food antigens, developmental antigens and antigens 
displayed during chronic infections are only a few examples of such antigens. 
Without peripheral tolerance mechanisms, recognition of those antigens by T cells 
can lead to the onset of autoimmunity. Induction of anergy in the periphery is one 
important mechanism to keep tolerance. For complete T cell activation, T cells need 
two signals. First, T cells need to receive a positive signal via their TCR upon 
recognition of the respective antigen presented by MHC. In addition, T cells depend 
on a second costimulatory signal derived from the APC, which is mediated, e.g., via 
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CD28 ligation. Successful antigen recognition is followed by cytokine secretion, such 
as IL-2. The PI3K/AKT-mTOR pathway is fully activated by subsequent signaling 
through the IL-2R complex. In case of a missing second signal, T cells remain in a 
long-term hyporesponsive state, which is termed anergy. Anergic T cells are 
characterized by active repression of both, TCR signaling and IL-2 expression [95]. 
mTOR was reported as a sensor for energy and nutrients and it was shown that by 
blocking mTOR activation, anergy in T cells could be induced. Powell and Degoffe 
suggested that several energy and nutrient sensing pathways, by measuring nutrient 
deprivation, ATP deprivation and hypoxa, might induce anergy through mTOR 
inhibition [96]. Tregs have been proposed to foster a hypoxic environment due to 
expression of 5’-ectonucleotidase CD73 and ATPase/ADPase CD39 [97, 98]. Both 
enzymes together convert ATP into adenosine and thus, Tregs may regulate T cell 
activation by promoting anergy. T cell activation depends on costimulatory signals; 
however costimulatory pathways can as well provide negative signals that can inhibit 
T cell responses and mediate tolerance. The programmed death 1 (PD-1) receptor and 
its ligands PD-L1 and PD-L2 is one example of such a negatively regulating 
costimulator molecule [99]. Ligation of TCR and PD-1 attenuates the activation of 
PI3K and Akt pathways through dephosphorylation of the proximal signaling 
molecules by SHP-1 and SHP-2. CTLA-4 is another important costimulatory 
molecule in anergy induction. CTLA-4 is induced at a late stage in T cell activation 
and binds to the B7 proteins CD80 and CD86 with high avidity competing with 
CD28. However, unlike CD28, CTLA-4 transduces a negative signal preventing cell 
cycle progression, and thus limits T cell responses. APCs not only induce immune 
responses but also can induce and maintain tolerance. Tolerogenic DCs present 
antigen but cannot deliver adequate costimulatory signals to antigen-specific T cells, 
thus T cell activation and proliferation is hindered [100]. Since the capability to 
promote tolerance is not restricted to a specific DC subset it is rather believed that 
tolerogenic DCs are DCs with incomplete maturation. It was shown that apoptotic 
cells are not able to trigger full DC maturation whereas necrotic cells can do so [101]. 
Additionally, an immunosuppressive environment (IL-10, TGF-β) supports the 
generation of tolerogenic DCs [102].  
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Peripheral deletion 
Peripheral deletion of self-reactive lymphocytes is another important mechanism to 
achieve tolerance. Fas (CD95) is expressed on T cells; upon repeated stimulation by 
their cognate or foreign antigen and IL-2, FasL (CD178) expression is induced on T 
cells [103, 104]. The so-called “death receptor” signaling leads to activation induced 
cell death (AICD) by activation of Caspase-8 and effector caspases which 
consequently promote apoptosis. Interestingly, the killing of activated T cells during 
the shutdown of an immune response is not dependent on Fas but on Bim [105, 106]. 
Bim activates Bax/Bak and thus, leads to the permeabilization of the outer 
mitochondrial membrane and eventually to apoptosis. It could be shown that Bim-
deficient mice spontaneously develop immune complex-glomerulonephritis at old age 
and that Bim actively is involved in maintenance of hematopoietic homeostasis [107].  
Regulatory T cells 
The heterogenous population of regulatory T cells is indispensable for providing 
dominant tolerance. Recently, a new nomenclature was suggested for the different 
subsets of regulatory T cells by well-known representatives of ‘regulatory T cell’ 
research [108]. Although, up-to-date it is impossible to distinguish different 
regulatory T cell subsets using surface markers, it could be shown that regulatory T 
cells can be of two different origins. They can be thymus-derived (tTreg), which 
previously were also called ‘natural Treg’; or they can develop in the periphery 
(pTreg) and so far often were described as ‘induced Treg’. These Treg populations 
found in vivo, should be clearly distinguished from in vitro induced Treg populations 
(iTreg) since the significance of in vitro findings are under debate. Furthermore, the 
term ‘regulatory T cells’ should only be used for defined FoxP3+ CD4+ T cell 
populations with a substantial suppressive ability. 
The first observations that eventually lead to the discovery of Treg cells were done by 
Nishizuka & Sakakura in 1969 [109]. Thymectomy (Tx) of female mice early in life 
resulted in infertility due to autoimmune oophoritis, however only in case when the 
thymus was removed from neonatal animals at day 3 after birth (d3Tx). Several 
thymus or lymphocyte grafting experiments followed. These experiments finally lead 
to the conclusion, that disease suppression was achieved by thymus-derived 
lymphocytes. Furthermore, these experiments provided evidence that these cells 
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developed in the thymus of the neonate, but were not released into periphery during 
the first 3 days of life [110].  
Later it could be shown that autoimmune oophoritis or gastritis could be transferred 
into newborns or adult nu/nu mice by injection of T cells derived from spleen of d3Tx 
mice with disease [111, 112]. Further studies verified that the effector and the 
suppressor T cell populations were CD4+ CD8- [113, 114]. The finding that removal 
of suppressor T cells from an otherwise healthy animal initiates autoimmune disease 
and that reconstitution of the recipient with suppressor T cells could reestablish self-
tolerance was a major advance in the field [115]. Until then, suppressor T cells were 
only known to be a minor population of the Thy1+ CD5high thymocytes. The next 
major progress in the field was the discovery by Sakaguchi and associates that 
suppressor T cells express high levels of CD25, the IL-2R α-chain [116, 117]. With 
this finding suppressor T cells could be further described as a subpopulation of about 
10% of the CD4+ thymocytes. In 2003, the transcription factor FoxP3 was 
demonstrated to have key regulatory function in regulatory T cell development and 
function in thymus as well as in periphery [72, 73, 118].  
The detailed mechanism for tTreg development is still unknown. However, there is 
evidence that T cells in the thymus enter the Treg lineage upon self-antigen 
recognition, e.g. there are studies observing an enrichment of FoxP3+ T cells in 
polyclonal thymocytes bearing superantigen-reactive TCRs [119, 120]. The current 
consensus concerning thymic T cell selection processes suggest, that a TCR – peptide 
presenting MHC interaction of intermediate strength results in positive selection of T 
cells whereas very strong signals would lead to negative selection. However, it is 
under debate what kind of signal determines signal strength. According to the affinity 
model, the affinity of a single TCR – peptide loaded MHC interaction, i.e. the quality 
of this interaction, determines the outcome of selection [34, 36]. However, several 
studies indicate that avidity might play a major role in thymic selection. Avidity takes 
all single TCR interactions into account and therefore quantity has higher priority 
then high quality signals derived from single interactions [121, 122]. There is 
evidence from in vitro [123] and in vivo [124] studies, that the number of developing 
Treg cells correlate inversely with the amount of antigen presented in the thymus. In 
contrast, increasing the antigen dose results in a higher incidence of concomitant 
negative selection [125]. Klein and associates very elegantly produced evidence for 
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the important role of avidity in Treg development. In AIRE-HA x TCR-HA double 
transgenic mice, the HA antigen is specifically expressed and presented by mTEC. 
This experimental set-up results in the deletion of about two thirds of HA-specific 
thymocytes, whereas a substantial fraction of the remaining cells differentiates into 
the Treg lineage [37]. In this system, MHC II was knocked-down through an RNAi 
approach. The decrease in HA presentation was shown to lead to a lower incidence of 
negative selection, but to an increase in Treg differentiation [38]. Altogether, these 
studies indicate that intermediate avidities favor Treg differentiation over negative 
selection [126]. Furthermore, developing tTreg seem to be more resistant to apoptosis, 
since CD27–CD70 co-stimulation in the thymus was shown to rescue those cells from 
negative selection and thereby promotes tTreg generation [127]. 
pTreg are naïve CD4+ T cells that in the periphery get committed to the Treg lineage. 
It is very likely, that converted Treg cells recognize a different set of antigens that 
cannot be displayed in the thymus, e.g. environmental or food antigens. Several 
studies support the hypothesis of distinct TCR specifities of pTreg [128, 129]. As for 
tTreg generation in the thymus, high affinity recognition of the respective antigen 
seems to be important for pTreg induction. It could be observed that transgenic T cells 
stimulated with cognate rare high-affinity antigen promoted more efficient FoxP3 
induction compared to low affinity stimulation [130]. Furthermore, there is evidence 
from several in vitro studies that conversion can take place when T cells are 
stimulated suboptimal, i.e. increased CTLA-4 but decreased CD28 signaling, in the 
presence of TGF-β [131-133]. Suboptimal T cell stimulation goes in parallel with a 
noninflammatory environment. In such an environment, chronic systemic 
administration of low-dose foreign antigen, which equals the occurrence of e.g. 
environmental antigens, was shown to induce antigen-specific pTreg in both TCR 
transgenic and polyclonal T cell populations [134-137].  
Although, Treg cells can be of different developmental origin, the main purpose of all 
Treg cells most likely is the same – the suppression of immune response to auto-
antigens and immune regulation. The understanding of the mechanisms of Treg 
suppression is only limited. However, the high expression level of CD25, the α-
subunit of the high affinity IL-2 receptor, suggests that Treg cells might deprive 
effector T cells of IL-2. Lack of IL-2 will inhibit effector T cell proliferation and thus, 
will hinder an immune response [138]. Several other mechanisms mediating T cell 
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tolerance are proposed. CTLA-4 mediated suppression [139, 140], induction of IL-10 
and TGF-β production by DCs [141] or expression of immunosuppressive cytokines 
by Treg (e.g. IL-10, IL-35, TGF-β; reviewed in [142, 143]) are only few of the 
suggested mechanisms reviewed by Rudensky and colleagues [144]. 
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Abstract 
 
Cytokines are essential regulators of hematopoiesis, acting in an instructive or permissive way. 
Fms-like tyrosine kinase 3 ligand (FLT3L) is an important cytokine for the development of 
several hematopoietic populations, such as dendritic cells, B cells, regulatory T cells and natural 
killer cells. The FLT3L receptor (FLT3) is expressed on both myeloid and lymphoid progenitors 
and deletion of either the receptor or its ligand leads to defective developmental potential of 
hematopoietic progenitors. In vivo administration of FLT3L promotes expansion of progenitors 
with combined myeloid and lymphoid potential. To investigate further the role of FLT3L in 
hematopoietic development, we generated transgenic mice expressing high levels of human 
FLT3L. FLT3L transgenic mice displayed a dramatic expansion of dendritic and myeloid cells, 
leading to splenomegaly and blood leukocytosis. Bone marrow myeloid and lymphoid 
progenitors were significantly increased in numbers but retained their developmental potential. 
Furthermore, transgenic mice developed anemia together with a reduction in platelet numbers. 
FLT3L was shown to rapidly reduce erythrocyte numbers when injected into wild-type mice, 
indicating a direct negative role of the cytokine on erythropoiesis. We conclude that FLT3L acts 
on multipotent progenitors in an instructive way, inducing their development into 
myeloid/lymphoid lineages while suppressing their megakaryocyte/erythrocyte potential.  
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Introduction 
 
The development of hematopoietic cells is a highly complex and tightly regulated process 
that in adults is initiated in the bone marrow (BM) from hematopoietic stem cells (HSC) and 
continues throughout life. All hematopoietic lineages are derived via intermediate multi-potent 
progenitors, which gradually lose their multi-potentiality and eventually become committed to 
one lineage. Several molecules are considered pivotal for the regulation of this process, including 
transcription factors, signaling proteins, adhesion molecules and cytokine receptors. Cytokines 
impart environmental signals into hematopoietic development and several of them have been 
identified as crucial for the generation of different hematopoietic lineages.(1) The role of 
cytokines in hematopoiesis is considered to be either instructive, by directly promoting 
differentiation of multi-potent progenitors into a specific lineage, or permissive, by selectively 
promoting the survival and/or proliferation of a particular lineage at the expense of others.(2) For 
most hematopoietic cytokines, their precise mode of action remains unknown. 
 As for other type III receptor tyrosine kinases, the Fms-like tyrosine kinase 3 (FLT3), or 
CD135, has an extracellular domain composed of 5 immunoglobulin-like domains and a tyrosine 
kinase motif in the cytoplasmic domain.(3-5) These features of FLT3 are shared with other 
hematopoietic cytokine receptors, such as Stem Cell Factor (SCF) receptor and platelet-derived 
growth factor (PDGF) receptor.(3) FLT3-Ligand (FLT3L) is the only known ligand for FLT3.(6) 
Both the soluble and the membrane bound form of FLT3L can bind FLT3, leading to receptor 
dimerization and subsequent activation of the tyrosine kinase domain.(7) Receptor activation 
initiates a signaling cascade involving proteins such as STAT5a, ERK1/2 and PI3K.(8)  
 FLT3 and its ligand have been the focus of considerable research due to their implication 
in leukemias, since several mutations in FLT3 have been identified in Acute Myeloid Leukemia 
(AML).(7) Amongst them, the most common is an internal tandem duplication of exon 14 of the 
FLT3 gene (FLT3-ITD) that results in constitutive activation of the kinase domain.(9) This 
mutation is found in ~25% of AML and its presence constitutes a poor prognostic factor. FLT3-
ITD confers growth factor-independent proliferation to leukemic cell lines and its expression in 
transgenic mice results in a fatal myeloproliferative syndrome.(10) 
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 FLT3 is expressed by several hematopoietic cell populations.(11) Initially, it is expressed 
by non-self-renewing, short-term HSC.(12, 13) Several downstream progenitors with myeloid 
and/or lymphoid potential continue to express FLT3 whereas megakaryocyte/erythrocyte 
progenitors do not.(11, 14-18) With the exception of dendritic cells (DC), which retain FLT3 on 
their surface, FLT3 expression is down-regulated as cells undergo myeloid or lymphoid 
commitment. Deletion of either FLT3 or FLT3L resulted in defects in the developmental 
potential of myeloid/lymphoid progenitors underscoring the importance of FLT3 in their 
development.(19, 20) In addition, FLT3L deficient mice displayed reduced numbers of B cells, 
DC and Natural Killer (NK) cells(20), while FLT3L has been shown crucial in sustaining adult B 
lymphopoiesis.(21) Interestingly, ablation of the FLT3/FLT3L axis alone did not result in a 
complete block in the generation of any hematopoietic lineage, suggesting that FLT3L might 
exert its crucial role in hematopoiesis through interactions with other cytokines, such as 
Inteleukin-7 (IL-7) or SCF.(19, 22, 23) 
 To elucidate the specific action of FLT3L on hematopoiesis in vivo, administration of 
FLT3L has been carried out. Results obtained confirmed the important role of FLT3L in DC 
generation.(24) We have previously shown that apart from DC, FLT3L injection leads to 
transient expansion of a FLT3+ progenitor population with lymphoid and myeloid potential.(25) 
In order to evaluate the role of FLT3L on the development of different hematopoietic lineages, 
we describe herein the effects of sustained over-expression of FLT3L in a transgenic mouse 
model. Our study confirms the positive role of FLTL in DC development and highlights the 
importance of this cytokine in the survival and expansion of lymphoid and myeloid progenitors. 
Furthermore, our data provide evidence for an instructive role of FLT3L in hematopoietic 
development. 
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Methods 
  
Mice 
All mice used herein were bred and maintained in our animal facility under pathogen free 
conditions and all animal experiments were performed within institutional guidelines (permission 
nos. 1887 and 1888). Immunizations to induce a T-dependent antibody response and FLT3L 
treatment of mice were carried out as previously described.(25)  
 
Cell cultures 
ST2, OP9 and OP9 stromal cells expressing the Notch ligand Delta-like 1 (OP9DL1) were 
maintained in IMDM supplemented with 5 x 10-5M β-mercaptoethanol, 1mM glutamine, 0.03% 
w/v Primatone (Quest Naarden, The Netherlands), 100U/mL Penicillin, 100 μg/mL Streptomycin 
and 5% fetal bovine serum. Co-cultures of stromal cells with sorted progenitor cells were 
performed as previously described.(25) and Suppl. Materials and Methods. 
 
Platelet counts 
Blood was drawn from the tail vein of mice and incubated with 1% ammonium oxalate for 10 
minutes at room temperature. Following incubation, live cells were counted in a Neubauer 
hemocytometer. 
 
Immunofluorescence 
Spleens were snap frozen and embedded in OCT-compound (Sakura, Zoetermeer, NL), and 5 μm 
sections were prepared. Sections were fixed in acetone for 10 min, air dried for 60 min and 
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subsequently stained with FITC-labeled anti-CD90, PE-labeled anti-IgM and APC-labeled anti-
CD11c antibodies for 30 minutes.  
 
 
Results 
 
Splenomegaly and lymphadenopathy in FLT3L transgenic mice. 
To investigate the effect of prolonged FLT3L over-expression, we generated mice 
expressing the human FLT3L gene under the control of the β-actin promoter (hereafter FLT3L-
Tg mice). FLT3L levels in the blood were at the range of 500-1000 ng/ml, as assesed by ELISA 
using an anti-hFLT3L antibody developed in our laboratory (data not shown). FLT3L-Tg mice 
were viable, fertile with no apparent signs of disease until the age of 2-3 months, when many 
developed diarrhea and tail necrosis. Examination of internal organs revealed a striking increase 
in spleen size. Indeed, total spleen cellularity in 8-14 week old FLT3L-Tg mice was 451 ± 127 x 
106 cells compared to 71 ± 12 x 106 cells in wild-type (WT) littermate controls, representing a 
6.3-fold increase in total cell number (Figure 1A). Splenic architecture was disrupted with no 
clearly formed T-cell follicles and a dramatic increase in CD11c+ dendritic cells (DC) (Figure 
1B). Analysis of axillary, brachial and inguinal lymph node cellularity demonstrated an increase 
from 23 ± 2.6 x 106 cells in WT to 69.6 ± 3.5 x 106 cells in FLT3L-Tg mice (Figure 1A). Thymus 
cellularity and CD4+/CD8+ T cell subpopulations did not show any difference between WT and 
FLT3L-Tg mice (data not shown). 
 
Increased FLT3L availability leads to alterations in the numbers of dendritic cells and B 
cells in the bone marrow. 
Bone marrow cellularity (2 femurs and 2 tibias) was increased from 40 ± 7.7 x 106 cells 
in WT to 73.8 ± 14.5 x 106 cells in FLT3L-Tg mice (Figure 1A). Further analysis of BM myeloid 
and lymphoid populations revealed no significant change in the numbers of GR1+CD11b+ 
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myeloid cells (data not shown). Staining for CD19+ B cell progenitors revealed no change in the 
earliest B cell committed CD19+CD117+ preB1 population but a dramatic 12-fold (from 7 ± 2 x 
106 in WT to 0.6 ± 0.3 x 106 cells in FLT3L-Tg) and 144-fold (from 8.3 ± 2.2 x 106 in WT to 
0.06 ± 0.09 x 106 in FLT3L-Tg) decrease in CD19+CD117-IgM- preB2 and CD19+IgM+ B cells, 
respectively (Figure 1C).  The apparent increase in total BM cellularity in FLT3L-Tg mice was 
partly due to a marked increase in DC populations. As shown in Figure 1D, CD11c+SiglecH+ 
plasmacytoid DC (pDC) showed a 41-fold increase (from 0.74 ± 0.15 x 106 in WT to 30 ± 8.8 x 
106 in FLT3L-Tg), while CD11c+SiglecH- conventional DC (cDC) numbers were increased 13-
fold (from 0.3 ± 0.06 x 106 in WT to 2.5 ± 1.2 x 106 in FLT3L-Tg). Overall, analysis of the 
FLT3L-Tg BM lymphoid and myeloid populations revealed decreased numbers of B cell 
progenitors and a significant increase in DC numbers.  
 
Diminished megakaryocyte/erythrocyte lineage differentiation, anemia and leukocytosis in 
FLT3L-Tg mice. 
Alterations in BM erythroid progenitors in FLT3L-Tg mice were also investigated 
revealing a significant 5.4-fold decrease in TER119+ erythroid progenitor numbers, from 2.7 ± 
0.2 x 106 cells in WT to 0.5 ± 0.2 x 106 cells in FLT3L-Tg mice (Figure 2A). This decrease in 
TER119+ erythroid progenitors prompted us to analyze the development of 
megakaryocyte/erythrocyte lineage in FLT3L-Tg mice. Hematocrit analysis showed that FLT3L-
Tg mice manifested a significant decrease in hematocrit (from 46.4 ± 2 in WT to 34 ± 3 in 
transgenics) already at 8-10 weeks of age, which dropped even further to 21.6 ± 5.9 at 19-22 
weeks of age (Figure 2B). Blood platelet counts also showed a significant drop, from 400 ± 89 x 
108 cells/ml in WT to 207.5 ± 61 x 108 cells/ml in FLT3L-Tg mice (Figure 2C). Thus, 
megakaryocyte/erythrocyte lineage development seemed to be diminished, leading to anemia in 
FLT3L-Tg mice. Finally, blood smear preparations showed a marked increase in the numbers of 
leukocytes in FLT3L-Tg blood compared to WT (Figure 2D), which was confirmed by a 
quantitative analysis demonstrating a 27-fold increase in numbers of leukocytes in FLT3L-Tg 
blood (Suppl. Figure 1).  
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Expansion of myeloid and lymphoid populations in spleens of FLT3L-Tg mice. 
Due to the observed splenomegaly we extended the analysis to mature hematopoietic populations 
in the spleen. Contrary to BM, the spleen of FLT3L-Tg mice displayed a significant (15-fold) 
increase of GR1+CD11b+ myeloid cells from 1.9 ± 0.7 x 106 cells in WT to 30.1 ± 7.6 x 106 cells 
in transgenics (Figure 3A). NK1.1+ natural killer (NK) cells were also significantly increased 
from 2.7 ± 0.8 x 106 in WT to 23 ± 6.3 x 106 (Figure 3A). A detailed analysis of DC subsets in 
the spleen of FLT3L-Tg mice showed a dramatic increase in DC numbers, reaching 368-fold for 
CD11c+SiglecH+ pDC (95.8 ± 26 x 106 versus 0.26 ± 0.06 x 106 in WT), 208-fold for 
CD11c+CD11b+ cDC (91.7 ± 25 x 106 versus 0.44 ± 0.29 x 106 in WT) and 161-fold for 
CD11c+CD8α+ cDC (21.6 ± 7.2 x 106 versus 0.13 ± 0.05 x 106 in WT) (Figures 3 B, D). These 
expanded DC populations in our FLT3L-Tg mice were shown to be functional (Suppl. Figure 2). 
We conclude from this data that the massive expansion of myeloid, NK and, mainly, DC 
populations accounts for the splenomegaly observed in FLT3L-Tg mice.  
 The apparent reduction in BM B lymphopoiesis was not reflected in a reduction of 
CD19+IgM+ mature B cell numbers in the spleens of FLT3L-Tg mice (Figure 3C). In contrast, 
despite the similarity in thymus cellularity, there was nevertheless a 3.2-fold increase (from 11.5 
± 4.3 x 106 in WT to 37.4 ± 19 x 106 cells in FLT3L-Tg) in splenic CD4+ T cells (Figure 3C). The 
increase in CD8+ T cell number was smaller (2.4-fold); from 7.8 ± 2.8 x 106 cells in WT to 18.9 
± 8.4 x 106 cells in FLT3L-Tg mice.  Using intracellular FACS staining, a 7.4-fold increase in 
Foxp3+CD4+ regulatory T cells (Tregs) (from 1.36 ± 0.2 x 106 in WT to 10.14 ± 1.3 x 106 in 
FLT3L-Tg), was also detected in the spleen of FLT3L-Tg mice (Figure 3C), as shown previously 
by in vivo FLT3L injection.(26) 
 The abnormal splenic architecture and alterations in some T cell numbers motivated us to 
test the quality of immune response in FLT3L-Tg. Thus, transgenic and WT control littermates 
were immunized with NIP protein and the levels of serum anti-NIP IgG antibodies were 
quantified 13 days later by ELISA. Anti-NIP IgG responses were somewhat weaker in FLT3L-
Tg mice compared to WT, even though a significant increase in IgG titers was still observed 
after immunization (Suppl. Figure 3). Interestingly, pre-immune serum of FLT3L-Tg mice 
contained slightly higher IgG immunoglobulin levels than that of controls.  
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Expansion of hematopoietic progenitors in the BM of FLT3L-Tg mice. 
 Increased availability of FLT3-ligand was previously shown to expand DC populations 
and increase numbers of an FLT3+ progenitor population named Early Progenitor with Lymphoid 
and Myeloid potential (EPLM).(25) In addition to EPLM, other lymphoid and myeloid 
progenitor populations such as LMPP (Lymphoid-primed Multipotent Progenitor 
Population),(27) CLP (Common Lymphoid Progenitors)(28) and CMP (Common Myeloid 
Progenitors)(29) are known to be FLT3+. To assess the potential effects of constitutive FLT3L 
over-expression on these progenitor populations, we analyzed them in the BM of FLT3L-Tg 
mice. Most of the CLP, EPLM and a fraction of myeloid restricted CD117+CD115+Sca1- cells 
were indeed FLT3+, but FLT3 expression was downregulated in FLT3L-Tg mice, presumably 
due to continuous engagement and internalisation of the receptor (Suppl. Figure 4). Therefore, 
we have not used FLT3 as a marker in our analysis. As shown previously,(25) upon increased 
FLT3L availability, there was a 14-fold increase in EPLM (CD117+B220lowCD19/NK1.1-) 
numbers from 0.2 ± 0.1 x 106 cells in WT to 2.8 ± 0.9 x 106 cells in FLT3L-Tg mice (Figures 4 
A, B). Increases in CLP (CD117+Sca1+CD127+) progenitors were even higher with a 75-fold 
increase from 0.04 ± 0.01 x 106 cells in WT to 3.2 ± 1.3 x 106 cells in FLT3L-Tg mice. While 
staining for CLP, we noted a CD117-CD127+ population that was increased in FLT3L-Tg mice. 
This population could not represent B cell progenitors, since they are reduced in FLT3L-Tg 
mice. Indeed, further analysis revealed these cells were CD11c+SiglecH+ pDC, which had 
expanded 41-fold in FLT3L-Tg mice BM and were all CD127+ (Suppl. Figure 5). 
CD117+CD115+Sca1- myeloid progenitors were also found to be significantly increased in 
FLT3L-Tg mice (from 0.4 ± 0.1 x 106 cells in WT to 5.1 ± 1.4 x 106 in FLT3L-Tg). The Lineage-
Sca1+CD117+ (LSK) fraction, which is to a large extent FLT3+ (Suppl. Figure 4), was also 
significantly increased in FLT3L-Tg mice (Figures 4 C, D). LSK cells contain FLT3- LT-HSC 
and FLT3+ ST-HSC and multi-potent progenitors.(12) Due to our inability to stain for FLT3 in 
FLT3L-Tg mice, we stained LSK cells with CD150 instead, which marks a population highly 
enriched in HSC.(30) Even though percentage wise they were reduced, no significant change 
was detected in absolute numbers of CD150+LSK cells in FLT3L-Tg mice (Suppl. Figure 6). 
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 The anemia and reduction in TER119+ erythroid progenitors and platelets prompted us to 
investigate the earliest identified megakaryocyte/erythroid progenitors. Staining the 
CD117+Sca1-CD127- fraction of BM with CD34 and CD16 allows the identification of Common 
Myeloid Progenitors (CMP), as well as progenitors with restricted Granulocyte-Macrophage 
(GMP) and Megakaryocyte-Erythrocyte (MEP) potential.(29, 31) We found a dramatic 9.7-fold 
decrease in numbers of MEPs in FLT3L-Tg mice compared to WT, as well as a significant 5.2-
fold increase in GMPs (Figures 4 C, D). These results indicate that increased FLT3L levels skew 
development towards the myeloid/lymphoid and away from the megakaryocyte/erythroid 
pathway and that this skewing occurs already at the level of FLT3+ multipotent progenitors. 
 Next, we determined whether the expansion of lymphoid and myeloid progenitors in 
FLT3L-Tg mice was accompanied by a change in their developmental potential. Therefore, 
EPLM, CLP and CD117+CD115+Sca1- cells were sorted from WT or FLT3L-Tg mice and plated 
in 96-well plates under differentiation conditions promoting myeloid (ST2 stromal cells), B-cell 
(OP9 stromal cells plus IL-7) and T-cell (OP9DL1 stromal cells plus IL-7) development. As 
shown in Table 1, our in vitro differentiation analysis showed no significant change in the 
developmental potential of the analyzed progenitor populations. To assess the in vivo potential of 
progenitors, CLP were sorted from FLT3L-Tg mice and transplanted into Rag2-/-γc-/- recipients. 
After 3 weeks, CLP from FTL3L-Tg demonstrated robust B and T cell reconstitution potential 
(Suppl. Figure 7). Transplantation of CD45.2  FLT3L-Tg EPLM into CD45.1 congenic mice 
revealed their combined lymphoid and myeloid potential (Suppl. Figure 8), as shown before for 
WT EPLM.(32) Finally, transplantation of FLT3L-Tg LSK in a similar setting demonstrated 
their potent myeloid reconstitution potential but a reduced erythroid potential compared to WT 
LSK (Suppl. Figure 9). We conclude that the lymphoid and myeloid potential of FLT3L-Tg 
progenitors is retained, while their erythroid potential is reduced.  
 
Kinetics of hematopoietic population changes suggest an instructive role of FLT3L in 
hematopoiesis. 
The observed alterations in hematopoietic populations in FLT3L-Tg mice could be the 
consequence of a direct, “instructive”, action of FLT3L on multi-potent progenitors, actively 
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guiding them to acquire a particular cell fate at the expense of other options (“instructive” 
model). Alternatively, over-expression of FLT3L could result in a vast expansion of FLT3+ cells 
which could leave little space and/or recourses for non-expanding cells, thus leading to a 
reduction in their numbers (“space” model). In a system with sustained elevated levels of FLT3L 
it would be difficult to distinguish between the two possibilities. To acquire data supportive of 
either model, we injected WT mice with recombinant FLT3L and monitored kinetic changes in 
numbers of different hematopoietic lineages. As shown in Figures 5 A and B, and in accordance 
with the anemic phenotype of FLT3L-Tg mice, the percent nucleated BM MEP and TER119+ 
erythroid progenitors showed a reduction by 3 days post FLT3L injection, which was already 
significant in the case of MEP. Considering the turnover of TER119+ erythroid progenitors, the 
speed by which increased FLT3L availability leads to MEP and TER119+ progenitor reduction 
would argue for an instructive, negative, role of FLT3L in their generation. 
 In addition, we quantified the percentages of other hematopoietic cells whose numbers 
were significantly altered in FLT3L-Tg mice, namely pDC and CD19+ B cell progenitors. 
Plasmacytoid DC seemed to also increase, demonstrating a 2.6-fold increase at 5 days after 
FLT3L injection and reaching a 5.8-fold increase at day 7 (Figure 5B). This would be consistent 
with a role of FLT3L in expansion of these FLT3+ cells, shown previously.(24, 25) 
CD19+CD117+ preB1 cells showed little reduction; rather an up to 2-fold increase in their 
percentage was observed at day 7 (Figure 5C). On the contrary, and in accordance with our 
FTL3L-Tg analysis, both CD19+CD117-IgM- preB2 and CD19+IgM+ B cells were reduced after 
FLT3L injection, becoming significant after 5 days (Figure 5 D-E). Overall, our FLT3L injection 
data would point towards an instructive role of FLT3L in development of certain hematopoietic 
lineages. 
 
 
Discussion 
 
Several lines of evidence point towards an important role of FLT3/FLT3L in 
hematopoiesis. The relatively mild phenotype of both FLT3 and FLT3L knock-out mice would 
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suggest that this cytokine exerts its role mainly in concert with other hematopoietic cytokines, 
such as Stem Cell Factor (SCF) or Interleukin-7 (IL-7).(19, 22) Administration of FLT3L to 
adult mice in vivo has been used as a means of elucidating its exact role in regulating 
hematopoiesis.(24, 25) In the present study we report for the first time a detailed in vivo analysis 
of the effect of elevated and sustained transgenic expression of FLT3L in different hematopoietic 
lineages. Our results suggest an instructive role of FLT3L in hematopoietic development. 
Analysis of FLT3L-Tg mice showed significant alterations in several hematopoietic 
lineages. The population with the highest increase was DC. Both in BM and spleen, all DC 
populations displayed a dramatic expansion ranging from 7- to 368-fold compared to WT mice. 
Previously, FLT3L was shown to be a crucial factor for the in vitro generation of DC,(33) 
whereas in vivo, absence of FLT3L resulted in a marked decrease in DC numbers.(20) Increases 
in DC were also noted in studies where either FLT3L was administered in vivo(24, 25) or when 
FLT3L was conditionally over-expressed by transgenesis.(34) The importance of FLT3L in DC 
generation has been shown for cDC and pDC, both of which are FLT3+ populations. Our results 
are in accordance with these observations. Particularly striking was the elevated numbers of 
pDC, the population most increased in our transgenic mice. Plasmacytoid DC are considered an 
important part of anti-viral immunity, mainly through their production of IFN-α.(35) The 
dramatic increase of IFN-α producing pDC upon sustained over-expression of FLT3L suggests a 
potential therapeutic use of this cytokine to combat chronic viral infections. Furthermore, our 
transgenic system constitutes a source for the ex vivo isolation of vast numbers of functional DC 
populations. 
 A significant reduction in CD19+CD117-IgM- preB2 and CD19+IgM+ B cell populations 
was noted in the BM of FLT3L-Tg mice. This phenotype was somewhat surprising, considering 
the decreased numbers of B cell progenitors in mice deficient in functional FLT3 or FLT3L, 
results that had suggested a positive role of FLT3L in B cell development.(19, 20, 36) 
Furthermore, coincident with CD19 expression and due to repression by PAX5, FLT3 is down-
regulated in B cell progenitors,(37) thereby excluding the possibility that FLT3L is necessary for 
the survival of CD19+ cells. Moreover, there was no evidence for reduced B cell potential among 
CLP and EPLM from FLT3L-Tg mice in which there were normal numbers of the earliest 
committed CD19+CD117+ preB1 cells. We consider decreased IL-7 availability the most likely 
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explanation for this apparent reduction in BM CD19+ cells. There was a dramatic increase in 
IL7Rα+ (CD127+) lymphoid progenitors, such as CLP (76-fold) and EPLM (14-fold) in FLT3L-
Tg mice. Furthermore, pDC, which we found to be IL7Rα+, were also increased (41-fold). 
Hence, there is an enormous expansion of IL7Rα+ cells in FLT3L-Tg mouse BM which, by 
absorbing IL-7, could lead to reduced levels of available IL-7 necessary for CD19+ cell survival 
and/or proliferation. As a population, preB2 cells are particularly sensitive to IL-7 availability, 
while the reduced numbers of IgM+ B cells might reflect the reduced input from the preB2 stage. 
To test this hypothesis we injected FLT3L-Tg mice with IL-7/anti-IL-7 complexes(38) and were 
able to increase preB2 and B cell percentages almost to WT levels (Suppl. Figure 10). Despite 
the reduction in BM preB2 and B cells, FLT3L-Tg BM output seemed sufficient to reconstitute 
the splenic B cell compartment. Overall, we believe that the diminished numbers of BM CD19+ 
B cell progenitors in FLT3L-Tg mice is a secondary effect, caused by the decreased availability 
of IL-7 rather than a negative role of FLT3L in B cell development and survival. 
 In the BM of FLT3L-Tg, numbers of FLT3+ lymphoid and myeloid progenitors were 
dramatically increased. In a previous study, EPLM were also increased following administration 
of FLT3L in vivo, while their B lineage potential in limiting dilution assays was decreased.(25) 
Despite their expansion in our FLT3L-Tg mice, the B, T and myeloid lineage potential of EPLM 
was unaltered. This apparent difference to the in vivo administration data could be due to the 
sustained elevated levels of FLT3L in FLT3L-Tg mice. This dramatic expansion without any 
apparent alteration in the developmental potential of lympho-myeloid progenitors analyzed 
would indicate a role of FLT3/FLT3L signaling in their survival and/or proliferation, rather than 
in instructing them towards a particular downstream lineage fate. In addition, elevated FLT3L 
levels could enhance the generation of these FLT3+ progenitors from HSC. Given the very small 
numbers of CMP, CLP and EPLM in a WT BM, our FLT3L-Tg mice provide an excellent mouse 
model for the isolation of these progenitors in large numbers for further in vitro, in vivo or 
molecular biology analyses.  
Strikingly, FLT3L-Tg mice became severely anemic a few months after birth. Both 
platelets and erythrocytes were diminished in these mice, suggesting a defect in the generation of 
the megakaryocyte/erythrocyte lineage. One explanation for this phenotype could be that the 
dramatic expansion of several other cell types in FLT3L-Tg mice would lead to a reduction of 
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FLT3- megakaryocyte/erythrocyte progenitors due to competition for space and/or resources. 
Nevertheless, the dramatic reduction in MEP in FLT3L-Tg mice and their rapid decrease 
following FLT3L treatment argues for a defect in their development rather than having no space 
to expand. This developmental defect would in turn suggest that erythrocytes originate from an 
FLT3L-responsive population that can be induced by FLT3 signaling to develop into lympho-
myeloid lineages at the expense of the erythroid lineage. Based on our data, we propose that 
FLT3+ non self-renewing HSC that receive sufficient FLT3L signal differentiate to lympho-
myeloid progenitors, while HSC that do not activate FLT3 signaling, due to either low FLT3 
expression and/or low FLT3L levels in their microenvironment, develop into megakaryocyte-
erythrocyte progenitors (Figure 6). Increased FLT3L availability would result in very few, if any, 
FLT3+ HSC not receiving an adequate FLT3L signal, thus leading to decreased 
megakaryocyte/erythrocyte developmental input and increased lymphoid-myeloid progenitor 
compartment, as is the case in our FLT3L-Tg mice. Our data strengthen the suggested 
importance of FLT3 signaling in promoting lympho-myeloid versus megakaryocyte-erythroid 
lineage development(27) and provide evidence for an instructive role of FLT3L in this process. 
Furthermore, they are in accordance with recent data demonstrating that platelets and 
erythrocytes originate from Flt3-expressing progenitors.(39-41) 
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Tables 
 
Table 1. 
In vitro developmental potential of CD117+CD115+Sca1-, CLP and EPLM populations from 
wild type and FLT3L-Tg mice. 
 B cell potential T cell potential Myeloid potential 
CD117+CD115+ 
Sca1- 
WT <1 in 120 1 in 76 1 in 3 
TG <1 in 120 1 in 42 1 in 2 
CLP WT 1 in 10 1 in 15 1 in 12 TG  1 in 5 1 in 3 1 in 5 
EPLM WT 1 in 5 1 in 10 1 in 16 TG  1 in 10 1 in 3 1 in 6 
 
Frequencies of progenitors with B cell, T cell and myeloid cell potential as assessed by in vitro 
limiting dilution analysis. One representative experiment is shown out of 3-6 for the different 
populations. CLP: Common Lymphoid Progenitor, EPLM: Early Progenitors with Lymphoid and 
Myeloid potential, WT: wild-type, TG: FLT3L transgenics. 
 
 
Figure1. Splenomegaly, lymphadenopathy and disrupted spleen architecture in FLT3L-Tg mice.
A. Total cellularity in spleen, lymph nodes (axillary, brachial and inguinal) and bone marrow (2 femurs and 2 
tibias) of 8-14 week old wild type (WT - white symbols) and FLT3L-Tg (black symbols) mice (5-7 mice per 
group). ***: P<0.0001. B. Immunofluorescence of spleen sections from 8-14 week old WT and FLT3L-Tg 
mice stained for B cells (anti-IgM, red), T cells (anti-CD90, green) and dendritic cells (anti-CD11c, blue). C. 
Numbers of CD19+CD117+ (preB1), CD19+CD117-IgM- (preB2) and CD19+IgM+ (B) B cells in WT 
(white symbols) and FLT3L-Tg (black symbols) mice (5-7 mice per group). ***: P<0.0001. D. CD11c+Si-
glecH+ plasmacytoid (pDC) and CD11c+SiglecH- conventional (cDC) dendritic cell numbers in WT (white 
symbols) and FLT3L-Tg (black symbols) mice (5-7 mice per group). ***: P<0.0001, **: P=0.0022.
Figure 2. Diminished megakaryocyte/erythrocyte lineage development, anemia and leukocytosis in FLT3L-Tg 
mice.
A. Numbers of TER119+ erythroid progenitors in the bone marrow (2 femurs and 2 tibias) of 8-14 week old WT 
(white circles) and FLT3L-Tg (black circles) mice (5-7 mice per group). ***: P<0.0001. B. Hematocrit levels in 
WT (white bars) and FLT3L-Tg (black bars) mice (5-7 mice per group). ***: P<0.0001. C. Numbers of platelets 
in the blood of WT (white circles) and FLT3L-Tg (black circles) mice (9-12 mice per group). ***: P<0.0001. D. 
Hematoxylin-eosin staining of blood smears from WT and FLT3L-Tg mice (40x magnification).
Figure 3. Alterations in myeloid, lymphoid and dendritic cell populations in the spleens of FLT3L-Tg mice.
A. Numbers of CD11b+GR1+ myeloid and NK1.1+ NK cells in spleens of 8-14 week old WT (white symbols) 
and FLT3L-Tg (black symbols) mice (5 or 6 mice per group). ***: P<0.0001. B. Numbers of CD11c+SiglecH+ 
plasmacytoid DC (pDC), CD11c+CD11b+ conventional DC (CD11b) and CD11c+CD8α+ conventional DC 
(CD8α) in spleens of WT (white symbols) and FLT3L-Tg (black symbols) mice (5 or 6 mice per group). ***: 
P<0.0001. C. Numbers of CD19+IgM+ B cells, CD4+ T cells, CD8+ T cells and Foxp3+CD4+ regulatory T cells 
(Tregs) in the spleens of WT (white symbols) and FLT3L-Tg (black symbols) mice (5 or 6 mice per group). 
*(CD4): P=0.149, *(CD8): P=0.0192, ***: P<0.0001. D. FACS plots showing the gating strategy used for stain-
ing the DC subpopulations included in B.
Figure 4. Hematopoietic progenitor populations in FLT3L-Tg mice.
Figure depicts numbers (B and D) and FACS stainings (A and C) of hematopoietic progenitor populations in the 
bone marrow (2 femurs and 2 tibias) of 8-14 week old mice. A. Representative FACS plots demonstrating the 
gating strategy used for staining CD117+CD115+Sca1- (upper panel), CLP (middle panel) and EPLM (lower 
panel) in WT and FLT3L-Tg bone marrows. B. Total numbers of CD117+CD115+Sca1-, CLP and EPLM in the 
bone marrow of WT (white symbols) and FLT3L-Tg (black symbols) mice (5-7 mice per group). ***: P<0.0001. 
C. Representative FACS plots demonstrating the gating strategy used for staining LSK (left panel) and MEP, 
CMP, GMP (centre and right panel) in WT and FLT3L-Tg bone marrows. D. Total numbers of LSK, MEP, CMP 
and GMP in the bone marrow of WT (white symbols) and FLT3L-Tg (black symbols) mice (MEP, CMP, GMP: 
6 mice per group; LSK: 10 mice per group). 
Figure 5. Kinetics of changes in percentages of hematopoietic populations following FLT3L injections into wild 
type mice.
Figure shows percentages of hematopoietic cells in the BM of WT mice injected with 10 μg of recombinant 
FLT3L 0, 3, 5 and 7 days after injection. A. Percentages of MEP. B. Percentages of nucleated TER119+ bone 
marrow cells. **: P=0.01, ***: P=0.0001. C. Percentages of CD11c+SiglecH+ plasmacytoid dendritic cells. *: 
P=0.0345, **: P=0.0007, ***: P<0.0001. D. Percentages of CD19+CD117+ preB1 cells. *(Day 5): P=0.0368, 
*(Day 7): P=0.0163. E. Percentages of CD19+CD117-IgM- preB2 cells. **: P=0.0049, ***: P=0.0001. F. 
Percentages of CD19+IgM+ B cells. ***(Day 5): P=0.0005, ***(Day 7): P=0.0002.
Figure 6. Proposed model for the instructive action of FLT3L in determining lymphoid/myeloid versus 
megakaryocyte/erythrocyte lineage development.
  
Supplementary Figure 1 
Leukocytosis in FLT3L-Tg blood. 
Blood was drawn from the tails of 8-14 week old WT (white circles) and FLT3L-Tg 
(black circles) mice. Following 5 minute incubation with NH4Cl to lyse erythrocytes, 
live white blood cells were counted in a Neubauer hemocytometer. ***: P<0.0001 
 
 
 
 
  
 
 
 
Supplementary Figure 2 
Functional analysis of FLT3L-Tg DC subsets 
A. CD11c+SiglecH+ pDC were sorted from FLT3L-Tg spleens and stimulated with 
increasing amounts of CpG for 24 hours. Following stimulation, supernatants were 
collected and the amount of IFN-α produced was quantified using the Mouse IFN-
alpha Platinum ELISA (eBioscience) according to manufacturer’s instructions. B. 
CD11c+CD11b+ cDC were sorted from spleens of FLT3L-Tg mice [(C57BL/6 x 
DBA/2)F1, herein named BDF1] and incubated with lymph node (LN) cells from WT 
C57BL/6 mice, as a source of T cells, for 5 days. Following incubation, proliferation 
of LN cells was quantified by measuring 3[H]-Thymidine incorporation. As a negative 
control, spleen cells from WT C57BL/6 were incubated with WT C57BL/6 LN cells 
(B6), while incubation of WT BDF1 spleen cells with WT C57BL/6 LN cells was 
used as a positive control for T cell proliferation (BDF1). 
 
  
 
 
 
 
Supplementary Figure 3 
IgG anti-NIP titers of FLT3L-Tg sera after immunization. 
Levels of anti-NIP IgG as assessed by ELISA analysis in the blood of WT (white 
symbols) and FLT3L-Tg (black symbols) mice before (circles) and 13 days after 
(squares) immunization with NIP 
  
Supplementary Figure 4 
FLT3 expression in WT and FLT3-Tg hematopoietic progenitors. 
FACS stainings of hematopoietic progenitor populations in WT (red line) and FLT3L-
Tg (blue line) mice. Cells were identified by FACS following the staining strategy 
showed in Figure 4 and additionally stained with an anti-FLT3 biotinylated antibody, 
followed by Streptavidin-PECy7 staining. Grey filled histogram: no anti-FLT3 
antibody. 
 
 
 
  
 
 
 
Supplementary Figure 5 
CD127 expression on FLT3L-Tg pDC 
FACS analysis of CD11c+SiglecH+ pDC from FLT3L-Tg BM incubated with a 
biotinylated anti-CD127 antibody, followed by incubation with PE-labeled 
streptavidin. Thin line histogram: no anti-CD127 antibody, thick line histogram: 
staining with anti-CD127 antibody. 
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Supplementary Figure 6 
CD150+ LSK cells in WT and FLT3L-Tg mice. 
Upper panels: representative FACS plots of CD150+ LSK cells in WT and FLT3L-Tg mice. LSK 
cells were stained as shown in Figure 4 and additionally stained with an anti-CD150-PE 
antibody. Percentages in gates indicate the percentage of CD150+ cells within the corresponding 
LSK population. Lower panel: total numbers of CD150+ LSK cells in WT (white circles) and 
FLT3L-Tg (black circles) mice (6 mice per group). 
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Supplementary Figure 7 
B and T cell potential of FLT3L-Tg CLP. 
CD117+Sca1+CD127+ CLP were sorted from FLT3L-Tg BM and intravenously transplanted into 
irradiated Rag2-/-γc-/- recipients (50.000 CLP per mouse). Analysis of T and B cells was 
performed 3 weeks after transplantation. Figure shows analysis of one representative out of 4 
recipient mice. A. CD4, CD8 and TCRβ staining of Rag2-/-γc-/- thymus. B. CD19, IgM staining 
of Rag2-/-γc-/- BM and spleen. 
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Supplementary Figure 8 
B and myeloid in vivo potential of FLT3L-Tg EPLM 
Thirty thousand EPLM were sorted from CD45.2 FLT3L-Tg BM and intravenously injected into 
congenic CD45.1 recipients together with 3 x 105 unfractionated CD45.1 BM cells, after lethal 
irradiation of the hosts. Spleens were analyzed 4 weeks following transplantation. Upper panel: 
percentage of CD45.2 donor cells in spleen. Lower panels: CD45.2+ CD19+ and GR1+CD11b+ 
cell stainings. 
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Supplementary Figure 9 
Myeloid and erythroid in vivo potential of WT and FLT3L-Tg LSK cells. 
Ten thousand WT and 15,000 FLT3L-Tg LSK cells (CD45.2) were sorted and intravenously 
injected into congenic CD45.1 recipients together with 3 x 105 unfractionated CD45.1 BM cells, 
after lethal irradiation of the hosts. BM were analyzed 7-10 days after transplantation and the 
percentage of the indicated hematopoietic cells within the CD45.2 compartment was calculated. 
For WT LSK 6 mice and for FLT3L-Tg 2 mice were transplanted. Upper-right panel: total 
percentage of CD45.2+ cells at the time of the analysis. *:P= 
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Supplementary Figure 10 
CD19+ cell percentages following IL-7/anti-IL-7 complexes injections in mice 
WT (squares) and FLT3L-Tg mice (circles) were injected with PBS (white symbols) or 15 
µg/mouse IL-7/anti-IL-7 complexes (black symbols) three times with 3-day intervals. BM (2 
femurs and 2 tibias) were analyzed 2 days after the last injection for the percentages of 
CD19+CD117+ (preB1), CD19+CD117-IgM- (preB2) and CD19+IgM+ (B) cells. ***(preB1): 
P=0.0006, ***(preB2): P=0.0001, **: P=0.0014. 
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Supplementary materials and methods 
 
Generation of FLT3L-Tg mice. 
Transgenic mice were initially generated in a C57BL/6 background. We have previously shown 
that in a model of C57BL/6 lymphocyte transplantation into (C57BL/6 x DBA/2)F1 hosts, 
treatment of the hosts with FLT3L provides protection against acute Graft Versus Host 
Disease(1). This prompted us to cross our C57BL/6 FLT3L-Tg mice to DBA/2 mice in order to 
obtain (C57BL/6 x DBA/2)F1 mice with sustained elevated levels of FLT3L. Subsequent 
analysis of both the C57BL/6 and (C57BL/6 x DBA/2)F1 genotypes revealed similar levels of 
FLT3L in their blood and an identical effect of FLT3L over-expression in hematopoietic 
populations (data not shown), with the exception of more profound splenomegaly in (C57BL/6 x 
DBA/2)F1 mice. All the data presented herein are from (C57BL/6 x DBA/2)F1 FLT3L-Tg mice, 
with the exception of certain transplantation experiments (Suppl. Figures 8 and 9) where CD45.2 
C57BL/6 FLT3L-Tg mice were used. 
 
Flow cytometry and cell sorting. 
FITC-, PE-, APC- and biotin-conjugated monoclonal antibodies specific for CD11c, CD11b, 
CD117, CD19, CD127, CD115, CD8α, CD4, SiglecH, GR1, IgM, B220, Sca1, TER119, F4/80, 
CD34, CD16, FLT3, NK1.1, CD45.1 and CD45.2 were purchased from BD Biosciences or e-
Biosciences or were made in our laboratory. Staining, flow cytometry and cell sorting were 
performed as previously described(2, 3).  
 
In vitro limiting dilution assays. 
OP9, OP9DL1 or ST2 stromal cells were plated in 96-well plates one day before the initiation of 
the experiment at 4000 cells per well. At the day of the experiment stromal cells were irradiated 
and subsequently co-cultured with hematopoietic progenitors at different concentrations. 
Cultures have been monitored with inverted microscope for generation of lymphoid or myeloid 
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cell colonies and after 2 (for OP9 cell cultures) or 3 weeks (for OP9DL1 and ST2 cell cultures) 
the total number of wells with no colonies was scored. For each experiment the number of wells 
with no colonies was plotted against the number of hematopoietic progenitors plated and the 
fraction of progenitor cells developing lymphoid or myeloid colonies was estimated. 
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Abbreviations 
DLL1 Notch ligand Delta like 1 
DLL4  Notch ligand Delta like 4  
DN  CD4 and CD8 double negative thymic T cell population 
DP CD4 and CD8 double positive thymic T cell population 
FL fetal liver 
ISP immature single positive thymic T cell population 
LSK lineage- Sca1+ c-kit+ fetal liver or adult BM haematopoietic progenitors  
SP CD4 or CD8 single positive thymic T cell population 
 3 
Summary 
Lymphopenia following bone marrow transplantation or due to T cell loss during 
disease, e.g. HIV, impedes the efficient clearing of infections. Thus, ordinary 
infectious diseases pose a serious risk for patients with low T cell frequencies and 
novel approaches for therapy are needed.   
We have developed an in vitro T cell culture system, which is not based on stromal 
cell lines and therefore is highly reproducable. To provide precursors with an 
adequate signal, a DLL4-Fc fusion protein is immobilized at the surface of cell 
culture flasks. Using this system, we studied the ability of surface-bound DLL4-Fc to 
induce prolonged and extensive expansion of ex vivo isolated Sca1+ c-kit+ fetal liver 
haematopoietic progentiors (LSK’s) in presence of SCF and IL-7. In vitro generated 
pro T cells could be shown to reconstitute the thymi of irradiated T cell deficient 
CD3ε-/-, T cell lymphopenic preTalpha-/- or WT mice and to generate a functional 
peripheral T cell compartment of both CD8+ and CD4+ antigen reactive T cells. 
However, reconstituted Rag- and CD3-deficient mice suffered from a wasting disease 
starting at week 5 to 8 following transplantation. Disease development could be 
prevented by co-injection of sorted CD4+ CD25high wild type Treg cells. In a T cell 
sufficient (C57BL/6)  or lymphopenic (preTα-/-) setting, host Treg cells were 
sufficient to impede the development of disease. Thus, this in vitro culture system 
represents a highly reproducibel and powerful tool for the generation of large 
numbers of progenitor T cells suitable for transplantation and reconstitution of the T 
cell compartment maybe even in a clinical situation.  
 4 
Introduction 
Like all other cells of the hematopoietic system T cells are derived from 
hematopoietic stem cells (HSC’s). However, unlike all the other cells of the 
hematopoietic system, T cell development takes place in the thymus and not in the 
bone marrow. The thymus does not harbor HSC’s and therefore has to be constantly 
colonized by progenitor cells from the bone marrow in order to keep the generation of 
T cells intact [1-3]. Transplantation experiments have shown that various bone 
marrow progenitors can enter the thymus and can give rise to the generation of T cells 
[4], however the physiological role of these progenitors is still a matter of debate.  
Based on the expression of the surface markers CD4 and CD8, T cell development in 
the thymus can be subdivided into 4 consecutive stages. The developmentally earliest 
ones are CD4 and CD8 negative and therefore called double negative (DN) cells.  The 
DN’s are the direct precursors of the CD4 and CD8 expressing cells called double 
positive (DP). Those that survive the positive and negative selection processes will 
then give rise to single positive CD4 or CD8 cells that are then allowed to leave the 
thymus and colonize the secondary lymphoid organs. 
Based on the expression of CD25, CD44 and CD117, DN cells can be subdivided into 
4 subpopulations. DN1 cells express high cell surface levels of CD44 and CD117, and 
are negative for CD25 whereas their DN2 progeny acquire the expression of all these 
3 markers. DN3 cells express high levels of CD25 and low levels of both CD44 and 
CD117 [5-7]. It is at this stage of development that rearrangement of the TCRβ-chain 
locus is completed, and cells are selected for a productive TCRβ-chain rearrangement, 
also known as the β-selection checkpoint. The vast majority of DN3 cells that express 
a TCRβ polypeptide will undergo a preTCR-mediated proliferative expansion [8, 9] 
and will differentiate into DN4 cells. DN4 cells have lost the expression of CD25, 
 5 
CD44 and CD117 and are the direct precursors of the immature single positive (ISP) 
CD8 cells [5-7]. ISP’s will then differentiate into CD4- and CD8-expressing double 
positive (DP) cells. At this stage of T cell development, the TCRα−chain locus will 
be rearranged and those cells that are able to express a functional αβ TCR will 
undergo positive and negative selection [10, 11].  
Several signaling pathways playing a crucial role in this complex T cell 
developmental program have been identified, and probably Notch signaling is the 
most crucial. Thus, it was shown that conditional inactivation of Notch 1 [12] or one 
of its ligands, Delta like ligand 4 (DLL4) [7, 13], resulted in a complete abrogation of 
T cell development in the thymus. Moreover, IL7-IL7R [14, 15] as well as stem cell 
factor (SCF)–c-kit [16, 17] signaling axis have been shown to be crucial for efficient 
T cell development. WNT and Sonic hedgehog have also been implicated in the 
development of T cells [18, 19] (and references herein) and additional signaling 
pathways might also be necessary for efficient T cell generation. 
Several years ago Zuniga-Pflücker and colleagues generated an OP9 stromal cell line 
expressing the Notch ligand Delta like 1 (DLL1). This stromal cell line is able to 
promote differentiation into the T cell linage of early hematopoietic precursors [20, 
21]. This culture system has been of great utility in our understanding of the early 
stages of thymocyte development. However, in such cultures, the density of DLL1 
distribution and kinetics of Notch signal delivery are hard to control and additional 
signals, either cell surface or soluble delivered by OP9 cells remain unknown.  
Therefore, in order to identify the minimal requirements necessary for T cell 
commitment and differentiation we developed a stromal cell-free culture system. This 
culture system consists of plate bound DLL4, soluble SCF and IL-7. Lineage 
negative, Sca1 positive and c-kit positive cells (LSK’s)  differentiate under these 
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culture conditions into DN2 like cells. These cells can then be used for transplantation 
to reconstitute the T cell compartments of T cell deficient mice. 
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Results 
Development of a stromal cell-free culture system for the study of  T-cell 
differentiation. 
Stromal cell-based culture systems have been useful for analyzing T cell development 
in vitro [20, 22]. However, several points emerged from using this culture system, the 
most notable being the heterogeneous response of cloned Pax-5 deficient pro B cells 
during their induction to differentiate towards the T cell lineage [23]. A possible 
reason for this heterogeneity was the variability in the strength and duration of Notch 
signaling. Therefore, in order to equalize the delivery of the Notch signals we 
prepared a soluble DLL4-Fc fusion protein [24-26]. However, initial experiments in 
vitro were not successful where soluble DLL4-Fc was added to the tissue culture 
medium containing progenitor cells. Therefore, we decided to fix the DLL4-Fc fusion 
protein to the surface of tissue culture plates via a mouse monoclonal antibody 
specific for the Fc-region of human IgG1. Thus, the mAb was coated to the plastic 
plates before addition of soluble DLL4-Fc (Fig. S1). 
Using the OP9-DL1 stromal cell system, we previously showed that Pax-5 deficient 
pro B cells differentiating towards the T cell lineage up-regulates CD117 and down-
regulates CD93 [17]. As shown in Fig. S2A these same cells undergo exactly the 
same phenotypic changes also on plate-bound DLL4. Optimal differentiation was 
achieved when plates were coated with 1µg/ml or more of DLL4-Fc (Fig. S2A).  
The initial finding that non coated (soluble) DLL4-Fc did not induce the 
differentiation of Pax-5 deficient pro B cells towards the T cell lineage suggests that 
soluble DLL4-Fc even might inhibit T cell differentiation. In order to test this 
hypothesis, Pax-5 deficient pro B cells were cultured in plates coated with 2 µg/ml 
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DLL4-Fc in the presence of IL-7 (100U/ml) and SCF (20 ng/ml) together with various 
amounts of soluble DLL4-Fc. 
As can be seen (Fig. S2B), differentiation could be completely inhibited at between 1 
and 10µg/ml soluble DLL4-Fc added to the cultures. Thus, the blocking of Notch 
cross-linking efficiently inhibits the signalling induced by the plate-bound DLL4. 
Now that differentiation of a cloned cell line towards the T cell lineage was 
homogeneous and occurred in a semi-synchronous fashion, it was decided to carry out 
gene expression analysis of cultured Pax 5 deficient pro B cells. In Figure S3A and B 
a summary of the T cell genes found to be up-regulated more then 3 fold and B cell 
genes found to be down-regulated more then 3 fold are shown. Thus, these findings 
strongly support the conclusion, that this stromal cell free culture system efficiently 
induces the development of Pax-5 deficient pro B cells towards the T cell lineage and 
moreover might well be an ideal system to identify Notch target genes necessary for T 
cell development.  
 
Developing T cells from ex vivo isolated progenitors. 
To further test this stromal cell-free culture system we initiated cultures with sorted 
undifferentiated hematopoietic progenitors, in this case lineage-negative, Sca-1+, c-
kit+, (also called LSK) from fetal liver (FL) cells. Fifty thousand mouse LSK cells 
were sorted and cultured in 1 ml medium supplemented with 100U/ml IL-7 and 20 
ng/ml SCF in 1 well of a 24 well plate coated with DLL4-Fc. After 5-6 days, cells 
became confluent and then re-plated in 2 times 4 ml IL-7 and SCF containing medium 
into 2 wells of a 6 well plate coated with DLL4-Fc. Thereafter, the cells were re-
cultured at 2 x 105/ml into fresh DLL4-Fc coated plates every 4 days in medium 
containing the cytokines.  Phenotypic analysis of the cells was performed at various 
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days after onset of the cultures. However, the phenotype of the growing cells did not 
change over time.  An example of such a phenotypic analysis is shown in Figure 1A-
C.  Thus, a small fraction of cells express high levels of CD44 and low levels of 
CD25 (4.0% in this example). Yet, another small fraction expresses low levels of 
CD25 and no CD44 (1.6% in this example). All the other cells express high levels of 
CD25 and around 70% of those were also CD44high , whereas the rest was CD44 
negative. Moreover, all cells expressed CD117 and the level of this expression 
correlated with the CD44 expression (Fig. 1B). Cytoplasmic staining revealed that 
over 85% of the cells expressed CD3ε (Fig. 1C). No cytoplasmic TCRβ, nor cell 
surface CD4 or CD8 was detectable in or on these cells (data not shown). Next, we 
analysed Dβ1 − Jβ1 TCR rearrangements in these cells (Fig. 1D). As expected, all 7 
rearrangements were readily detectable in total ex vivo isolated thymocytes and no 
germline band was detectable (lane 1). In marked contrast, Pax5 deficient pro B cells 
did not show any rearrangements but only the germline band (lane 2). In two 
independently established pro T cell lines (lanes 3 and 4) all 7 rearrangements were 
readily detectable but also the germline band was clearly visible. Based on these 
phenotypic and rearrangement analyses our in vitro propagated pro T cells seem to 
closely resemble DN2/3 thymocytes isolated ex vivo.    
Moreover, we also analysed the long-term proliferative capacity of these pro T cells.  
A cumulative growth curve of a typical experiment of this nature is shown in Figure 
1E. As can be seen, growth was exponential for the duration of the experiment, in this 
case 79 days, with cells expanding from 105 to 1024, a 1019-fold increase with an 
average doubling time of such cultures of about 1.5 days for the total culture. This 
finding indicates that these pro T cells have self-renewal capacity in vitro. 
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Additional non-TCRαβ  subpopulations among in vitro-generated DN cells  
NK and TCRγδ cells are frequently found among DN cells in vivo and the complete 
elimination of such cells from analysis and sorting is often difficult. To investgate this 
point further, we analysed LSK-derived in vitro-generated pro T cells further. As 
shown in Figure 2A, a distinct population of NK1.1+ cells could be observed and 
these cells were brightly stained for CD44 (Fig. 2B) and were practically negative for 
CD25, i.e. are part of the DN1 population. After isolation by cell sorting, these cells 
killed the classical NK target YAC (Fig. 2E, dashed line) and their killing activity 
could be improved more than 10 fold after culture for 5 days in 100 U/ml of IL-2 
(Fig. 2E, solid line). However, the sorted NK1.1+ cells could not be propagated in 
vitro using plates coated with DLL4-Fc in the presence of IL-7 and SCF, suggesting 
that some DN1 cells constantly differentiate into NK cells but then die (data not 
shown). Likewise, TCRγδ-expressing cells were also present in these long-term 
cultures. Phenotypically, they were heterogeneous for CD44 expression and were to a 
large extent negative for CD25, i.e. are part of the DN1 and DN4 populations (Fig.2C 
and D). In order to test whether these TCRγδ-expressing cells could be propagated in 
vitro they were isolated by cell sorting and then cultured in DLL4-Fc coated plates or 
non-coated plates in the presence of IL-7 and SCF. As shown in Figure 2F, robust 
growth was observed in DLL4-Fc coated plates (solid line) but not in un-coated plates 
(dashed line). This finding suggests that part of TCRγδ-repetoire is Notch signaling 
dependent for its development and growth. 
 
FL derived pro T cells differentiate into CD4/CD8 expressing cells upon withdrawal 
of IL-7.  
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Previously we showed that fetal derived pro T cells grown on OP9-DL1 stromal cells 
in the presence of IL-7 and SCF differentiated into CD4/CD8 expressing cells upon 
withdrawal of IL-7 [22]. More recently, Ikawa et al [26] reported a similar finding 
with fetal pro T cells grown in a stromal cell-free culture system. Now, we tested 
whether the pro T cells grown on DLL4 coated plates in the presence of IL-7 and SCF 
would also upregulate CD4 and CD8 expression upon IL-7 withdrawal. As shown in 
Figure 3A fetal liver derived pro T cells cultured for 5 days like this but in the 
absence of IL-7 differentiated into DP, and CD4 or CD8 single positive cells 
Additional staining with antibodies to TCRγδ or TCRβ indicated that gated DN cells 
(Fig. 3B) contained a few TCRγδ (dashed line) and TCRαβ (bold  line) cells. DP cells 
(Fig. 3C) expressed TCRβ but not TCRγδ, whereas both single CD8 (Fig. 3D) and 
CD4 (Fig. 3E) subpopulations expressed TCRβ weakly with some TCRγδ cells 
present in the CD8SP population. Taken together, these results indicate that 
progression beyond the DN stage in vitro for fetal liver derived pro T cells was 
impeded by the presence of IL-7; a similar scenario is seen in pro B cell cultures in 
vitro where the presence of IL-7 prevents B cell differentiation into surface IgM 
expressing immature B cells [27]. 
 
In vivo T cell reconstitution of  T cell deficient recipients by T cell progenitors 
generated in stromal cell-free cultures 
Recently it was shown that pro T cells propagated on OP9-DL1 stromal cells were 
able to partly reconstitute the T cell compartments in vivo [28]. To test whether our 
stromal cell free generated pro T cells could reconstitute all T cell compartments in 
vivo, we performed the following experiment.  CD45.1 CD3ε deficient mice were 
lightly irradiated (400 rad) and reconstituted intravenously with 5x106 T cell 
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progenitors generated from fetal liver LSK’s of CD45.2 mice cultured on plate bound 
DLL4-Fc in the presence of SCF and IL-7 for more than 5 weeks. As shown in Figure 
4A (histogram), at 3 weeks after transfer, practically all thymocytes were CD45.2 
postive. Moreover, these thymi contained all CD4 and CD8-defined subpopulations 
(Fig. 4B) and TCRβ was brightly expressed on the expected proportions of CD4- and 
CD8-defined subsets (Fig. 4C). In these experiments, reconstitution of the thymus 
was transient and the peripheral compartment (Fig. 4D) was still relatively 
lymphopenic (data not shown). Staining for FoxP3 in peripheral CD45.2 positive 
cells, revealed the complete absence of putative CD4+ T regulatory cells (Fig. 4E). 
As previously reported, after syngeneic BM transplantation into adult RAG- or 
CD3ε−deficient mice, T cell reconstitution of recipients thymi was readily 
demonstrable, but at between five and eight weeks, when mice were still relatively 
lymphopenic, mice died from a wasting disease marked by diarrhea, weight loss and 
signs of auto-immunity [29]. This phenotype may partly be explained by our findings 
of massive lymphocyte infiltrations in both liver (Fig 4F) and colon (Fig. 4G). We 
have also shown previously that this wasting/autoimmunity can be prevented by the 
co-injection of exogenous mature regulatory T cells (Treg) [29]. Therefore, to be able 
to test the functionality of the T cell compartment generated by the in vitro 
propagated pro-T cells, lightly irradiated (400 rad) adult CD45.1 CD3ε deficient 
mouse recipients were reconstituted with a mixture of 1x105 ex-vivo sorted CD45.1 
Treg cells (CD4+CD25high) from CD45.1 B6 mice and 5x106 CD45.2 B6 T cell 
progenitors from in vitro cultures. As shown in Figure 5A, where peripheral blood 
was analysed, CD45.1 CD4+ Treg cells (identified as CD45.2-negative, left 
population) could still be seen alongside CD45.2 donor progenitor-derived cells 
comprising both CD4 and CD8 lymphocytes (right population) at 10 weeks after 
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transfer. At this time after transfer, the mice remain healthy with no signs of wasting 
disease. Thus, provision of a small number of Treg cells protects adult mice from the 
development of autoimmunity following transplantation of progenitor T cells. In fact, 
upon analyses of the peripheral CD4+ compartment, not only the injected Treg’s 
(CD45.1+) can be found, but now also have allowed the development of FoxP3 
expressing cells among the injected 45.2+ in vitro grown pro T cells (Fig. 5B). 
In order to test whether these peripheral T cells are functional, mice were immunised 
with NIP-OVA in CFA. At day 14 after immunisation, the IgG anti-NIP antibody titer 
was determined. As shown in Figure 5C, the IgG anti-NIP titer in CD3ε-deficient 
mice injected with in vitro propagated pro T cells together with Treg cells was 
practically indistinguishable from that found in immunised normal B6 mice. In 
marked contrast, in CD3ε-deficient mice that had received only Treg, the anti-NIP 
antibody titer after immunisation was very low. Thus, the T cells derived from the in 
vitro-propagated pro T cells are functional in that they can help the antibody response 
to classical T-dependent antigen. 
 
Long-term in vitro propagated pro T cells efficiently reconstitute T lymphopenic 
mice 
PreTα deficient mice are highly T cell lymphopenic [8] and  show an enrichment for 
CD4+CD25high cells, many of which express FoxP3 and have a regulatory functions 
[30]. In order to test, whether our long-term in vitro grown pro T cells could fully 
reconstitute the peripheral T cell compartment of such mice, we transplanted CD45.1+ 
in vitro grown pro T cells into sublethally irradiated CD45.2+ preTα-/- mice. Analyses 
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of the spleen 6 weeks after transplantation show some 6% of the total lymphoid cells 
to be derived from the injected CD45.1+ cells (Fig. 6A) showing the normal 
proportion of CD4 and CD8 single positive cells (Fig. 6B). The vast majority of these 
express the TCRβ-chain (Fig. 6C)  and some 10-15% of the CD4+ cells also express 
FoxP3 (Fig. 6D).  Thus, in the presence of host derived CD4+ Treg cells, our long 
term in vitro grown pro T cells show developmental capacities upon transplantation 
similar to normal ex vivo  isolated progenitor cells. 
 
Long term in vitro propagated pro T cells fully reconstitute all T cell compartments 
of lethally irradiated mice. 
To investigate the developmental capacity of our in vitro grown pro T cells, we 
transplanted them to lethally irradiated CD45.1+ B6 mice using an equal mixture of 
bone marrow from a CD45.1+ CD3e-/- mouse and CD45.2+ in vitro grown pro T cells. 
FACS analyses of thymi and spleens was performed 3 weeks after reconstitution and 
is shown in Fig. 7. Virtually all thymocytes are CD45.2+ (Fig. 7A) with the expected 
CD4- and CD8-defined subpopulations (Fig. 7B) with TCRβ brightly expressed on 
the expected proportions of SP thymocytes (Fig. 7C). The spleens showed some 15-
20% donor derived cells (Fig. 7D) with the majority (more than 80%) being CD4 and 
CD8 single positive cells (Fig. 7E) expressing the TCRβ at the surface (Fig. 7F). 
Some 10-15% of the donor derived CD4+ cells also express FoxP3 (Fig. 7G). The 
spleens contain the normal proportions of donor derived γδ T cells as well as NK1.1 
positive cells (Fig. 7H). Thus, our in vitro propagated pro T cells efficiently 
reconstitute all T cell compartments of lethally irradisted wild type mice. 
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Discussion 
Here we report on a novel tissue culture system not requiring stromal cells for the 
long-term propagation of mouse progenitor T cells. The system employes tissue 
culture dishes with surface-bound Delta Like Ligand 4 (DLL4) for propagation of 
progenitor cells in the presence of SCF and IL-7. The extracellular domain of mouse 
DLL4 is produced as a soluble fusion protein containing the Fc fragment of human 
IgG1 so as to allow binding in the right orientation to tissue culture plastic plates 
previosly coated with a  mouse anti-human Fc specific monoclonal antibody. 
Following the initiation of cultures with sorted fetal liver derived multi-potent LSK 
progenitors incubated with IL-7 and SCF in such DLL4-coated plates, a continuous 
expansion of cells was seen for up to six months and beyond, providing that cells are 
replated at 105 cells/ml every 4 days onto freshly DLL4-coated plates in medium 
containg SCF and IL-7. During this time, the number of cells doubeled every 30 hours 
and remained at a constant ratio of a mixture of DN1-like and DN4-like cells.  Thus, 
given that the minimum cell cycle time is 30 hours or less, such cultured cells have 
passed well beyond the so called Heyflick limit [31] without going through any 
noticeble “crises” (Fig. 1E) and remain stricly dependent on simultanous signalling by 
DLL4 and the cytokines SCF and IL-7. 
For the most part, differentiation was uni-directional, however, sorting experiments 
indicated that CD44+CD25+ (DN2) cells generated in vitro could relatively rapidly re-
adopt a CD44+CD25- DN1 phenotype (data not shown). During normal T lineage 
differentiation in the thymus, intracytoplasmic CD3ε protein begins to be expressed 
among DN2 cells with complete expression being achieved at the DN3 stage. 
Following V to DJβ gene rearrangements at the DN3 stage, intracytoplasmic TCRβ 
protein appears in DN3 cells and then, following the process of so-called TCRβ 
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selection, all post-DN3 TCRαβ lineage cells are universally intracytoplasmic TCRβ+. 
Analysis of intracytoplasmic CD3ε and TCRβ expression among in vitro-grown DN 
cells indicated some differences with this in vivo pattern. Notably, DN1 cells in this in 
vitro system contained a disctinct population of intracytoplasmic CD3ε+ cells, again 
presumably indicative of some degree of de-differentiation from intracytoplasmic 
CD3ε+ DN2 cells. In addition, unlike their in vivo counterparts, DN4 cells contained 
many i.c. TCRβ-, probably TCRγδ cells. 
Additional subpopulations of TCRγδ and NK cells could be found among cultured 
DN cells.  For NK cells, these mostly appeared to have a DN1-like phenotype 
whereas TCRγδ cells were a mixture of mostly DN1 and DN4 cells. The presence of 
of a significant proportion of TCRγδ cells could account for both the intracytoplasmic 
CD3ε+ DN1 and TCRβ- DN4 cells. Previously it had been shown that some human 
NK clones are intracytoplasmic CD3ε+ [32]. It could well be that mouse DN1-like 
NK cells show the same and thus could also account for some intracytoplasmic 
CD3ε+ DN1 cells. In the presence of IL-7, cells remained DN, but upon withrawal of 
IL-7, fetal liver derived pro T cells acquired both CD4 and CD8 surface antigens, 
differentiating to DP cells and later to CD4+ or CD8low SP cells. The latter were 
clearly not mature cells in that they expressed very low levels of CD3ε and TCRβ and 
did not respond to anti-CD3 stimulation (data not shown). Thus, like in cultures 
containing Notch-ligand expressing stromal cells [22] differentiation of T cells is 
incomplete also in the culture system described herein.   
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Bone marrow transplantation is a frequently used treatment modality in medical 
practice. However, following infusion of HSC, reconstitution of the T lymphocyte 
compartment is often delayed and protracted because of the lag in thymus 
colonisation by donor-derived precursors [33]. In mouse model systems, we have 
encountered additional difficulties of T cell reonstitution with in vitro-generated T 
cell progenitors, difficulties related to Treg. In essence, during the initial stages of 
reconstitution of T cell deficient recipient mice using either T cell-depleted bone 
marrow preparations or purified T cell progenitors, although the thymus is adequately 
re-colonized, the peripheral T cell compartment contain low numbers of Treg cells. 
After about four weeks, the imbalance between Treg numbers and newly produced 
naïve T cells results in the development of auto-immune disease marked by weight 
loss, wasting, diarrhea and death of mice [29]. We have shown that co-injection of ex 
vivo isolated CD4+ CD25high wild type Treg cells can rescue T cell deficient recipient 
mice from autoimmunity and death. In this study, we have carried out some additional 
experiments to explore the Treg issue. Confirming our previous results, reconstitution 
of irradiated lymphopenic mice with in vitro-generated T cell progenitors results in 
robust thymus reconstitution with phenotypically mature T cells. This result indicates 
firstly that T cell progenitors generated in a stromal cell-free culture system retain the 
ability to home to the recipient thymus. Secondly, it shows that differentiation of in 
vitro-generated progenitors proceeds to completion in the thymus in vivo, with the 
development of fully functional TCRαβhigh single positive cells. Even though TCRhigh 
CD4+ cells can be found in the lymphoid organs and blood of adult T cell deficient 
recipients (Fig. 4), the proportion of Treg is insufficient to protect mice from auto-
immunity. Interestingly, use of lymphopenic recipients overcomes this problem with 
approximately 20% TCRhigh, CD4 PBL T cells being Treg (Fig. 5).  
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Nevertheless, our experiments clearly show that to rescue adult T cell deficient 
recipients, co-injection of small numbers of additional Tregs is necessary to avoid the 
development of auto-immunity (Fig. 5). 
In conclusion, we have shown that practically limitless numbers of functional T cell 
progenitors can be generated from multi-potent fetal liver derived progenitors in an in 
vitro system containing the cytokines IL-7 and SCF without the need for stromal 
cells. Such cells can be frozen and thawed and as previously shown for stromal cell-
generated progenitors, can be genetically manipulated for therapeutic purposes. Using 
this system for human progenitors might offer numerous therapeutic applications. 
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Material and Methods 
Mice 
Female C57BL/6 45.1, C57BL/6 45.2 and CD3ε deficient [34] as well as preTα 
deficient [8] mice of 5–8 weeks of age were used. All mice were bred and maintained 
in our animal facility under specific pathogen-free conditions. All animal experiments 
were carried out within institutional guidelines (authorization number 1888 from 
Kantonales Veterinäramt, Basel). 
Cell lines 
Pax5-/- fetal liver derived pro B cells were generated and maintained on OP9 stromal 
cells in the presence of IL-7 as previously described [35]. 
Recombinant DLL4-Fc fusion protein 
The production and purification of a fusion protein consisting of the extracellular 
portion of mouse DLL4 (amino acids 1–521) and the Fc portion of human IgG1 has 
been described before [36]. 
Monoclonal antibody against human IgG1 Fc 
A mouse monoclonal IgG antibody against the Fc part of human IgG1 (clone Huf5.4) 
was produced by conventional techniques using the fusion partner Sp2/0. 
Flow cytometry and cell sorting 
FITC-, PE-, APC- or biotin-labeled mAb specific for CD3, CD4, CD8α, CD25, 
CD45.1, CD45.2, CD117, Sca-1, TCRβ, TCRγδ and NK1.1 were purchased from BD 
Biosciences or e-Biosciences. Staining of the cells was performed as described [23]. 
Flow cytometry was performed using a FACS Calibur (BD Biosciences) and data 
were analyzed using the Cell Quest Pro Software (BD Biosciences). For cell sorting, 
the FACS Aria (BD Biosciences) was used. Re-analysis of the sorted cells indicated 
 20 
that in all instances they were over 98 % pure. LSK’s were defined and sorted as 
previously described [37-39]. 
Cell cultures 
In initial experiments, 48- or 24-well tissue culture plates from Nunc (Nunc A/S, 
Roskilde, Denmark) were used. Once established, cells were maintained in 6-well 
bacterial grade plates (Greiner Bio-One, Kremsmünster, Austria), because of their 
higher coating capacity. Wells were pre-coated overnight or longer with 10 µg/ml 
mAb anti-human IgG1-Fc in PBS (0.25 mL per well for 48 well plates, 0.5ml per well 
for 24 well plates or 2 ml per well for 6 well plates) at 4°C. Thereafter, wells were 
washed twice with IMDM (BD Biosciences) supplemented with 5 - 10 % FCS, 5x10-
5M β-mercaptoethanol, 1mM glutamine, 0.03 % w/v Primatone (Quest, Naarden, The 
Netherlands), 100 U/ml penicillin, 2 % serum (complete medium) and then used for 
coating with DLL4-Fc at 2 µg/ml (or as indicated) in IMDM overnight, washed and 
used for cell culture. 
NK cell cytotoxicity assay 
NK cell cytotoxic activity was determined using YAC-1 cells as targets [40]. The 
assay was performed as previously described [23]. 
PCR analyses of TCRβ gene rearrangements 
DNA was isolated from indicated cells and analysed by PCR for Dβ1 to Jβ1 
rearrangements as described before [39]. 
Gene expression pattern of a cultured pro B cells 
Isolation and processing of RNA from Pax 5-/- pro B cells cultured as described in 
Fig. S3 as well as its analyses on Affymetrix  Mouse  Genome  1.0  ST  gene  array 
was performed as previously described [41]. 
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Transfers of cultured progenitor cells  
Recipient mice were irradiated as indicated using a 137Cs source. Sorted populations 
were infused intravenously. Spleen and marrow from one femur were collected 
separately from recipient mice, and donor- and host-derived cells were assayed by 
flow cytometry. 
4-Hydroxy-5-iodo-3-nitrophenyl (NIP)-specific IgG responses 
Mice were immunized subcutaneously at day 0 with 100 µg NIP-OVA in a 1:1 
complete Freunds adjuvant (CFA) emulsion and serum IgG against NIP was analyzed 
at day 14 using ELISA as described in [42]. 
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Figure 1. Phenotype, genotype and proliferative capacity of LSK derived pro T cells.
Fetal liver derived LSK’s were cultured for 55 days on plate-bound DLL4 in the presence of SCF and IL-7. 
(A) Double staining for CD44 and CD25. (B) Double staining for CD44 and CD117. (C) Intracellular staining 
for CD3ε in CD25 gated cells. (D) PCR analyses of Dβ1 to Jβ1 rearrangements in genomic DNA isolated 
from wild type thymus (lane 1), Pax5-/- pro B cells (lane 2) and two samples of in vitro generated pro T cells 
(lanes 3 and 4). (E) Cumulative growth curve of pro T cells propagated on plate-bound DLL4.
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Figure 2. Co-development of NK cells and γδ T cells during culture of LSK’s on plate-bound DLL4.
Long-term cultured pro T cells were stained for CD44 and NK1.1 (A) as well as CD25 (B). A second staining 
for CD44 and TCRγδ (C) as well as CD25 (D) was performed on cells from the same culture. Sorted NK1.1 
positive cells were assayed for cytotoxic activity against YAC-1 target cells (E) either directly after sorting 
(dashed line) or after 5 days of culture in the presence of IL-2 (solid line). Cumulative numbers of sorted TCR
γδ positive cells were cultured (F) in the presence of IL-7 and SCF on plates coated (solid line) or not coated 
(dashed line) with DLL4.
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Figure 3. Fetal liver derived pro T cells differentiate into CD4 and CD8 expressing cells 
upon withdrawal of IL-7.
Long term grown pro T cells were washed and cultured in DLL4 coated plates in the pres-
ence of SCF but without IL-7 for 5 days. Cells were analysed for surface expression of CD4 
and CD8 (A) as well as TCRαβ and TCRγδ (B-E). Bold lines in the histograms show stain-
ing for TCRβ, dashed line for TCRγδ and thin lines indicate auto-fluorescence of unstained 
cells.
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CD45.1+ CD3ε deficient mice were sublethally (400R) irradiated and reconstituted with 5x106 long-term in vitro 
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Figure 5. Prevention of autoimmunity and wasting in T cell deficient recipients by co-injection of Treg’s together 
with T cell progenitors.
CD45.1+ CD3ε deficient mice were sublethally (400 rad) irradiated and reconstituted with a mixture of 105 
CD45.1+ CD4+ CD25+ cells and 5x106 CD45.2+  fetal liver derived, long-term in vitro propagated pro T cells. 10 
weeks after reconstitution, peripheral blood was analysed for CD4+ cells (A) and CD45.2+  FoxP3 expressing 
cells (B). At the time for blood analyses, reconstituted CD3ε deficient mice and wild type C57BL/6 mice were 
immunized with NIP-OVA and their IgG anti-NIPA serum titers determined 14 days later (C).
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Figure 7. In vitro generated pro T cells can reconstitute the T cell repertoire in a bone marrow transplantation 
model.
CD 45.1+ C57BL/6 wild type mice were lethally irradiated (950 rad) and reconstituted with an equal mixture 
of bone marrow from CD45.1+ CD3ε-/- mice and CD45.2+ in vitro generated pro T cells. 3 weeks after transplan-
tation thymus reconstitution by CD45.2+ in vitro generated pro T cells  was analyzed (A).  Expression of CD4 
and CD8 (B) or CD4 and TCRβ (C) on CD45.2+ thymocytes  is shown in the respective dot plot. Reconstitution 
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Fig. S3. Gene expression pattern of a Pax5-/- pro-B cell line in its response to Notch signaling. 
Cells were collected on day 5 after culture on plate-bound DLL4 and sorted to isolate RNA from a homogenous 
population, which was analyzed on Affymetrix Mouse Genome 1.0 ST gene array. Fold increased or decreased 
expression of selected T-cell (A) or B-cell (B) specific genes are indicated in comparison to non-induced Pax5-/- 
pro-B cells.
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Abbreviations 
6.5+, cells positively stained by the rat anti-TCR HA clonotype specific mAb 6.5 
ANA, anti-nuclear auto-antibodies 
CD11c HAhigh, mouse expressing a membrane bound form of HA under control of the 
CD11c promoter at a high level 
CD11c HAlow, mouse expressing a membrane bound form of HA under control of the 
CD11c promoter at a low level 
CD4sp, CD4 single positive 
CD62L, CD62 ligand 
CD8sp, CD8 single positive 
DC, dendritic cell 
F1 HAhigh, F1 double transgenic mouse of the breeding TCR HA x CD11c HAhigh 
F1 HAlow, F1 double transgenic mouse of the breeding TCR HA x CD11c HAlow 
HA, hemagglutinin protein from the PR8 influenza virus strain 
Igκ HA, mouse expressing a membrane bound form of HA under control of the Ig 
kappa promoter 
TCR HA, mouse expressing I-Ed restricted, HA-specific transgenic αβ T cell receptor 
TEC, thymic epithelial cell 
Treg, regulatory T cell 
TSA, tissue-specific antigen 
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Summary 
Autoimmune diseases develop when self-specific T cells that escaped negative 
selection initiate a harmful immune response against self. However, factors, which 
influence the initiation and progression of an autoimmune response, remain 
incompletely understood. By establishing a double transgenic mouse system in which 
different amounts of a cell-surface neo-self antigen are expressed under the CD11c 
promoter, we demonstrate that antigen dose dramatically influences T cell tolerance 
mechanisms. Moderate antigen expression favors the development of antigen-specific 
regulatory T cells and the establishment of a tolerogenic environment. In marked 
contrast, high dose of antigen expression results in very stringent negative selection, 
in poor development of antigen-specific regulatory T cells and the early onset of 
anemia and splenomegaly and the late development of arthritis and high titers of IgG 
auto-antibodies. Disease is initiated by autoreactive T cells, which escape negative 
selection by expressing a second T cell receptor with a different specificity or an 
altered affinity. Transfer of antigen-specific regulatory T cells ameliorates the early 
onset signs of disease but does not prevent the development of long-term chronic 
pathologies. 
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Introduction 
The rearrangement of T cell receptor (TCR) α- and β-chain loci is a random process 
and therefore can result in the development of T cells expressing an autoreactive 
TCR. Under physiological conditions these T cells are deleted by a process called 
negative selection [1-5]. However, as various model systems have indicated, the 
development into Foxp3+ regulatory CD4 T cells (Treg) is an alternative fate for 
autoreactive T cells in the thymus [6-11]. Nevertheless, despite negative selection 
and/or Treg induction, mature self-specific T cells may be found in the periphery due 
to e.g. weak or absence of tissue-specific antigen (TSA) expression in the thymus. 
These T cells are prevented from causing autoimmunity by mechanisms such as 
anergy [12, 13] or control by regulatory T cells [6-11]. Self-specific mature T cells 
may differentiate into Foxp3 positive or negative regulatory T cells under conditions 
that involve low antigenic stimulation in absence of co-stimulation or antigen 
presentation by particular subsets of antigen presenting cells [14-21]. 
Autoimmune diseases develop when one or several mechanisms of T cell 
tolerance fail. In mice and man, Foxp3 deficiency leads to a very severe disease due 
to complete absence of Foxp3+ regulatory T cells [22, 23]. Aire is a transcription 
factor that contributes to expression of TSA in the thymus [24, 25]. Aire deficiency 
causes a disease that affects many organs and glands likely due to absence of negative 
selection of TSA-specific T cells [24, 25]. Similarly, in NOD mice, β-cell destruction 
is caused by cells that escape negative selection [26]. 
It has been shown, both in mice and humans, that up to one third of mature T cells 
express two different TCR α-chains [27-32]. This suggests, that self-specific T cells 
may escape negative selection by expressing a second non-self specific TCR during 
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development and give rise to autoimmunity. A study by Sarukhan et al [28] strongly 
supports such a scenario. 
In the present study, we describe two transgenic mouse lines that express 
different amounts of influenza virus hemagglutinin (HA) under the CD11c promoter. 
By crossing these mice with transgenic mice expressing an MHC class II restricted 
HA-specific TCR (called TCR HA hereafter), we investigated the role of antigen dose 
in immune tolerance induction. Our findings clearly demonstrate that the antigenic 
dose dramatically influences T cell tolerance. The amount of antigen expressed by 
DC’s and TECs in the thymus does seem to influence the stringency of negative 
selection. Thus, low HA expression correlates with the induction of Treg 
development, whereas high HA expression correlates with a very stringent negative 
selection process and poor regulatory T cell development, increased T cell activation 
and development of autoimmune disease. 
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Results 
Mouse model 
To target the expression of HA protein to dendritic cells, we generated transgenic 
mice expressing a membrane bound form of HA under control of the CD11c 
promoter. Two different transgenic mouse lines were obtained. As shown in Figure 
1A (left panels), HA expression was readily detectable on CD11c bright splenocytes 
from both of the HA transgenic lines but not WT BALB/c mice. However, the amount 
of HA protein expressed by CD11c+MHCII+ cells from the spleen and the thymus 
was dramatically different between the two transgenic lines named hereafter “CD11c 
HAlow” and “CD11c HAhigh” respectively (Figure 1A, middle and lower panels). 
Differences in HA expression might be explained by differences in copy numbers of 
the transgene integrated. Southern blot analysis indeed revealed an at least 10 fold 
higher HA copy number in CD11c HAhigh than in CD11c HAlow mice (Figure 1B). In 
order to verify that HA expression correlated with peptide presentation by MHC class 
II molecules, we addressed the ability of sorted dendritic cells from the different 
CD11c HA transgenic mice or wild type mice to induce the proliferation of CD4+ T 
cells from TCR HA mice which express an I-Ed restricted, HA-specific transgenic T 
cell receptor [33]. As shown in Figure 1C, at a ratio of 10 to 1 (CD4 T cells : DC) 
dendritic cells from both of the CD11c HA transgenic mice induced robust 
proliferation of HA specific CD4 T cells compared to dendritic cells from wild-type 
mice, which are non-stimulatory (Figure 1C, upper panels). At a ratio of 90:1 
(CD4:DC), dendritic cells from CD11c HAhigh transgenic mice induce T cell 
proliferation as efficiently as dendritic cells from CD11c HAlow transgenic mice at a 
ratio of 10:1. Thus, dendritic cells from CD11c HAhigh transgenic mice are about ten 
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fold more potent in their ability to induce HA-specific CD4 T cell proliferation as 
compared to dendritic cells from CD11c HAlow mice due to increased HA 
presentation by surface expressed MHC class II on dendritic cells. The expression 
level of MHC II, CD80, CD86 and CD40 was very similar between dendritic cells 
from the spleen of WT, CD11c HAlow or CD11c HAhigh transgenic mice 
(Supplemental Figure 1). Therefore, HA expression per se does not change the 
maturation status of dendritic cells as monitored by expression of costimulatory 
molecules. HA expression under the CD11c promoter was not tightly restricted to the 
DC compartment. By qPCR, it could be shown that HA is expressed strongly by 
cDC’s of the CD11c HAhigh mouse strain. NK cells, as well, were found to express 
HA on a high level in CD11c HAhigh mice. T and B lymphocytes of the same strain 
showed a very weak amplification signal. Expression of the HA transgene in the 
CD11c HAlow mouse strain was lower in all subsets. Only in myeloid cells of the 
CD11c HAhigh and of the CD11c HAlow mouse strain, as well as in all cell samples 
derived from WT BALB/c mice, HA expression could not be detected (Figure 1D). 
Thus, HA expression is not only restricted to the DC compartment. Thymic epithelial 
cells (TEC) were shown to express the HA antigen as well. However, for detection of 
HA expression in TECs a more sensitive approach was chosen and results are shown 
and will be discussed referring to the chimaera data shown in Figure 3 and 5. 
Autoimmune disease develops in TCR HA x CD11c HAhigh mice but not in TCR HA x 
CD11c HAlow mice 
In order to investigate the role of dendritic cells in immune tolerance we generated 
(TCR HA x CD11c HAlow)F1 mice (called F1 HAlow hereafter) and (TCR HA x 
CD11c HAhigh)F1 mice (called F1 HAhigh hereafter) and monitored their health status. 
All young (< 4 weeks old) F1 HAhigh mice suffered from severe anemia as determined 
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by hematocrit levels (33.5±3.0 versus 42.5±2.6 in TCR HA mice) and showed 
splenomegaly, which to a large extent was due to an accumulation of myeloid cells 
(16.5±6.4x106 versus 0.8±0.4 x106 in TCR HA mice) (Figure 2, A and C). In sharp 
contrast, hematocrit levels and myeloid cell numbers in the spleen of F1 HAlow mice 
were comparable to what was found in TCR HA mice (Figure 2, A and C). Moreover, 
histological analysis revealed a completely disturbed organization of the T and B cell 
zones in the spleens of young F1 HAhigh mice whereas these were normal in F1 HAlow 
mice of the same age (Figure 2, E and F). No germinal centers were detectable in the 
spleens of young F1 HAhigh or F1 HAlow mice (Figure 2E).  
In marked contrast hematocrit levels in adult F1 HAhigh mice (> 8 weeks old) 
were normalized (46.8± 1.9 versus 48.3±1.0 in TCR HA mice) (Figure 2B). 
Moreover, decreased but still significant myeloid cell accumulation was observed in 
the spleens of adult F1 HAhigh mice (11.0± 5.9 x106 versus 3.1±0.8 x106 in TCR HA 
mice) (Figure 2D). In adult F1 HAhigh but not F1 HAlow mice high titers of IgG anti-
nuclear auto-antibodies (ANA) were detected in the blood (Figure 2G). Unlike in 
young, adult F1 HAhigh mice showed a normal T and B cell zone organization in the 
spleen (Figure 2F). Moreover, high numbers of germinal centers were detectable in 
the spleen of F1 HAhigh but not in F1 HAlow mice (Figure 2E). All adult F1 HAhigh mice 
showed with time a thickening of their paws. Histological examination of the joints 
revealed a severe arthritis characterized by mainly acute inflammation with massive 
swelling, cellular infiltration of the synovial membrane and focal destruction of the 
cartilage surface; polymorphonuclear granulocytes along with fibroblasts and 
histiocytes were the major component of the cellular infiltrate (Figure 2I and J). In the 
joints of the control mice no histological abnormalities were observed (Figure 2H). 
 	
   10 
Altogether, young F1 HAhigh mice suffer from severe anemia, display a 
massive accumulation of myeloid cells in the spleen and show a complete disturbed T 
and B cell zone architecture in their secondary lymphoid organs during the first weeks 
after birth. On the other hand, in adult F1 HAhigh mice anemia faded away and T and B 
cell zone architecture in their secondary lymphoid organs was normalized. However, 
these adult mice all developed arthritis and had high titers of IgG ANA. In sharp 
contrast, the phenotype of F1 HAlow mice was similar to the phenotype of TCR HA 
single transgenic mice suggesting that F1 HAlow mice did not suffer from any disease.  
Central tolerance in F1 HAlow and F1 HAhigh mice 
The finding that F1 HAhigh mice developed various types of autoimmune like diseases 
strongly suggested that the induction of HA specific T cell tolerance was impaired in 
these mice. Therefore we investigated the induction of central tolerance by 
monitoring the fate of thymocytes encountering their cognate antigen in F1 HAlow or 
F1 HAhigh as opposed to TCR HA and WT mice. In the thymus of TCR HA mice, 
approximately 40% of CD4 single positive (CD4sp) cells express the HA-specific 
transgenic T cell receptor as indicated by the binding of the idiotype specific 6.5 mAb 
that recognizes only the combination of transgenic Vβ8 and Vα4 (idiotype specific) 
(Figure 3A, upper panel). The rest of CD4sp cells expressed the transgenic Vβ8-chain 
and, based on being negative for 6.5, an endogenous rearranged α-chain (Figure 3A, 
upper panel to the right). When HA antigen was expressed a dramatic negative 
selection of HA-specific 6.5+ CD4sp cells occurred regardless of the dose of antigen 
expressed (Figure 3A, upper and lower middle panels). All CD4sp cells from F1 
HAlow mice did express Vβ8, whereas about 20% of the CD4sp in the thymus of F1 
HAhigh were Vβ8 low/negative, suggesting an even stronger negative selection due to 
higher expression of HA. Importantly, despite drastic deletion of HA-specific CD4sp 
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T cells in F1 HAlow and F1 HAhigh, 2-5% of the CD4sp cells were found to be 6.5+ 
and therefore expressed the transgenic TCR (Figure 3A, middle panels). No 6.5+ 
CD4sp were detectable in WT mice (Figure 3A, lower panel).  
The development of low numbers of 6.5+ CD4sp cells in both F1 HAlow and F1 
HAhigh suggests that these cells escaped negative selection. To investigate whether 
these cells underwent positive and negative selection while expressing solely the HA-
specific T cell receptor or whether cells could develop by expressing an endogenously 
rearranged receptor, we bred F1 HAlow and F1 HAhigh mice onto a Rag-2 deficient 
genetic background. In TCR HA transgenic Rag-2 deficient mice, all CD4sp cells 
were 6.5+ and almost no CD8sp could be found (Figure 3B, upper panel). In marked 
contrast, both F1 HAlow and F1 HAhigh mice on a Rag-2-/- genetic background showed 
an arrest of thymocyte development at the double positive stage (Figure 3B, middle 
and lower panel). Moreover, no T cells could be found in the periphery of these 
animals (data not shown). This finding demonstrates, that the development of CD4sp 
cells in F1 HAlow and F1 HAhigh mice on a rearrangement sufficient genetic 
background, requires the expression of another TCR with no or only low affinity for 
HA.  
Peripheral tolerance in F1 HAlow and F1 HAhigh mice 
In the next set of experiments we analyzed the peripheral CD4 T cell compartment in 
F1 HAlow and F1 HAhigh mice and compared this to TCR HA and WT mice. In the 
peripheral lymphoid organs of both F1 HAlow and F1 HAhigh mice around 3 – 5% of 
CD4 T cells express the transgenic TCR as indicated by being 6.5+. In TCR HA mice 
the percentage of CD4 cells expressing 6.5 varied from 20 – 40%, whereas no 6.5+ 
cells were detectable in WT mice (Figure 4A). Since T cell development in F1 HAlow 
and F1 HAhigh mice on a Rag-2 deficient background is blocked at the double positive 
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stage in the thymus (Figure 3B) it was likely that 6.5+ CD4 T cells in F1 HAlow and F1 
HAhigh mice express yet another non-transgenic TCR or non-transgenic TCR 
component. The TCR α-chain of the HA specific TCR uses a Vα4 variable region. 
The fact that 10 – 20% of the 6.5+ CD4 cells in F1 HAlow and F1 HAhigh mice 
expressed a TCR α-chain using a Vα2 variable region strongly supported this 
assumption (Figure 4B, middle and right panel). To our surprise, about 25% of the 
6.5+ CD4 T cells in TCR HA mice also expressed a TCR α-chain using a Vα2 
variable region (Figure 4B, left panel). One possible reason for this might be that T 
cells expressing only the HA specific TCR are poorly positively selected.  
In order to determine the activation status of CD4 T cells in the various mice 
we analyzed their CD44, CD62L and CD69 surface expression patterns. The vast 
majority (87%) of the 6.5+ CD4 T cells in TCR HA mice had a naïve phenotype 
(CD62L+ and CD44intermediate/low) and only around 10% had an activated/memory 
phenotype (CD62L- and CD44high) and around 30% of these expressed the early 
activation marker CD69 (Figure 4, C and D, left panels). More than half (56.2%) of 
the 6.5+ CD4 T cells in F1 HAlow mice had a naïve phenotype (CD62L+ and 
CD44intermediate/low) whereas around 40% had an activated/memory phenotype (CD62L- 
and CD44high). Of these around 40% expressed the early activation marker CD69. In 
marked contrast, only 15% of the 6.5+ CD4 T cells in F1 HAhigh mice had a naïve 
phenotype and over 80% had an activated/memory phenotype. Of these 70% 
expressed CD69 (Figure 4, C and D, middle and right panels). Thus, the relative 
number of activated 6.5+ CD4 T cells in F1 HAlow mice was about 3 fold higher than 
in TCR HA mice whereas in F1 HAhigh mice practically all 6.5+ CD4 T cells were 
found to be activated. Since the 6.5+ CD4 T cell population comprises only a small 
part of the total CD4 compartment in F1 HAlow and F1 HAhigh mice, we also analyzed 
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the activation status of the total CD4 T cells in the different mice. The CD44, CD62L 
and CD69 expression patterns of CD4 T cells from WT, TCR HA and F1 HAlow mice 
were practically identical in that over 75% of the cells had a naïve phenotype 
(CD62L+ and CD44intermediate/low) whereas around 20% had an activated/memory 
phenotype (CD62L- and CD44high) of which around 30% expressed CD69 
(Supplemental Figure 2, A and B). In marked contrast only 32% of the CD4 T cells in 
F1 HAhigh mice showed a naïve phenotype whereas more than 65% had an 
activated/memory phenotype of which around half expressed CD69 (Supplemental 
Figure 2, A and B). This latter finding suggests that 6.5- CD4 T cells are HA reactive 
and get activated in F1 HAhigh mice. The fact, that about 30% of the 6.5- CD4 T cells 
from TCR HA mice showed a proliferative response, when stimulated with HA 
expressing dendritic cells, supports this hypothesis (Supplemental Figure 2C).   
We also determined the percentage of CD4 cells producing GM-CSF, IFN-γ, 
IL-4 and IL-17 in young and adult TCR HA, F1 HAlow and F1 HAhigh mice. In none of 
the mice significant numbers of IL-4 and IL-17 producing CD4 T cells were detected 
(data not shown). Moreover, in young and adult TCR HA and F1 HAlow mice also no 
significant numbers of GM-CSF and IFN-γ producing CD4 T cells were detectable 
(Figure 4, E-H). In marked contrast, in young F1 HAhigh mice around 5% (5.2 ± 1.7%) 
CD4 T cells produced GM-CSF and around 23% (23.6 ± 3.7%) produced IFN-γ 
(Figure 4, E and G). In adult F1 HAhigh mice the percentage of CD4 cells producing 
GM-CSF or IFN-γ decreased but was however still significantly higher than the 
percentages found in adult TCR HA and F1 HAlow mice (Figure 4, F and H).   
Overall, our findings show that CD4 T cells in F1 HAhigh mice are activated 
and that relative high numbers of cells produce GM-CSF and IFN-γ likely causing 
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pathologies observed in F1 HAhigh mice. No autoimmunity and no or only poor CD4 T 
cell activation was observed in TCR HA and F1 HAlow mice. 
B cells from CD11c HAhigh mice efficiently stimulate 6.5+ T cells 
The strong B cell activation observed in F1 HAhigh mice suggests to underly a cognate 
interaction between HA specific T cells and HA peptide-presenting B cells. Therefore 
we analyzed whether CD11c expressing B cells could be found in the spleens of 
CD11cHAlow, CD11cHAhigh and WT BALB/c mice and whether a correlation with HA 
expression existed. About 1.5% of the cells in the spleens of these mice expressed 
CD11c and CD19 (Supplemental Figure 3). Moreover, in CD11c HAhigh mice the 
majority of these expressed HA although about one order of magnitude lower than 
dendritic cells (CD11cbright CD19-). A low level of surface HA expression was 
detectable on CD11c negative B cells (Supplemental Figure 3). No HA expression 
was detectable on CD11c+CD19+ or CD11c-CD19+ B cells derived from CD11c HAlow 
or BALB/c mice. The CD11c+CD19+ were bona fide B cells since they expressed 
IgM, IgD, CD21 and CD23 (Supplemental Figure 4). In fact the CD11c+CD19+ cells 
seemed to be enriched for marginal zone B cells since the percentage of IgMhighIgDlow 
cells and the percentage of CD21highCD23low cells was 2 – 4 fold higher than in the 
total splenic CD19 population (Supplemental Figure 4).   
In order to test the capacity of the CD11c+ and CD11c- B cells to stimulate HA 
specific T cells CD11c+CD19+ and CD11c-CD19+ cells were sorted and cultured with 
lymph node cells from TCR HA mice. CD11cbrightCD19- dendritic cells were used as 
controls. As expected no proliferation was observed using dendritic cells, CD11c+ or 
CD11c- B cells from wt BALB/c mice as stimulator cells (Supplemental Figure 5). On 
the other hand dendritic cells from both CD11c HAlow and CD11c HAhigh mice 
induced a strong proliferation of T cells derived from TCR HA mice (Supplemental 
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Figure 5). No or only marginal proliferation was observed when CD11c+ and CD11c- 
B cells from CD11c HAlow mice were used as APC’s (Supplemental Figure 5). In 
marked contrast, CD11c+ B cells from CD11c HAhigh mice induced a strong 
proliferative response whereas CD11c- B cells from these mice induced a weaker, but 
still significant, proliferative response. Therefore, the B cell activation observed in F1 
HAhigh mice is likely to be caused by the cognate interaction of HA specific transgenic 
T cells and B cells expressing HA as well as B cells that might have picked up HA. 
Increased frequency of HA specific regulatory T cells in the thymus and periphery of 
F1 HAlow mice 
In order to determine the number of 6.5+ CD4sp Treg cells in the thymus of the 
various mice, we tested Foxp3 expression. In young and adult TCR HA mice only 
around 1% of the 6.5+ CD4sp cells expressed Foxp3 (young: 1.0 ± 0.1% and adult: 0.6 
± 0.2%) (Figure 5, A and B). Thus, in the absence of HA, T cells specific for HA very 
poorly develop into Treg. In young F1 HAlow mice around 15% (16.2 ± 9.2%) and in 
adult F1 HAlow mice around 10% (9.0 ± 0.9%) of the 6.5+ CD4sp expressed Foxp3. In 
marked contrast, in the thymus of young F1 HAhigh mice only 1.5% (1.3 ± 0.3%) of the 
6.5+ CD4sp expressed Foxp3 whereas around 4% (3.7 ± 1.1%) of the 6.5+ CD4sp 
expressed Foxp3 in adult F1 HAhigh mice (Figure 5, A and B). These findings indicate 
that although antigen expression by dendritic cells favors negative selection, low level 
of antigen expression correlates with increased development of antigen-specific Treg 
as compared with high antigen expression. 
The relatively high frequency of HA specific Treg’s in the thymus of F1 HAlow 
might suggest that the apparent absence of CD4+ T cell activation in F1 HAlow mice 
might be due to an increased frequency of 6.5+ regulatory T cells in the periphery. 
Therefore we determined the proportion of Foxp3+ cells among the 6.5+ CD4+ cells in 
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the spleen of TCR HA, F1 HAlow and F1 HAhigh transgenic mice. As shown in Figure 
5, C and D, about 34% (34.0 ± 7.2%) and 18% (18.4 ± 2.1%) of the 6.5+ CD4+ T cells 
expressed Foxp3 in young and adult F1 HAlow mice respectively. In sharp contrast, 
practically no 6.5+ CD4+ T cells expressing Foxp3 were detectable in young F1 HAhigh 
mice (2.9 ± 1.1%). In adult F1 HAhigh mice the frequencies of 6.5+ Treg cells was still 
very low but significantly higher than in their young counterparts (6.1 ± 1.6% vs 2.9 ± 
1.1%). As expected, 6.5+ T cells generated in the absence of the antigen HA (TCR HA 
mice) only very poorly develop into Foxp3 positive cells. Thus, low expression of HA 
correlates with increased ratio of antigen-specific Treg and establishment of tolerance 
whereas high antigen expression favors effector T cell differentiation over Treg 
development causing autoimmunity. 
HA transgene expression in non-hematopoietic cells and its contribution to thymic 
selection 
Since HA expression under the CD11c promoter was not restricted to DC’s only, we 
tested whether HA is expressed in the non-hematopoetic compartment as well. TEC 
are non-hematopoietic antigen-presenting cells in the thymus and were shown to play 
an important role in Treg development. For effective thymic selection processes 
already very low levels of presented antigen can be sufficient. To reveal the low 
antigen expression level of TEC’s, BM chimaeras were generated to use the very 
sensitive thymic selection processes as read-out. Lethally irradiated CD11c HAhigh, 
CD11c HAlow and Igκ HA mice were reconstituted with bone marrow derived from 
TCR HA mice. In Igκ HA mice the HA antigen is expressed under control of the κ 
light chain promoter leading to HA expression by TEC’s and B cells [34]. Expression 
of the transgenic TCR HA within the CD4 T cell compartment of thymus and spleen 
was analyzed after 6 weeks (Figure 6A). In addition BM chimaeras were analyzed for 
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expression of the transcription factor FoxP3 (Figure 6B and C). In all hosts TCR HA 
expressing CD4 T cells could be positively selected. However, percentages of 6.5+ 
CD4 single-positive T cells differed among the different hosts in the thymus (Figure 
6A). In CD11c HAhigh BM chimaeras only 4.4±0.5% of the single-positive CD4 T 
cells expressed the TCR HA, whereas in CD11c HAlow BM chimaeras about 
18.9±4.9% 6.5+ CD4 single-positive T cells were detected. In BALB/c and Igκ HA 
BM chimaeras, 43.2±5.2% and 9.5±2.1% 6.5+ CD4 single-positve T cells were found 
respectively. In the periphery slightly lower percentages for 6.5+ CD4 T cells were 
observed compared to levels detected in the thymus (CD11c HAhigh: 5.0±0.2%, CD11c 
HAlow: 11.1±3.7%, BALB/c: 25.5±3.1%, Igκ HA: 5.7±0.8%). According to these 
results the HA transgene under the CD11c promoter is expressed in the TEC 
compartment and TECs could be shown to efficiently contribute to positive and 
negative selection processes independently of transgene expression in the lymphoid 
compartment.  
To reveal the contribution of the TEC compartment to the development of 6.5+ Treg’s, 
FoxP3 expression was detected by intracellular staining in BM chimaeras (as 
described before) 6 weeks after reconstitution. Dramatic differences in the 6.5+ Treg 
compartment were found comparing the different hosts, namely CD11c HAhigh, 
CD11c HAlow, Igκ HA and BALB/c. In absolute numbers only about 100 6.5+ Treg’s 
were detected in the thymus of CD11c HAhigh BM chimaeras, whereas in CD11c 
HAlow BM chimaeras 3.3*104±3.0*104 6.5+ Treg’s were found. BALB/c mice 
generated 1.5*104±1.0*104 and Igκ HA mice 1.9*103±1.2*103 6.5+ Treg’s. In the 
periphery total numbers of 6.5+ Treg’s were increased in all hosts compared to 
thymus. However, in CD11c HAhigh BM chimaeras the 6.5+ Treg population 
(4.5*103±1.6*103) still was markedly smaller compared to the other hosts (CD11c 
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HAlow: 4.2*104±2.1*104, BALB/c: 7.2*104 ±3.4*104, Igκ HA: 1.8*104±0.6*104). 
Considering the size of the complete CD4 T cell compartment, only CD11c HAlow and 
Igκ HA BM chimaeras showed with 32.2±4.1% and 17.8±1.9% an increased 
generation of 6.5+ Treg’s compared to BALB/c controls (1.0±0.2%) and CD11c 
HAhigh BM chimaeras (3.8±0.6%) in the thymus (Figure 6B). In the periphery similar 
results were found for 6.5+ Treg’s comparing CD11c HAlow (39.9±3.5%), Igκ HA 
(58.3±5.1%), BALB/c (8.5±2.1) and CD11c HAhigh (13.7±3.3%) BM chimaeras 
(Figure 6C). Thus, TECs could not only be shown to efficiently contribute to positive 
and negative selection processes but as well to Treg development in systems featuring 
a low antigen expression level. 
Transfer of HA specific Treg’s can in part inhibit the development of autoimmunity in 
F1 HAhigh mice 
The findings described above suggested that the autoimmunity observed in F1 HAhigh 
mice was due to an inefficient development of a HA specific Treg compartment. In 
order to test this hypothesis, we sorted HA-specific regulatory T cells from TCR HA 
x Igκ HA double transgenic mice that were described to generate high percentages of 
HA specific Treg’s [8] as well as polyclonal Treg’s from WT BALB/c mice and 
transferred them into newborn F1 HAhigh mice. As summarized in Figure 7A, the 
transfer of 6.5+ Treg’s (HA-Treg’s) but not polyclonal Treg’s (WT Treg’s) prevented 
the onset of anemia in young F1 HAhigh mice. Moreover, the frequency of IFN-γ and 
GM-CSF producing CD4 T cells reduced by a factor of 2 upon transfer of antigen 
specific Treg’s but not by polyclonal Treg’s (Figure 7, B and C). These results 
suggest that the signs of autoimmunity observed in young F1 HAhigh mice is due to an 
absence of HA specific Treg’s. However, the onset of arthritis and the development of 
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IgG auto-antibodies in adult F1 HAhigh mice could not be inhibited by HA-specific 
Treg’s (data not shown). 
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Discussion 
Here, using transgenic mice expressing HA under control of the CD11c promoter we 
studied the influence of the dose of antigen presented by DC’s on central and 
peripheral T cell tolerance and the development of autoimmunity. CD11c is widely 
regarded as a dendritic cell marker [35, 36]. However, low levels of CD11c are also 
expressed by NK cells [37] and B cells expressing CD11c have also been described 
[38, 39]. In our system, expression of the neo-self-antigen HA under the CD11c 
promoter was not only directed to DC’s. In the CD11c HAhigh mouse strain, also NK 
cells were found to express HA. The highest HA expression level in the CD11c HAlow 
strain was as well found in the DC compartment. However, the HA transgene 
expression pattern in CD11c HAlow mice differed from the one observed in CD11c 
HAhigh mice, probably due to different transgene insertion sites. Results derived from 
BM chimaeras indicate that the HA transgene is as well expressed by TEC’s.  
Our findings show, that independent of the dose of the neo-self-antigen HA 
expressed in the thymus and of mouse age, negative selection of HA-specific 
thymocytes is efficient since DC’s from both F1 HAlow and F1 HAhigh mice were 
equally able to delete 6.5+ (mAb specific for TCR HA) thymocytes and negative 
selection was complete in both systems, on a Rag-2 deficient background. However, 
we observed interesting differences in the negative selection process in F1 HAlow and 
F1 HAhigh mice. All CD4sp thymocytes in F1 HAlow, as in TCR HA mice, expressed 
high levels of the transgenic Vβ8 chain (Figure 3), indicating that in F1 HAlow mice 
TCR β-chain allelic exclusion is very efficient. In contrast, in F1 HAhigh mice, about 
20% of the CD4sp cells expressed only low or not detectable levels of Vβ8. This 
finding suggests, that negative selection in F1 HAhigh mice is more stringent and 
therefore CD4sp T cells, that escaped negative selection by not obeying the rule of 
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TCR β-chain allelic exclusion, are proportionally enriched. In both, F1 HAlow and F1 
HAhigh mice, on a Rag-2 deficient background, negative selection is complete. 
Nevertheless, the finding that double positive thymocytes from Rag-2 deficient F1 
HAlow mice express low levels of transgenic TCR on their surface whereas double 
positive thymocytes from Rag-2 deficient F1 HAhigh mice are 6.5 negative (Figure 3), 
also suggests that in the case where DC’s express higher amounts of antigen negative 
selection is more stringent. Thus, negative selection seems to be determined by the 
affinity and avidity of the interaction between TCR and its corresponding antigen.  
The finding that mature T cells are absent in F1 HAlow and F1 HAhigh mice on a 
Rag-2 deficient background demonstrates that in Rag-2 proficient mice, T cells can 
only escape negative selection by expression of a second non-HA specific TCR or of 
a TCR with an altered affinity to the antigen HA. The expression of a non-transgenic 
TCR α-chain by a proportion of mature CD4 cells in F1 HAlow and F1 HAhigh mice 
supports this hypothesis. As already suggested by others [40], the rearrangement of an 
endogenous α-chain is probably occurring in a stochastic manner prior to negative 
selection. In other words, it is likely that T cells expressing an endogenous rearranged 
TCR α-chain with a pairing efficiency to the transgenic TCR β-chain higher than the 
one of the transgenic α-chain will not or poorly express the transgenic HA-specific 
TCR and therefore could escape negative selection. It is important to note that under 
physiological conditions, significant numbers of T cells expressing 2 different α-
chains have been found both in human blood and the periphery of WT mice [27-32]. 
Moreover, it has been indicated that T cells expressing two TCR α-chains can induce 
autoimmunity [28]. 
In the periphery of F1 HAlow and F1 HAhigh mice CD4 T cells with a HA specific TCR 
could be found. Based on the fact that no peripheral T cells were detectable in F1 
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HAlow and F1 HAhigh mice on a Rag-2 deficient background these T cells must have 
escaped negative selection by the expression of a second TCR in both double 
transgenic mouse strains. However, the phenotype of the overall CD4 T cell 
population, including the 6.5+ ones, in the spleen of F1 HAlow and F1 HAhigh mice 
differed dramatically. Unlike F1 HAlow CD4 cells, most of the splenic CD4 cells in F1 
HAhigh mice had an activated phenotype and, especially in young mice, a high number 
of them produced IFN-γ and GM-CSF. Disease phenotype is rather unlikely to be 
caused by a strong T cell proliferation due to lymphopenia, that could be caused by 
extensive negative selection in F1 CD11c HAhigh mice. Lymphopenia induced 
proliferation was shown to correlate with a memory-phenotype T cell compartment 
[41].  
 It has been demonstrated that TCR stimulation in absence of co-stimulation 
leads to T cell tolerance by deletion, anergy or Treg conversion mechanisms. It is 
therefore surprising that T cells get activated in the first place since dendritic cells 
from CD11c HAhigh mice are not more activated than dendritic cells from CD11c 
HAlow or WT mice. We would argue, that even in the absence of infectious agents, it 
is very likely that few dendritic cells get activated due to tissue damage, contact with 
commensal bacteria or local inflammation. The chance that any HA-specific T cells 
encounter one of the few activated DC’s is considerable and cumulative chances over 
time probably reach 100%. Once a T cell gets activated, it will express CD40L and be 
able to activate dendritic cells through CD40-CD40L interaction, newly activated 
dendritic cells will activate more T cells therefore creating an activation loop that 
never stops.  
Differences in T cell activation go in parallel with the presence or absence of 
Treg cells. A remarkable difference between CD4sp T cells of F1 HAlow and F1 HAhigh 
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mice is the Foxp3 expression in the thymus. Around 10 – 20% of 6.5+ CD4sp cells of 
F1 HAlow mice express Foxp3, whereas only very few of them of F1 HAhigh mice do 
express Foxp3 in absolute numbers.  
TEC’s were described to be able to induce Treg development [42]. To study if HA 
expression under the CD11c promoter leads to HA expression by TEC’s CD11c 
HAhigh, CD11c HAlow and Igκ HA mice were lethally irradiated and reconstituted with 
bone marrow derived from TCR HA mice. In CD11c HAlow as well as in Igκ HA BM 
chimaeras 32.2±4.1% and 17.8±1.8% 6.5+ Treg’s which corresponds to about 33000 
and 2000 cells in absolute numbers, were generated respectively. These results 
suggest that the HA antigen is not only expressed by DC’s as thymic APC but as well 
by TEC’s. In contrast, in CD11c HAhigh BM chimaeras only 3.8±0.6% 6.5+ Treg’s 
were detected. In absolute numbers that corresponds to about 100 6.5+ Treg cells only. 
Thus, the avidity of the TCR – thymic APC interaction seems to control not only the 
stringency of negative selection but as well Treg formation i.e. for a strong TCR self-
affinity, low avidity allows Treg development whereas high avidity seems to 
contribute to a very stringent negative selection process. Very recently, it was shown 
that not only TEC’s but as well a subset of the DC compartment was able to support 
Treg development by rescue of developing Treg cells from apoptosis via CD27-CD70 
pathway [43]. These findings suggest, that in our HA mouse model several APC’s 
contribute to thymic selection and that avidity seems to be a superior factor for these 
selection processes. In a recent study by Hinterberger et al, a similar conclusion was 
drawn based on the findings, that Treg development in the thymus increased upon 
decrease of MHC class II expression [44]. Moreover, in this context, it is noteworthy, 
that conversion of conventional T cells into Treg’s in the periphery can be achieved 
by targeting low but not high concentrations of antigen to DC’s [19, 20, 45]. 
 	
   24 
The exact mechanism for Treg development is not yet understood. One plausible 
explanation for Treg generation in our system would be the selection into Treg 
lineage by usage of a second endogenously rearranged TCR. In this case, Treg’s 
would be selected upon interaction with an unknown endogenous antigen. Only in the 
periphery these Treg’s could reexpress the transgenic TCR on the surface and mediate 
Treg function. However, assuming Treg selection is based on a second endogenously 
rearranged TCR, we have no explanation for differences in total thymic Treg 
occurrence comparing F1 CD11c HAlow and F1 CD11c HAhigh as well as CD11c HAlow 
and CD11c HAhigh TCR HA BM chimaeras. In case Treg selection is based on a 
second TCR with unknown specificity, one would expect a comparable amount of 
total thymic Treg’s as the selecting ligands would be expected to be expressed on 
comparable levels. However, one could argue that negative selection is more stringent 
in CD11c HAhigh background as deletion of thymocytes affects as well thymocytes 
expressing the transgenic Vβ8 in combination with an endogenous Vα chain. In 
CD11c HAlow background thymocytes are almost all positive for vβ8 and therefore it 
is likely that in such a system more T cells expressing 2 TCRs are generated. Thus, 
Treg numbers could be increased in general. Several groups provided data supporting 
an instructive Treg model [46, 47]. According to this model the number of selected 
Treg cells is inversely proportional to the fraction of thymocytes expressing 
transgenic TCR. This finding was interpreted as evidence that Treg precursors need 
an intense interaction with a selecting ligand which is achieved by "diluting" Treg 
precursors. In our model, only few HA reactive thymocytes are present in the F1 
CD11c HAlow mice due to a strong negative selection. Those clones show a high 
incidence for developing further into Treg lineage. F1 CD11c HAhigh mice show an 
even stronger negative selection. In this system only very few clones are not deleted 
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but could be selected into Treg lineage. However, it is well possible that these few 
Treg cells after leaving the thymus are overwhelmed by the inflammatory milieu in 
the periphery especially in the young F1 CD11c HAhigh mice and therefore are not able 
to perform adequate suppressive function. Some of them might proliferate over time 
and eventually contribute to the minor increase in 6.5+ Treg’s in adult F1 CD11c 
HAhigh mice.  
Moreover, like in the thymus, practically no 6.5+ CD4 T cells expressing 
Foxp3 were detectable in the spleen of young F1 HAhigh mice whereas around 35% of 
these were Foxp3 positive in young F1 HAlow mice. The absence of HA specific 
Treg’s in young F1 HAhigh mice might well be the cause of the anemia and the 
myeloid hyperplasia since mice that cannot generate Treg’s show a similar phenotype 
[48-50]. The findings that the cytokine production by CD4 cells, the anemia and the 
myeloid hyperplasia can to large extent be overcome by the transfer of HA specific 
Treg’s into newborns, but not by polyclonal Treg’s strongly supports this hypothesis. 
The myeloid hyperplasia observed in young F1 HAhigh mice is likely to be due to the 
relative high number of GM-CSF producing CD4 T cells. Moreover it could well be 
envisaged that the observed anemia is indirectly caused by the high number of GM-
CSF producing CD4 T cells in that this causes an increase of myelopoiesis at expense 
of erythropoiesis in the bone marrow. 
In adult F1 HAhigh mice the relative numbers of IFN-γ and GM-CSF CD4 cells 
decreased and a normalization of the hematocrit values was observed. Moreover, a 
small but significant increase in HA specific Treg’s was observed. Nevertheless, all 
adult F1 HAhigh mice developed arthritis and had high titers of IgG ANA. In other 
words from young to adult the disease observed changed from an acute to a more 
chronic type. We should stress that HA-specific regulatory T cells transfer did not 
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improve the disease in adult F1 HAhigh mice. One explanation is the possible 
disappearance or exhaustion of transferred cells over time. However, even if HA-
specific Treg cells were to be transferred throughout life of F1 HAhigh mice, it is very 
likely that the ratio of thymus output of HA-specific effector cells versus transferred 
HA-specific Treg cells would still be imbalanced towards effector cells. Therefore, 
our model would argue that, autoimmune diseases that are sustained by a constant 
thymus output of self-specific cells are unlikely to be successfully treated by one or 
several transfers of Treg cells. 
 Autoimmune disease was remarkably different in young versus adult F1 
HAhigh animals correlating with differences in the level of T cell activation. The 
difference is likely to be explained by the number of HA specific Treg’s. In young F1 
HAhigh mice they are practically absent whereas in adult mice their number is low but 
significantly increased. This increased number of HA specific Treg’s is likely to be 
responsible for the change in the observed autoimmunity disorder in these mice. The 
increase of these Treg’s in adult mice might well be due to an IL-2 driven 
proliferative expansion of the very low numbers generated in the young thymus.  
As described before, HA under control of the CD11c promoter was found to 
be expressed not only by DC’s but as well, e.g., at a low level by B cells. The strong 
B cell activation observed in the F1 HAhigh mice might at least in part be due to 
cognate interaction between HA specific T cells and CD11c+ HA expressing B cells. 
Moreover, although less efficient B cell activation seems also to be due to the cognate 
interaction of HA specific T cells and B cells, that picked up HA molecules and 
processed them for presentation. The strong B cell activation in the F1 HAhigh mice 
results in the formation of high titers of IgG ANA. However, whether the strong B 
cell activation is also involved in the development of arthritis is still unclear. We are 
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currently generating a B cell deficient BALB/c mouse in order to address this 
question. However, unlike in several other model systems [51, 52] arthritis could not 
be transferred by serum from diseased mice (data not shown). 
 Models of autoimmune disease caused by concomitant transgenic expression 
of a TCR together with cognate antigen have already been reported by others [28, 53-
55]. Interestingly, when mice expressing HA under SV40 [56], Igκ [57], 
phosphoglycerate kinase [58, 59] or Aire [42] promoter are crossed with TCR HA 
mice, offspring develop normal without any signs of autoimmunity. In contrast, HA-
specific cells in these mice are enriched for Foxp3+ CD4 cells and/or IL-10 secreting 
cells as a result of regulatory T cell development in the thymus or effector cell 
conversion in the periphery. However, a recent publication showed that mice 
expressing a transgenic TCR specific for HA crossed to a transgenic mouse 
expressing HA under control of the MHC class II promoter developed arthritis [54]. 
Somehow surprising, the development in this model is not dependent on T cells 
escaping negative selection by expressing two TCR’s since arthritis development was 
also observed on a Rag deficient background. Whether these double transgenic mice 
when they are young suffer from anemia has not been documented. Altogether, the 
comparison of all these double transgenic models suggests that the nature of the cell 
type expressing a self-antigen critically influences T cell biology.  
Our results demonstrate, that not only the identity of the antigen presenting 
cells, but also the dose of antigen expression, influences the establishment of 
tolerance versus autoimmunity. Overall, it is well established that dendritic cells play 
a crucial role in thymic negative selection of T cells expressing a TCR with high 
affinity for MHC peptide complexes. Our data presented here, argue that also the 
avidity between TCR and MHC peptide complexes might play a role in thymic 
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selection in that high avidity interaction results in a more stringent negative selection, 
whereas low avidity interaction seems to support Treg formation.  
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Materials and Methods 
Mice  
BALB/c, BALB/c Rag-2 deficient, Igκ HA BALB/c [34] mice and BALB/c mice 
expressing a transgenic αβ TCR specific for peptide 111 – 119 of HA [33, 60] were 
bred under SPF conditions in our animal unit. For the generation of transgenic mice 
expressing HA under control of the CD11c promoter, the complete coding region of 
the HA gene of influenza virus A/PR8/34 was PCR amplified from the cDNA clone 
pGEM-4-HA (kindly provided by Dr. A. Caton, Wistar Institute, Philadelphia, 
PA)[61]. The HA PCR product was inserted as a blunt-end product into the EcoRI site 
of rabbit β-globin gene of the CD11c-promoter vector as previously described [36], 
(the CD11c-promoter vector was kindly provided by Dr. T. Brocker, University of 
Munich, Germany). The plasmid DNA was linearized by XhoI and NotI digestion and 
injected into fertilized oocytes from BALB/c mice. HA transgenic mice were selected 
by PCR analysis using mouse tail DNA as a template and the following HA-specific 
primers: 5’-TCCCTCAGCTCCTCATAGTC-3’ and 5’-
GAAAGGACTCTGGATTTCCATG-3’. Of the nine different founder mice, five 
expressed the HA transgene as determined by RT-PCR and by FACS analysis using a 
rat anti HA monoclonal antibody for surface staining of dendritic cells (kindly 
provided by Dr. A. Caton, Wistar Institute, Philadelphia, PA; used as described in 
[34]) for surface staining of spleen cells. All founder mice expressed the HA 
transgene in a CD11c specific manner. Two founders that surface-expressed the HA 
antigen either at a high (CD11c HAhigh) or a low (CD11c HAlow) level were used in the 
following experiments. 
All animal experiments were approved by the State veterinary authorities of Basel 
(Kantonales Veterinäramt, Basel-Stadt). 
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Southern Blot analyses of HA transgene copy numbers 
Genomic DNA of thymus-derived cells was isolated from different founders by 
phenolic extraction. 5 µg of DNA was digested over night with PvuII and separated 
on a 1.8% agarose gel. The gel was blotted onto a nylon membrane (Roche 
Diagnostics GmbH, Mannheim) over night and UV crosslinked (0.12 J/cm2). A DIG-
labeled probe specific for HA with a size of 373 bp was PCR amplified using the 
following primer set: forward primer 5’-GACAGCCACAACGGAAAACT-3’ and 
reverse primer 5’-GGTATGAGCCCTCCTTCTCC-3’. As PCR template the HA gene 
of influenza virus A/PR8/34 cloned blunt-ended into the LXP plasmid via the EcoRI 
restriction site. Probe labeling, hybridization and chemiluminescence detection were 
performed according to standard protocols (Roche Diagnostics GmbH). 
HA transgene expression in different cell lineages 
cDC’s, pDC’s were derived from 7 day BM cultures (1x106 cells/ml, 200 ng/ml 
FLT3L) and were sorted according to their expression level of CD11c, MHCII and 
Siglec H [62]. NK cells were derived from 5 day BM cultures (1x106 cells/ml, 104 
U/ml of recombinant mouse IL-2) [63]. B and T cells were sorted from spleen 
suspension ex vivo according to the expression of CD19 or CD3. RNA was prepared 
from all cell samples using Tri Reagent (MRC). 400 ng RNA were used in a first 
strand synthesis reaction. Expression of the HA transgene was revealed by qPCR 
using the forward primer 5’-GACAGCCACAACGGAAAACT-3’ and the reverse 
primer 5’-CCCTCAGCTCCTCATAGTCG-3’ (amplicon: 205 bp). HPRT was 
amplified as endogenous control gene and results were shown as fold expression 
referring to cDC cDNA derived from CD11c HAhigh mice.  
Antibodies and flow cytometric analysis 
 	
   31 
FITC-, PE-, APC- or biotin-conjugated mAb specific for CD4 (L3T4), CD8α (53-
6.7), CD69 (H1.2F3), CD44 (IM7), CD62L (MEL-14), anti-TCR β-chain (H57-597), 
CD19 (6D5), Gr1 (RB6-8C5), CD11b (M1/70), Vβ8 (F23.1) and Vα2 (B20.1) were 
purchased from BD Bioscience (Allschwil, Switzerland). Streptavidin, conjugated to 
PE, APC or PE/Cy7 were also purchased from BD Bioscience. Anti-FoxP3 (FJK-
16s), anti-IFN-γ (XMG1.2) and anti-GM-CSF (MPI-22E9) were purchased from 
eBioscience. The rat anti-CD19 (ID3) monoclonal antibody and the rat anti-TCR HA 
clonotype specific mAb 6.5 [33] were purified from hybridoma supernatants and 
labeled with biotin in our laboratory by standard methods. Flow cytometry was 
performed using a TMFACS Calibur (BD Biosience) and sorting using the TMFACS-
ARIA (BD Biosience). Data were analyzed using the TMCell Quest Pro Software (BD 
Bioscience). CFSE labeling was performed according to standard procedures; briefly, 
sorted cells were labeled in the dark at 37oC for 5 minutes. In Figure 1 and 2, 
dendritic cells were enriched from thymus or spleen as described elsewhere [62].  
Immunohistochemical and histological analyses 
Spleens were snap frozen and embedded in OCT-compound (Sakura, Zoetermeer, 
NL), and 5 µm sections were prepared. Sections were fixed in acetone for 10 min and 
then air dried for 60 min. To analyze B and T cell organization in spleen and to 
determine the presence of germinal centers in spleen, sections were incubated with 
biotinylated anti-IgM (clone M41) and FITC labeled anti-Thy1 (T24) or with anti-
IgM FITC (M41) and biotinylated peanut agglutinin (PNA) (Vector, Burlingame, CA) 
for 30 min. After 20 min washing in PBS, anti-IgM and PNA binding were revealed 
with PE conjugated streptavidin (SouthernBiotech, Birmingham, AL). Paw joints 
were detached and fixed in 4% buffered formalin, decalcified in 20% EDTA and 
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embedded in paraffin. Standard frontal sections of the joints were stained with 
hematoxylin and eosin (H&E) according to standard procedures. 
Hematocrit determination 
Mice were bled into Na-heparinized micro-haematocrit tubes (Huber&Co.AG, 
Reinach). Red blood cells were separated from plasma by a 10 min centrifugation step 
at 10,000 rpm in a Haemofuge A (Heraeus AG, Switzerland) and hematocrit values 
were calculated as percentage of red blood cell volume of whole blood sample 
volume. 
IgG anti-nuclear autoantibody determination 
IgG autoantibodies against nuclear antigens were detected by an indirect 
immunofluorescence technique (described in [64]), using a FITC labeled goat anti-
mouse IgG (Jackson Immunoresearch, Milan Analytica, La Roche, CH); 5 µm 
cryosections of kidneys from Rag-2 deficient mice were used as substrate. The titer 
was defined as the highest serum dilution still giving a positive nuclear staining. 
PMA/ionomycine stimulation 
Total lymphocytes were stimulated at 37°C during 4 hours using 1 µg/ml ionomycine 
(Sigma-Aldrich) and 5ng/ml phorbol-12-myristate-13-acetate (PMA) in the presence 
of 10 µg/ml brefeldin A (Calbiochem). Cells were harvested and stained by standard 
intracellular staining procedure. In brief, surface staining was followed by a fixation 
step using 2% paraformaldehyde in PBS followed by intracellular staining in FACS 
buffer containing 0.5% saponin. 
T cell proliferation assays 
T cells expressing or not expressing the transgenic HA specific TCR recognized by 
the anti- clonotypic 6.5 mAb were sorted from TCR HA mice. Various numbers of 
these cells were co-cultured with 5 x 105 2400 rad irradiated spleen cells from CD11c 
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HAhigh mice or WT BALB/c mice. At day 3 of culture proliferation was determined by 
3[H]-Thymidine uptake. To test the ability of CD11c+ B cells to stimulate HA specific 
T cells, CD11c+ CD19+, CD11cbright CD19- and CD11c- CD19+ cells were sorted from 
single transgenic CD11c HAhigh, CD11c HAlow and WT BALB/c mice and various 
numbers of these were co-cultured with 2 x 105 lymph node cells from TCR HA mice. 
At day 4 of culture proliferation was determined by 3[H]-Thymidine uptake. 
Treg transfer into newborn F1 HAhigh mice 
Treg cells were purified from (Igκ HA x TCR HA)F1 mice by magnetic enrichment 
of CD4 cells followed by cell sorting of CD25+, 6.5+ CD4 T cells using the FACS 
ARIA. As control, Treg cells were isolated from WT BALB/c mice. 1.5 x 105 HA 
specific or polyclonal Treg’s were injected i.p. into newborn F1 HAhigh mice. 
BM chimaera 
Bone marrow (BM) was isolated from femur and tibia of TCR HA donor mice. BM 
cell suspension was incubated with anti-CD4 (RL172) and anti-CD8 mAb (31M) 
prior to complement depletion of T cells by incubating the sample with rabbit serum 
(1:20 in DMEM) for 30 min at 37°C. The procedure was followed by erythrocyte 
lysis buffer treatment. Single transgenic BALB/c, CD11c HAhigh, CD11c HAlow and 
Igκ HA recipients were lethally irradiated (750 rad) prior to injection of 4*106 T cell 
depleted BM cells/mouse. BM chimaeras were analyzed in week 6 after BM 
reconstitution. 
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Figure 1 
Expression of HA by CD11c positive cells in the spleen and thymus of CD11c HA transgenic mice. (A) Dot plots show CD11c versus 
HA expression on the dendritic cells enriched fractions from the spleen of WT BALB/c, CD11c HAlow and CD11c HAhigh transgenic 
mice. Histograms show HA expression on CD11c high cells from the spleen (left) or thymus (right) of WT BALB/c, CD11c HAlow and 
CD11c HAhigh transgenic mice.  (B) The difference in copy number of the inserted HA transgene in CD11c HAlow and CD11c HAhigh 
founders was assessed by Southern blotting using a DIG-labeled HA specific probe (373 bp). Below is a picture of the Red Safe® stained 
gel prior to transfer to the nylon membrane as loading control. (C) Sorted- CFSE-labeled 6.5+ CD4+ cells from TCR HA mice were 
co-cultured with sorted and irradiated DCs from WT BALB/c, CD11c HAlow or CD11c HAhigh mice in several T cell to dendritic cell 
ratios (T : DC). T cell proliferation was measured by monitoring CFSE-dilution at day 4. (D) The expression of HA antigen under the 
CD11c promoter was analyzed by qPCR using cDNA of sorted NK, cDC, pDC, T, B and myeloid cell populations of the CD11cHAhigh 
(to the left), CD11cHAlow (middle) and WT BALB/c (to the right) mouse strains. For each sample HA and HPRT (control) cDNA was 
PCR amplified and the fold change 2(-ΔΔct) was determined referring to the cDC sample derived from CD11cHAhigh mice. All panels show 
representative experiments, which have been performed at least 3 times on separate and independent occasions. 
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Figure 2 
Disease indicators in the serum and tissues of young (week 4) and adult (> week 8) double transgenic (TCR HAxCD11c HA) F1 mice 
(A-D) and immunoflourescence of spleen sections, serum anti-nuclear antibodies and histology of joints from double transgenic mice 
(E-J). (A-B) Hematocrit values for young (A) and adult (B) mice of double transgenic F1 HAlow, F1 HAhigh and single transgenic TCR 
HA mice. Hematocrit values of healthy WT mice are within the range of 40-50%. (C-D) Total number of myeloid cells (Gr1+, CD11b+) 
in the spleen of young (C) and adult (D) animals of the same mouse strains. Asterisks indicate P< 0.01 for the groups compared as 
indicated by the horizontal bars. (E) Spleen sections from young and adult double transgenic F1 HAlow, F1 HAhigh mice stained for IgM 
(green; monoclonal anti-µ) and peanut agglutinin (red) to reveal B cell organization and germinal center formation (scale bar: 350 µm). 
(F) Spleen sections from young and adult double transgenic F1 HAlow, F1 HAhigh stained for IgM (red; monoclonal anti-µ) and T cells 
(green; monoclonal anti-Thy1) to examine B and T cell organization (scale bar: 350 µm). (G) Titers of IgG anti-nuclear autoantibodies 
(ANA) in the serum of adult double transgenic F1 HAlow, F1 HAhigh and single transgenic TCR HA mice. Each symbol represents an 
individual mouse. The titer is defined as the highest serum dilution still giving a positive nuclear staining in the indirect-immunofluores-
cence assay (nd: not detectable level). (H) Histological section of normal joint with no inflammation (x25 H&E). (I) Joint from an adult 
F1 HAhigh mouse with severe arthritis (x25 H&E), showing (J) granulation tissue, synovial destruction as well as mononuclear inflamma-
tion (x100 H&E). All panels show representative experiments, which have been performed at least 3 times on separate and independent 
occasions.
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Figure 3
Negative selection of HA-specific thymocytes in the thymi of F1 HAlow and F1 HAhigh double transgenic mice. (A) FACS analyses of 
the expression of CD4 and CD8 on thymocytes from single transgenic TCR HA, double transgenic F1 HAlow, F1 HAhigh and WT 
BALB/c mice (to the left). Histograms (to the right) showing the expression of the transgenic HA specific TCR (vβ8 and vα4, 
detected by the idiotype specific antibody 6.5, bold line) or transgenic vβ8 chain only (dashed line) versus unstained cells (solid line). 
Histograms were generated after gating on CD4sp thymocytes as indicated in the dot plots to the left. (B) FACS analyses of the 
expression of CD4 and CD8 on thymocytes from single transgenic TCR HA, double transgenic F1 HAlow and F1 HAhigh mice on a 
Rag-/- genetic background (to the left). FACS analyses of the expression of CD4 and HA-specific TCR (6.5) on thymocytes from 
single transgenic TCR HA, double transgenic F1 HAlow and F1 HAhigh mice on a Rag-/- genetic background (to the right). All panels 
show representative experiments, which have been performed at least 3 times on separate and independent occasions. 
CD8 6.5/vβ8
6.5
C
D
4
11.1 62.7
1.0 25.2
42.4 46.4
1.4 9.8
80.1 9.6
4.4 5.9
3.1 4.1 17.6 13.0 65.2 4.6
CD62L
C
D
44
C
D
69
TCR HA F1 HAlow F1 HAhigh
CD62L
A
C
D
33.7 11.6 3.1 0.7 2.8 0.4
B
Vα2
6.
5
WT BALB/c
38.6
6.0
25.6
29.8
0.7
0.9
29.5
68.9
1.7
0.7
49.3
48.3
0.1
0.1
51.6
48.2
0.0
2.5
5.0
7.5
TCR HAF1 HAlow F1 HAhigh
Young
0.5±0.1
5.2±1.7
0.1±0.2
C
D
4+
,G
M
-C
SF
+  c
el
ls
 [%
]  * *
0
5
10
15
20
25
30
35
C
D
4+
,IF
N
-γ
+  c
el
ls
 [%
]  
  
TCR HAF1 HAlow F1 HAhigh
2.4±1.2
23.6±3.7
1.0±0.7
* *
0
5
10
15
20
25
30
35
TCR HAF1 HAlow F1 HAhigh
3.3±0.6
7.4±1.8
2.8±0.9
C
D
4+
,IF
N
-γ
+  c
el
ls
 [%
]  
* *
0.0
2.5
5.0
7.5
TCR HAF1 HAlow F1 HAhigh
Adult
0.6±0.2 1.5±0.8 0.5±0.2
C
D
4+
,G
M
-C
SF
+  c
el
ls
 [%
]  
* *
E F
HG
Figure 4
Absence of peripheral tolerance and activation of HA-specific CD4 T cells in F1 HAhigh mice. (A) Dot plots show 
CD4 versus HA-specific TCR (6.5) expression on cells from lymph nodes of adult single transgenic TCR HA (left 
panel), adult double transgenic F1 HAlow (middle, left panel), F1 HAhigh (middle, right panel) and adult WT 
BALB/c (right panel) mice.  (B)  Endogenous Vα2 and HA-specific TCR (6.5) expression by CD4 positive cells 
from lymph nodes of single transgenic TCR HA, double transgenic F1 HAlow and F1 HAhigh mice. (C-D) For fur-
ther analysis cells were gated on CD4+6.5+ cells and examined for naïve (CD62L+ and CD44intermediate/low) or 
activated/memory (CD62L- and CD44high) cell phenotype (C) and for expression of the early activation marker 
CD69 (D). (E-H) Inflammatory cytokine GM-CSF (E- F) and IFN-γ (G-H) secretion after PMA/ionomycine 
stimulation of CD4+ spleen cells from 4 week (E- G) or 8 week (F-H) old mice. Asterisks indicate P< 0.02 for the 
groups compared as indicated by the horizontal bars. All panels show representative experiments, which have 
been performed at least 3 times on separate and independent occasions.
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Autoimmunity correlates with poor HA-specific Treg development in F1 HAhigh mice. (A-B) Histograms show the percentages of FoxP3 
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All panels show representative experiments, which have been performed at least 3 times on separate and independent occasions. 
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TECs express the HA transgene and contribute to thymic selection. (A) FACS analyses of the expression of CD4 and CD8 on thymocytes 
from WT BALB/c, single transgenic CD11c HAlow, CD11c HAhigh and Igĸ HA lethally irradiated hosts reconstituted with BM derived 
from TCR HA mice (to the left). To the right, FACS analyses of the expression of CD4 and HA-specific TCR (6.5) on CD4sp thymocytes 
of respective chimaeras. (B-C) Histograms show percentages of FoxP3 positive cells among HA-specific (6.5 positive) CD4sp cells from 
the thymus (B) or spleen (C) of WT BALB/c, CD11c HAhigh, CD11c HAlow or Igκ HA chimaeras reconstituted with BM derived from 
TCR HA mice. Dots represent individual animals and the mean ± SD is given in the plots for the different groups of mice. Asterisks 
indicate P<0.05 for the groups compared as indicated by the horizontal bars. All panels show representative experiments, which have 
been performed at least 3 times on separate and independent occasions.
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Figure 7
Transfer of HA specific Tregs into newborn F1 HAhigh mice. Newborn double transgenic F1 HAhigh mice were 
injected i.p. with sorted CD4+CD25high Treg cells from (Igĸ HAxTCR HA)F1 mice (HA Treg) or from WT 
BALB/c mice (WT Treg). Untreated F1 HAhigh mice were used as controls. After 4 weeks hematocrit values (A) 
as well as the fraction of CD4+ spleen cells secreting IFN-γ (B) or GM-CSF (C) upon PMA/ionomycine stimula-
tion were determined. Dots represent individual animals and the mean ± SD is given below for the different 
groups of mice. Asterisks indicate P< 0.01 for the groups compared as indicated by the horizontal bars. All panels 
show representative experiments, which have been performed at least 3 times on separate and independent occa-
sions. 
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Supplemental Figure 1
No phenotypic changes of dendritic cells from CD11c HA transgenic mice. Histograms show surface expression of HA, 
MHC II, CD80, CD86 and CD40 on isolated CD11c+ spleen cells from WT BALB/c, CD11c HAlow and CD11c HAhigh 
transgenic mice. All panels show representative experiments, which have been performed at least 3 times on separate and 
independent occasions.
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Supplemental Figure 2 
Activation of CD4 T cell population in the periphery of F1 HAhigh transgenic mice. (A) Dot plots show surface expression of CD62L and 
CD44 or (B) CD62L and CD69 on CD4+ lymph node cells from adult single transgenic TCR HA mice, adult double transgenic F1 HAlow, 
F1 HAhigh mice and adult WT BALB/c mice. (C) Sorted CD4+6.5+ and CD4+6.5- from a single transgenic TCR HA mouse or sorted CD4+ 
T cells  from a WT BALB/c mouse were cultured for 3 days with irradiated spleen cells from a single transgenic CD11c HAhigh mouse 
as a source of APC. Proliferation was determined by 3[H]-Thymidine uptake. All panels show representative experiments, which have 
been performed at least 3 times on separate and independent occasions.
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Supplemental Figure 3
HA expression on dendritic cells and B cells from CD11c HAhigh transgenic mice versus CD11c HAlow transgenic and WT 
mice.  (A) CD11c and CD19 expression profiles of CD11c HAhigh (left panel), CD11c HAlow (middle panel) and WT 
BALB/c (right panel) mice were examined and (B) three distinguishable antigen presenting cell populations were analyzed 
for HA expression: DCs (CD11cbrightCD19-; upper histograms), CD11c+ B cells (CD11c+CD19+; histograms in the middle) 
and B cells (CD11c-CD19+; lower histograms) (solid line: cells unstained for HA; faint line: HA-stained cells). All panels 
show representative experiments, which have been performed at least 3 times on separate and independent occasions.
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Supplemental Figure 4 
Enrichment of marginal zone B cells in the CD11c+CD19+ B cell population in CD11c HAhigh mice.  (A-B) 
CD11c+ B cells (CD11c+CD19+; to the left) isolated from CD11c HAhigh mice have an increased ratio for 
marginal zone B cells (CD21high, CD23low, IgMhigh, IgDlow) to follicular B cells (CD21+, CD23+, IgMlow, IgDhigh) 
compared to the total CD19+ cell population (to the right). All panels show representative experiments, which 
have been performed at least 3 times on separate and independent occasions.
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Supplemental Figure 5
CD11c expressing B cells stimulate HA specific T cells.  Sorted DC’s (CD11c+CD19-), CD11c+ B cells (CD11c+CD19+) and B cells 
(CD11c-CD19+) from the spleen of CD11c HAhigh (A), CD11c HAlow (B) or WT BALB/c (C) mice were used for in vitro stimulation of 
HA-specific T cells (total lymph node cells isolated from TCR HA mice). The extent of proliferation after 3 days was determined by 
3[H]-Thymidine incorporation. All panels show representative experiments, which have been performed at least 3 times on separate and 
independent occasions.
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Summary 
Some signs of potential autoimmunity, such as the presence of anti-nuclear antibodies 
(ANA) or rheumatoid factor (RF) become more prevalent with age. In most cases, 
these elderly people remain healthy. In the study reported here we have investigated 
whether the same holds true for inbred strains of mice. We found, that when they 
reach the age of 12 months, almost all mice of the C57BL/6 (B6) strain spontaneously 
produce high titers of IgG ANA. At this time, large numbers of germinal centers are 
present in the spleen, IgG deposition can be found in kidney glomeruli and 
lymphocyte infiltrates are found in the salivary glands. Despite all these signs of a 
potential autoimmune response, the mice remain healthy.  
In contrast to B6 mice, DBA/2 mice do not produce IgG ANA’s at that age. The F1 
hybrids of these two strains (BDF1), show an intermediate incidence and lower titers 
of IgG ANA, pointing out the importance of genetic background and suggesting a 
mechanism of suppression of ANA production in DBA/2 mice. The production of 
ANA is CD4 T cell dependent, since B6 mice deficient for MHC class II do not 
produce IgG ANA’s upon ageing. Experiments with irradiated bone marrow chimeras 
clearly show that ANA production is not determined by age related changes in 
radiosensitive, hemopoitic precursor cells, and that the CD4 T cells that promote 
ANA production is radioresistent. Thymectomy of young adult B6 mice leads to 
premature alterations in T cell homeostasis and ANA production, mimicking the 
conditions observed in old mice. Our findings indicate that a disturbed T cell 
homeostasis is closely associated with and likely to drive the onset of some 
autoimmune features. 
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Introduction 
It is well established that the functional activity of the immune system declines with 
age [1]. The fact that mortality and morbidity during annual influenza epidemics 
increases in the elderly population is a clear example of this [2]. Moreover, influenza 
vaccinations are only marginally protective for the elderly [3, 4]. Yet, another 
example is the reactivation of the Varicella zoster virus. The frequency of this 
reactivation increases in individuals after the fiftieth year [5] and is thought to be due 
to a generalised decreased memory responses to chronic infections. In addition, some 
malignancies are more often found among the elderly [6]. For multiple myeloma the 
median age of diagnosis is 66 years and only 2% of all patients are younger than 40 
years of age. The increased incidence of this plasma cell tumor and of certain other 
malignancies with age might suggest that in these cases immune surveillance is 
effective in young individuals, but declines with age. 
The decline in immune competence is thought to be due to an age-related decrease in 
production of both B and T cells. We and others have shown that in both mouse and 
man, B cell production deceases with age [7-9]. Thus, the frequency of mouse bone 
marrow (BM) derived pro-B cells, that can be grown on stromal cells in the presence 
of IL-7 decreases with age: from around 1 in 50 at 2 weeks of age, whereas these drop 
to 1 in 500-1000 at 8 months of age. Similar findings were reported by others using 
FACS analysis of pro-B cells in BM [10]. In the BM of man, the decrease in B cell 
generation with age is even more striking, in that pro- and pre-B cells are practically 
undetectable by FACS in individuals older than 50 years of age [7, 8]. The finding, 
that the peripheral B cell repertoire in adults consist to a large extent of memory B 
cells (reviewed in [11]) might therefore be due in part to the fact that the turnover of 
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mature B cells, including memory B cells, is slow or even absent, since they do not 
have to compete for space with newly formed B cells from the BM.  
The generation of T cells also decreases with age [12, 13]. Thus, the number of  
thymocytes and epithelial cells dramatically decreases with age. The mechanisms 
underlying this thymic involution are not understood. As a consequence of this the 
generation of new, naïve T cells is very low and therefore, replacement of mature 
peripheral T cells by newly formed ones is also very low. Most peripheral T cells 
found in an older individual have a memory phenotype [14, 15]. This shift in 
populations from a predominance of naïve cells to a predominance of memory cells 
with age is thought to be due to cumulative exposure to foreign antigens as well as the 
homeostatic proliferation of T cells in response to reduced thymus output. 
While the generation of naïve T and B cells decrease with age, the incidences of 
autoimmunity and diseases increase in elderly persons. Autoantibody production to 
nuclear antigens (ANA’s) [16, 17] and other autoimmune symptoms [18] are more 
frequently found in elderly individuals, and autoimmune diseases such as rheumatoid 
arthritis, Sjögren’s syndrome and giant cell arteritis occur and/or peak in the second 
half of life [19-22]. The cellular mechanisms underlying the development of these 
auto-antibodies and diseaes are not understood. 
Here, we studied inbred strains of mice for their capacity to develop autoimmune 
symptoms with age. We found that B6 mice develop autoimmune symptoms similar 
to those seen in elderly humans and began to study the underlying mechanisms.  
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Results 
High incidence of potential autoimmity in aged C57BL/6 mice 
We determined the IgG anti-nuclear antibody (ANA) titers in the sera of a cohort of 
young (2 – 3 months of age) and old (8 – 12 month of age) B6 mice. In the group of 
young B6 mice (n=14) IgG ANA were undetectable (Fig.1A). However, 85% (39 out 
of 46 mice) of old B6 mice were ANA positive and 20% (8 mice) of these had ANA 
titers of over 1 in a 1000  (Fig.1A). Histological analyses of spleen sections revealed 
the presence of large numbers of germinal centers in older mice (Fig.1B). Since high 
IgG autoantibody titers can be accompanied by the deposition of immune complexes 
in the kidney, cryosections of kidneys from old and young B6 mice were compared. 
As shown in Fig. 1C, IgG was readily detectable in the glomeruli of old mice but was 
undetectable in young mice (Fig.1D). The deposition of IgG in the glomeruli of old 
mice did not result in proteinuria (data not shown).  
In man, the incidence of Sjögren’s syndrome also increases with age [23]. Sjögren’s 
syndrome is characterized by T and B cell infiltrations in the salivary glands. In order 
to test whether aging B6 mice also develop a Sjögren-like syndrome, immuno-
histological analysis of salivary glands was performed. As shown in Fig. 1E, 
infiltrations of mononuclear cells were readily detectable in salivary glands of old B6 
mice, but undetectable in the glands of young mice (data not shown). 
Immunofluorescence analysis revealed, that these infiltrates mainly consisted of T  
and B cells  (Fig.1F).  
Thus, aging B6 mice develop autoimmune features similar to aging humans. 
Therefore, analyses performed with these mice might unravel the mechanisms 
underlying the development of autoimmune features and eventually autoimmune 
diseases in elderly humans.  
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Kinetics of IgG ANA formation in various normal mouse strains 
In the previous section, we have shown that around 80% of 1-year-old B6 mice had 
high IgG ANA titers in their blood. In order to determine the onset of IgG ANA 
formation, we determined the serum titers of these antibodies in a cohort of B6 mice 
(n=20) over time. As shown in Fig. 2A, the first ANA positive B6 mice were found at 
week 20 of age and their number steadily increased with time, reaching 90% of the 
mice after 1 year of age. IgG ANA titers in these B6 mice at 1 year of age were 
similar to those described in Fig. 1A. Different results were obtained when the same 
analysis was performed in other mouse strains. In 20 BALB/c mice IgG ANA were 
found at lower titers (1/160) in 1 mouse at week 36 and in 4 mice at 1 year of age, In 
the DBA/2 strain none of 15 mice developed IgG ANA during more than one year of 
observation. Taken together, these findings indicate that B6 mice are genetically 
prone to spontaneously develop IgG ANA, whereas BALB/c and especially DBA/2 
mice are much more resistant to the development of this autoimmune feature.  
The high incidence of IgG ANA in B6 mice and the absence of these in DBA/2 mice 
prompted us to follow a large cohort (n=60) of BDF1 mice for the presence of IgG 
ANA in their sera. As shown in Fig. 2A, the first ANA positive mice were found at 
week 32 of age when already 40% of the parental B6 mice were ANA positive. By 
week 60, 25% (15 out of 60) of the BDF1 mice were IgG ANA positive.  The ANA 
titers of these mice varied from 1 in 40 to 1 in 160, i.e. were relatively low. Thus, the 
incidence and severity of IgG ANA formation in aging mice is strongly dependent on 
genes that are present in B6 mice, but are absent in DBA/2 mice. 
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The IgG ANA production in B6 mice is CD4 T cell dependent 
The fact that the ANA in ageing B6 mice were of the IgG class indicates that ANA 
formation in these mice is a T cell-dependent process. We confirmed the crucial role 
of  CD4 T cells by comparing  IgG ANA production in normal B6 mice with that of 
B6 mice that were MHC class II -/- and thus deficient in CD4+ T cells. As found 
before, practically all (18 out of 20) normal B6 mice had IgG ANA in their serum at 1 
year of age (Fig. 2B). In contrast, only 1 out of 14 MHC class II -/- B6 mice developed 
IgG ANA at a very low serum titer of 1/20.  
 
The IgG ANA is not dependent on age related changes in radiosensitive 
hematopoietic progenitor cells  
In a first approach to determine in which cells age related changes are required for 
IgG ANA production we generated a set of 4 syngeneic bone marrow chimeras. Thus, 
old ANA positive and young ANA negative B6 mice were lethally irradiated and 
reconstituted with T cell depleted bone marrow (BM) cells derived from either old 
ANA positive or young ANA negative B6 mice. At 6-8 weeks after BM 
reconstitution, IgG ANA titers were determined in the various chimeras. All chimeras 
in which the host was old produced IgG ANA irrespective of the BM origin. The 
ANA titers in these mice varied from 1 in 40 to 1 in 640 (Fig. 3A). In contrast, no IgG 
ANA was detectable in the chimeras in which the host was young.  The lack of IgG 
ANA formation in young hosts reconstituted with BM cells from young or old donors 
indicates that age related changes in hematopoietic progenitor cells are insufficient for 
ANA formation. The fact that IgG ANA production depended on the age of the host, 
but not the age of donor cells indicates that the relevant age related change must occur 
in radioresistant cells of the host.  
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CD4 T cells involved in IgG ANA formation in aging B6 mice are radioresistant  
The radioresistant cells in old B6 hosts that are crucial for IgG ANA production could 
be nonhematopoietic cells, for example cells which express the relevant nuclear 
antigens in an immunogenic form only with age. However, the role of radoresistant 
hematopoietic cells could not be excluded. We and others have shown that 
hematopoietic cells, especially T cells, can be radio-resistant [24-26]. Therefore, 
ANA production in old B6 hosts could be driven by radio-resistant T cells of these 
mice. In order to analyze this possibility we generated another set of chimeras. ANA 
positive B6 mice were lethally irradiated and reconstituted with either B6 MHC class 
II-/-, B6 RAG-2-/-, B6 µMT or B6 CD3-/- BM cells. At 6-8 weeks after reconstitution 
IgG ANA titers were determined. No IgG ANA was detectable in B6 RAG-2-/- and B6 
µMT chimeras, indicating a complete ablation of the host B cell compartment due to 
irradiation (Fig. 3B). Only one out of five chimeras receiving MHC class II-/- BM 
showed a low titer of IgG ANA. However, all 6 chimeras reconstituted with B6 CD3-/- 
BM cells showed very significant IgG ANA titers (Fig.3B). Since the B6 chimera-
hosts were CD45.2+ and the B6 CD3-/- BM cells were CD45.1+ we were able to 
identify and analyze host derived hematopoietic cells in these chimeras. As shown in 
Fig. 4A about 14% of the cells found in the spleen of these chimeras were of host 
origin and practically all of those (96%) were T cells. In contrast, all B cells were 
derived from the transferred B6 CD3-/- BM cells (Fig. 4B). In order to directly show 
that the host derived T cells were involved in the IgG ANA formation, the CD4+ cells 
of these chimeras were sorted and 2 x 105 transferred into non-irradiated young 
CD45.1+ B6 CD3-/- or CD45.1+ wild type B6 mice. At 5 weeks after transfer, all 5 of 
the CD45.1+ B6 CD3-/- mice were IgG ANA positive (titers varying from 1 in 40 to 1 
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in 320) and 2 out of 5 CD45.1+ B6 mice were IgG ANA positive (titers 1 in 40 and 1 
in 160) (Fig. 4E). Thus, the radio-resistant CD4 T cells found in old B6 mice could, 
upon transfer, induce IgG ANA formation in young B6 hosts. As shown in Fig. 4C, 
transferred cells were readily detectable in the injected T cell deficient, young 
CD45.1+ B6 CD3-/- mice, i.e. around 7% of the spleen cells were CD45.2+ CD4 T 
cells. In the young CD45.1+ B6 recipient which are not T cell deficient, the 
transferred CD45.2+ CD4 T cells were also detectable, albeit at very low numbers 
only, i.e. 0.1% of the spleen cells were CD45.2+ CD4 T cells (Fig. 4D). The low 
numbers of transferred cells in  the normal B6 recipients could be due to competition 
by recipient T cells or their elimination by a response of the recipient T cells to the 
CD45.2 antigen. In any case, the low survival of transferred cells is the most likely 
explanation for the absence of IgG ANA in sera of 3 out of 5 recipients (Fig. 4E). 
However, a specific suppression of IgG ANA by recent thymus emigrants cannot be 
excluded. 
 
Disturbed T cell homeostasis seems to underlie the formation of IgG ANA in old B6 
mice. 
It is well established that the thymus involutes with age. In our animal unit, B6 mice 
at 2 months of age have around 140 x 106 thymocytes, whereas this number declines 
to 40 x 106 at one year and to 20 x 106 at two years of age. Therefore, the peripheral 
homeostasis of T cells in old mice is different from that in young mice and thus might 
be responsible for the onset of IgG ANA formation in old B6 mice. Another 
explanation for the observed autoimmune phenomena might be that negative selection 
of T cells in an old thymus is impaired. To discriminate between these two 
possibilities, we followed the IgG ANA formation in a cohort of B6 mice (n=20), that 
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had been thymectomized (Tx) at 5 weeks of age, i.e. well before any IgG ANA 
production had commenced and compared them to non-thymectomized B6 mice.  In 
the case of disturbed T cell homeostasis, Tx B6 mice should generate IgG ANA much 
earlier in life than normal B6 mice. However, if impaired negative selection of T cells 
in the old thymus is the cause of IgG ANA formation, Tx B6 mice should not 
generate IgG ANA at any age. We found that B6 mice thymectomized at the age of 5 
weeks start to develop IgG ANA already at week 12 of their life (Fig. 5A). At week 
15, 90% of the thymectomized mice, but only 5% of non-thymectomized B6 mice, 
have significant levels of IgG ANA in their circulation.  In a first attempt to 
understand the IgG ANA production in old normal and young thymectomized mice 
we analyse the peripheral T cell compartment in these mice. 
6-8 week old B6 mice have 10-15 x 106 CD4+ T cells in their spleens of which more 
than 80% have a naïve (CD62L+) phenotype (Fig. 5B). 8 months old normal B6 mice 
have around the same number of splenic CD4+ T cells, but more than 60% of those 
have a memory (CD44+) phenotype. 18-20 weeks after thymectomy, spleens contain 
8-10 x 106 CD4+ T cells of which 90% display a memory phenotype. Both old normal 
and thymectomized young B6 mice show a dramatically increased proportion of 
CD4+ T cells expressing the transcription factor Foxp3, and thus are regulatory T cells 
(Tregs) (Fig. 5C). Likewise, old as well as young thymectomized mice showed 
increased proportions of CD4+ T cells expressing the cytokines IFN-γ and IL-2 (Fig. 
5D and E). 
Thus, the impaired homeostasis induced by thymectomy generates a pool of 
peripheral T cells phenotypically resembling that found in old mice. 
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Discussion 
We report herein that in ageing mice, like in elderly humans, development of features 
characteristic of autoimmunity is a common occurrence [1]. Thus, we find that 
virtually all 1 year-old mice of the C57BL/6 (B6) strain spontaneously show high 
titers of IgG anti-nuclear antibodies (ANA). A majority of them also display 
infiltrates of T and B lymphocytes in their salivary glands (Sjögren-like syndrome) 
and some 10% have deposits of IgG in kidney glomeruli. Despite all these signs of 
autoimmunity, like in most elderly humans, these ageing animals remain healthy. 
Like in many animal models of spontaneously developing autoimmune disease, the 
time of onset and the severity of symptoms is highly variable, even among 
genetically-identical individuals. Some of our B6 mice start to produce IgG ANA 
already at 13 weeks of age, whereas others, even of the same litter, kept in the same 
cage, only start ANA production at week 60 or later. Viral transmission would seem a 
very unlikely cause of this since mice with or without IgG ANA were found in the 
same cage. The reasons for this variability among genetically identical individuals are 
not known. 
The incidence of IgG ANA production is reduced (30%) and delayed (week 30) in our 
ageing BALB/c mice and completely absent in the MHC haplotype identical DBA/2 
mice, which are known to generate normal immune responses to immunization [27].  
Thus, the B6 strain is highly susceptible for the spontaneous development of IgG 
ANA autoantibodies. In some cases where IgG ANA could be detected in serum, 
deposits of IgG were observed in the glomeruli of kidneys. However, we never 
observed severe kidney damage with leaking of proteins into the urine. We do not 
know whether these deposits represent IgG antibodies directly binding to the 
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basement membranes, or are immune complexes, perhaps of the very ANA’s in 
complex with their nuclear antigens.  
Interestingly, previous studies have shown that B6 mice congenic for lupus 
susceptible loci rather often develop spontaneous pathological autoimmunity [28-30]. 
Thus, little genetic change is needed to transform B6 mice producing harmless IgG 
ANA into an autoimmune disease prone mouse strain. 
As expected, the IgG ANA production is T cell dependent, since B6 mice deficient in 
MHC class II expression almost never show any IgG ANA production. Moreover, the 
findings that lethally irradiated old B6 mice reconstituted with wild type or CD3 
deficient BM develop IgG ANA, whereas those reconstituted with BM from MHC 
Class II deficient mice generally do not, strongly indicates that cognate interaction 
between T and B cells is required for IgG ANA production. 
When the highly permissive B6 strain is crossed to the non-permissive DBA/2 strain, 
the resulting F1 animals show a much-delayed onset of IgG ANA production with 
only a 25% penetrance at 60 weeks of age. Thus, it seems, that the DBA/2 genotype 
exercises some kind of dominant suppression over the permissive B6 genotype in its 
ability to produce IgG ANA. The nature of this suppression remains to be determined. 
Since the T cell dependent IgG response to ANA is so dramatically different between 
young and old mice, and since it is observed in young thymectomized mice, we 
characterized the peripheral T cell compartment in young and old B6 mice as well as 
in thymectomized mice. We find that memory-type CD4+ T cells accumulate in the 
spleens of both older and thymectomized animals , and that these T cells produce the 
pro-inflammatory cytokines IFN-γ and IL-2. As these cells survive lethal irradiation 
in old B6 mice, they can be isolated from such mice and shown to induce IgG ANA 
production upon transfer to young mice. The T cell compartment of thymectomized 
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young mice also consisted of increased numbers of memory-phenotype CD4+ T cells, 
similar to that of old mice. In old, as well as in thymectomized mice, an increase in 
Treg’s was observed. The elevated expression of IL-2 might drive antigen 
independent proliferation of Treg’s. Thus, the IgG ANA production in old B6 mice 
and young thymectomized B6 mice is associated with the disturbance of T cell 
homeostasis that is caused by the reduction or lack of thymic output of naïve T cells. 
However, it should be noted that not in all situations in which T cell homeostasis is 
disturbed, this results in the development of autoimmune features. Thus, preTα 
deficient mice display a severely disturbed T cell development in the thymus and a 
largely reduced peripheral T cell compartment [31, 32]. However, these mice do not 
show early signs of autoimmunity (own unpublished observation). Yet, another 
example is the Coronin 1 deficient mouse, which has a disturbed and reduced 
peripheral T cell compartment but does not show autoimmunity [30, 33]. To the 
contrary, a Coronin 1 deficiency in MRL.lpr mice blocks, to a large extent, the 
development of Lupus-like disease in these mice [30]. 
Two key questions remain to be answered: what is the nature of the T cell dependent 
antigens and how is tolerance to these antigens broken? It is obvious from our 
experiments that the antigens relevant for ANA production is present already in 
young B6 mice in an immunogenic form, because ANA responses can be provoked in 
young mice by thymectomy (Fig. 5) or by transfer of radioresistant CD4 T cells from 
old mice into young recipients (Fig. 4) and by the induction of a chronic graft-versus-
host disease in young mice (data not shown). The requirement of a cognate interaction 
between T and B cells for obtaining an ANA response argues that the antigen has to 
be expressed by B cells. In SLE patients the nuclear antigens recognized by ANA 
include single and double stranded DNA. We also observe some 40% of our IgG 
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ANA from ageing B6 mice to be specific for DNA (data not shown). The fine 
specificity of ANA in the serum of SLE patients and in the disease causing deposits of 
immune complexes in the kidney have only partly been determined [34, 35]. The 
antigenic determinants that are recognized by the IgG ANA inducing T cells are not at 
all known. However, as pointed out above, an age dependent appearance of these 
antigens cannot explain the age dependency of IgG ANA formation. 
How is tolerance of CD4 T cells involved in IgG ANA production broken in old 
mice? Various other mouse models for autoimmune disease, and in particular ANA 
production in strains of mice developing a Lupus-like disease, have identified 
different genetic loci responsible for the breaking of T cell tolerance [30, 36-39]. How 
these loci operate in ageing, normal B6 mice remains to be determined. 
In general, tolerance of T cells to self antigens can be broken by the failure of 
negative selection in the thymus, or by the failure of suppression in the periphery. We 
exclude the age dependent failure of negative selection in aged mice as a cause of 
ANA production by showing that ANA production does occur in young 
thymectomized mice. On the other hand a failure of suppression is consistent with our 
observation that IgG ANA production is reduced in a cross between ANA producing 
B6 mice and DBA/2 mice which do not produce ANA. However, the mechanisms 
underlying the suppression of IgG ANA responses remains to be determined. Loss of 
suppression of ANA responses by a loss of Treg in old mice is unlikely, since the 
number of these cells increases as a result of  reduced thymic output. However 
supression of ANA responses by Treg or other cells that are recent thymic emigrants 
in young mice and loss of this suppression in old mice cannot be excluded as the 
cause of IgG ANA production in old mice.    
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The major cause of a disturbed T cell homeostasis in ageing animals is a decreased 
thymic output of naïve T cells due to the process of thymic involution [40]. It is 
possible, that the variability of onset of ANA production which we observe between 
animals of the same strain and particularly between different strains has its origin in 
differences among animals regarding the onset of thymic involution. Our findings 
suggest that the incidence and/or severity of autoimmune disease may be reduced by 
treatment modalities that improve thymic output and prevent or delay thymic 
involution. Such therapies may be initiated in genetically susceptible individuals or in 
individuals with very early signs of autoimmunity. 
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Materials and Methods 
Mice  
C57BL/6 (B6), BALB/c, DBA/2, (C57BL/6  x DBA/2)F1 (BDF1), MHC class II-/- 
(C57BL/6 IAα-/-) [41], B6 RAG-2-/- [42], B6 µMT (C57BL/6-Igh-6tm1Cgn) [43] and B6 
CD3-/- [44] mice were bred under SPF conditions in our animal unit. The State 
veterinary authorities of Basel (Kantonales Veterinäramt, Basel-Stadt) have approved 
all animal experiments. 
Antibodies and flow cytometric analysis 
FITC-, PE-, APC- or biotin-conjugated mAb specific for CD4 (L3T4), CD8α (53-
6.7), CD69 (H1.2F3), CD44 (IM7), CD62L (MEL-14), anti-TCR β-chain (H57-597), 
were purchased from BD Bioscience (Allschwil, Switzerland). Streptavidin, 
conjugated to PE, APC or PE/Cy7 were also purchased from BD Bioscience. Anti-
FoxP3 (FJK-16s), anti-IFN-γ (XMG1.2) and anti-GM-CSF (MPI-22E9) were 
purchased from eBioscience. The anti-IL2 (S4B6), anti-CD45.1 (A20-1.7), anti-
CD45.2 (104-2.1), anti-IgM (M41) and anti-CD90 (T24) mAb’s were purified from 
hybridoma supernatants and labeled with biotin, FITC or A647 in our laboratory by 
standard methods. Flow cytometry was performed using a TMFACS Calibur (BD 
Biosience) and sorting using the TMFACS-ARIA (BD Biosience). Data were analyzed 
using the TMCell Quest Pro Software (BD Bioscience).  
Immunohistochemical and histological analyses 
Spleens, kidneys and salivary glands were snap frozen on dry ice and embedded in 
OCT-compound (Sakura, Zoetermeer, NL), and 5 µm sections were prepared. 
Sections were fixed in acetone for 10 min and then air dried for 60 min. To analyze B 
and T cell organization in spleen and to determine the presence of germinal centers in 
spleen, sections were incubated with biotinylated anti-IgM (clone M41) and FITC 
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labeled anti-CD90 (T24) or with anti-IgM FITC (M41) and biotinylated peanut 
agglutinin (PNA) (Vector, Burlingame, CA) for 30 min. After 20 min of washing in 
PBS, anti-IgM and PNA binding were revealed with PE conjugated streptavidin 
(SouthernBiotech, Birmingham, AL). Fixed salivary gland sections were additionally 
stained with hematoxylin and eosin (H&E) according to standard procedures. Kidney 
sections were incubated with FITC labeled goat anti-mouse IgG mAb (Jackson 
Immunoresearch, Milan Analytica, La Roche, CH) to reveal IgG deposits in 
glomeruli.  
IgG anti-nuclear autoantibody determination 
IgG autoantibodies against nuclear antigens were detected by an indirect 
immunofluorescence technique (described in [25]), using a FITC labeled goat anti-
mouse IgG (Jackson Immunoresearch, Milan Analytica, La Roche, CH); 5 µm 
cryosections of kidneys from RAG-2 deficient mice were used as substrate. The titer 
was defined as the highest serum dilution still giving a positive nuclear staining. 
Titers lower than 1/20 are denoted “not detectable”. 
PMA/ionomycine stimulation 
Total lymphocytes were stimulated at 37°C during 4 hours using 1 µg/ml ionomycine 
(Sigma-Aldrich) and 5ng/ml phorbol-12-myristate-13-acetate (PMA) in the presence 
of 10µg/ml brefeldin A (Calbiochem). Cells were harvested and stained by standard 
intracellular staining procedure. In brief, surface staining was followed by a fixation 
step using 2% paraformaldehyde in PBS followed by intracellular staining in FACS 
buffer containing 0.5% saponin. 
BM chimaera 
Bone marrow (BM) was isolated from femur and tibia of donor mice. BM cell 
suspension was incubated with anti-CD4 (RL172) and anti-CD8 mAb (31M) prior to 
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complement depletion of T cells by incubating the sample with rabbit serum (Low-
Tox®-M, Cederlane Laboratories Ltd. 1:20 in DMEM) for 30 min at 37°C. The 
procedure was followed by erythrocyte lysis buffer treatment. Six weeks or >8 
months old B6 recipients were lethally γ-irradiated (900 rad) 4 hours prior to 
intravenous injection of 5 x 106 T cell depleted BM cells/mouse. BM chimaeras were 
analyzed in week 6 after BM reconstitution.  
T cell transfer 
Radioresistant host CD45.2+ CD4+ T cells isolated from spleens of old B6 CD3-/- BM 
chimaera (IgG ANA positive) were sorted and 2 x 105 cells were transferred into non-
irradiated 6 week old CD45.1+ B6 CD3-/- or CD45.1+ wild type B6 mice. IgG ANA 
titers were analyzed 5 weeks after T cell transfer. 
Thymectomy of B6 mice 
At 5 weeks of age, mice were anesthetized and the thymus removed by suction 
through a small upper sternal incision. Completeness of thymectomy was verified in 
each animal by anatomical inspection at the time of sacrifice. 
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Figure 1. Old mice show high incidence of circulating IgG ANA, germinal center formation, and kidney depositions of IgG as well 
as development of lymphocyte infiltrates in salivary glands. Titers of IgG ANA in sera of young (to the left) and old (to the right) B6 
mice (ND denotes not detectable) (A). Section of spleen from an old B6 mouse stained with PNA (red) and anti-IgM (green) antibody 
(B). Section of kidney from old (C) and young (B) B6 mice stained with FITC anti-IgG antibody (green). Section of salivary gland 
from an old B6 mouse stained with H&E (E) or anti-CD90 (green) and anti-IgM (red) antibodies (F) (scale bar: 150 μm).
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Figure 2. Kinetics of IgG ANA appearance in sera of different inbred mouse strains. Titers of IgG ANA were determined at indicated 
times after birth in various inbred mouse strains (A) as well as in MHC class II deficient mice (B).
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Figure 3. IgG ANA titers in BM chimeras. Young or old B6 host mice were lethally irradiated and reconstituted with T cell depleted 
BM from young or old B6 mice. Mice were bled 6-8 weeks after reconstitution and the ANA titers determined (A). Old ANA positive 
B6 host mice were lethally irradiated and reconstituted with T cell depleted BM from indicated donors. ANA titers were determined 
6-8 weeks after reconstitution (B). ND denotes not detectable.
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Figure 4. Radioresistant CD4+ T cells can transfer the capacity for ANA production in young hosts. Old ANA 
positive B6 host mice were lethally irradiated and reconstituted with BM from CD3-/- donor mice. 8 weeks after 
reconstitution spleens were analyzed by FACS for host derived, CD45.1 negative T cells (TCRβ+) (A) or donor 
derived CD45.1+ B cells (CD19+) (B). Host derived (CD45.2+) T cells were sorted and transferred to 
non-irradiated CD3-/- (C) or wt (D) mice. 5 weeks after transfer, recipient mice were bled and their serum ANA 
titers determined (E) and their spleens analyzed for donor derived (CD45.2+) CD4 positive T cells (C and D). 
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